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ABSTRACT
Changes in the health sector in South Africa have been widespread since 1994 with
restructuring of the public sector being the focal point of legislation. The limelight has
recently shifted focus to the health sector with the Medicine and Related Substances
(MRSCA) Amendment Act, 59 of 2002 in which generic substitution was finally
promulgated, after disputes in the international arena about patent rights, due to the
government's policy on parallel imports. Section12 ofPharmacy Act 90, which forms
part of the Act is an attempt to further regulate the industry, that eventually became
effective this year. This legislation addresses issues of sampling and perverse
incentives and calls for the establishment of a Marketing Code for the pharmaceutical
industry. The South African government has, as part of the amendment, called for
input from all stakeholders including: trade associations, the pharmaceutical industry
and the medical profession. All role players were invited to be part of the decision-
making process as to what should constitute the Marketing Code and its' regulatory
body.
The Society of Psychiatrists (SASOP), an affiliate of the South African Medical
Association (SAMA), has not yet prepared a response to SAMA for submission to
government with regard to the Marketing Code, in the field of central nervous system
(CNS) products. The impact of the banning of samples on psychiatric private practice
is not known and there is insufficient data available about the marketing activities of
drug companies and the link to the prescription habits of medical professionals.
Further, to date, there has been no canvassing of opinions with regard to the impact of
the legislation on the consumer. In this case study analysis, an evaluation of the
impact of legislative changes in the South African pharmaceutical industry is made.
Recommendations as to what should constitute a Marketing Code for th((
pharmaceutical industry are highlighted.
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The South African (SA) pharmaceutical industry has historically relied on the
'traditional' marketing mix and relationship marketing to conduct its' business.
Recent changes in legislation by the SA government include the Medicines and
Related Substances Amendment Act (MRSCA) that was initially formulated in 1997,
but only registered as Act 59 of 2002, in the Government Gazette, in January 2003.
This was as a result of a legal challenge by the international community to the
controversial areas in the Act, which advocates parallel imports and generic
substitution of drugs and the licensing of dispensing doctors.
The Act also seeks to regulate the marketing behaviour of the pharmaceutical industry
in several areas by banning the practice of sampling and the provision of bonus and
rebate schemes, and strictly controlling sponsorship of medical education events, all
of which have been considered perverse incentives. Provision is made within the Act
for the introduction of a marketing code and a regulatory body to monitor its
implementation. This chapter will provide a background to the legislative changes and
its potential impact on stakeholders. The research objectives, methodology and
limitations of the case study analysis are also discussed.
1.2 BACKGROUND
The South African pharmaceutical industry has been the focus of international
attention since 1997, with widespread changes in legislation with regard to generic
medication and dispensing doctors. One of the changes to legislation that has evaded
the limelight until recently has been what was called Section12 of Pharmacy Act 90
that was included in Act 101 of 1965, in 1997. This legislation that in part, calls for
the establishment of a Marketing Code for the pharmaceutical industry has been
debated in the National Assembly and forms part of the Medicine and Related
Substances (MRSCA) Amendment Act. The South African government has, as part of
the amendment, called for input from all stakeholders including: trade associations,
the pharmaceutical industry and the medical profession., All role players were invited
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to be part of the decision-making process as to what should constitute the Marketing
Code and its' regulatory body.
The South African Society ofPsychiatrists (SASOP), an affiliate of the South African
Medical Association (SAMA), has not yet prepared a response to SAMA for
submission to government with regard to the Marketing Code, in the field of central
nervous system (CNS) products. There is insufficient data available on response to
marketing activities, the level of brand awareness amongst psychiatrists and the link
between the marketing strategy of pharmaceutical companies and the prescription
habits of medical professionals. Further, to date, there has been no canvassing of
opinions with regard to the legislation amongst service providers or any exploration of
the impact it would have on stakeholders.
The current value of the pharmaceutical industry is over RI0bn. Public health care,
funded by government accounts for most of the demand but only a small percentage
of the pharmaceutical sector's value and has little impact at present on the marketing
strategy of pharmaceutical companies. Most of the industry's revenue comes from the
private sector, which is funded mainly by member's contributions to medical aid
schemes, so private practitioners are regarded by the industry as their primary focus
(Internet 1).
The local pharmaceutical industry is highly competitive in nature and companies'
market shares often run neck and neck. This is especially so in the market for CNS
products, where there is a race for innovative products and creative marketing
strategies by the major role players. These include the leading pharmaceutical
companies internationally, who have South African subsidiaries. Pfizer South Africa,
Lilly South Africa, Lundbeck South Mrica and GlaxoSmithKlein operate alongside
South African companies like Adcock-Ingram and Aspen. In the CNS product
portfolio, the branded antidepressant market is under attack from a growing generic
market, which has the support of government and most medical aid schemes. In its
response, the bigger industry players have increased the capacity of or established
generic divisions, even though there is an international trend of growth within the
branded product market, with new products being launched and strong 'pipelines' in
most market leader's research facilities (Internet 2).
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The marketing activities of the local industry have historically had to be consistent in
quality and content with the global industry. Multinational companies (MNC's)
usually have their strategic marketing portfolios based at head office with regional
management platforms that incorporate the local ethos into the global corporate
vision. The restrictive nature of the new legislation poses a threat to that strategy and
product managers will have to strategically respond to the changes to ensure that they
retain and grow market share.
In this case study analysis, the impact of the legislative changes on stakeholders
within the antidepressant market was evaluated. An assumption was made that this
construes a fair reflection of the response of the industry as a whole. Opinions
regarding a Marketing Code for the pharmaceutical industry were canvassed and
recommendations formulated.
1.3 THE STAKEHOLDERS
The stakeholders in the SA pharmaceutical industry include the medical profession,
the SA government, the pharmaceutical companies, pharmacists and consumers
whose interests in the private sector are represented by medical aid schemes and
consumer advocacy groups.
1.3.1 The Medical Profession
SAMA is a professional association for medical doctors without any statutory or
disciplinary powers. It is also a registered trade union for its members employed in
the public sector. At present some 70% of doctors in both the public and private
sectors are voluntary members of the association, which is registered as an
independent, non-profit, Section 21 company. The Association's activities focus on
both professional and business aspects of medical care in SA. Its stated goal is "to
influence the health care environment to meet the needs and expectations of the
community by promoting improvements to health reform, policy and legislation"
(Internet 3).
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1.3.2 The South African Society of Psychiatrists
The South African Society of Psychiatrists is affiliated to the Health Professionals
Council of South Africa. It is not a statutory body but an association of psychiatrists
that is registered as a non-profit organisation. It has a membership of 360
psychiatrists, including retired psychiatrists and psychiatrists residing abroad and is
representative enough to be regarded as the 'voice' of psychiatry in SA. It has good
relationships internationally with the American Psychiatric Association and the Royal
College ofPsychiatry. Its stated aim is to protect the rights of patients with psychiatric
illnesses and assist its members in the practice of the discipline of psychiatry. The
Private Psychiatrists of South Africa (PPSA), an affiliate of SASOP, with executive
committee representation in the Private Psychiatrists Interest Group, is a registered
Company that represents psychiatrists in private practice. The PPSA, which has a
Board ofDirectors who are representative of all the provinces, have been tasked with
lobbying with the medical aid industry and the Board of Healthcare Funders (BHF')
regarding tariffs for psychiatrists and medical aid limits on psychiatric benefits
(Internet 2).
1.3.3 Pharmaceutical Companies
The pharmaceutical industry in South Africa is represented by the National
Association ofPharmaceutical Manufacturers (NAPM), which deals largely with local
pharmaceutical companies' concerns, and the Pharmaceutical Manufacturers
Association (PMA), which deals with international concerns of companies with a
presence in SA. It also represents the interests of local companies, on a global level
(Internet 1). The major role players in the branded local antidepressant market include
Lundbeck SA, Pfizer SA, Lilly SA and GlaxoSmithKlein (Internet 1).
1.3.3.1 The Roleplayers in the Antidepressant Market
The major pharmaceutical companies that operate in the SA antidepressant market are
Lilly SA with its product Prozac, Lundbeck SA marketing Cipramil,
GlaxoSmithKlein with Aropax and Pfizer SA, with Zoloft. Other players include
Wyeth SA, with Efexor, Donmed with Remeron and Solvay with Luvox. There are
several new entrants into the market who have recently launched products from
companies with a limited investment in CNS products and a restricted marketing
budget. Other major players with a CNS product portfolio include Janssen-Cilag and
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AstraZeneca SA, who do not compete in the antidepressant market but have other
branded products which have relevance to psychiatry (Internet 1).
1.3.4 Pharmacists
The interests of pharmacists in South Africa are represented by the Pharmaceutical
Society of South Mrica (PSSA). The legislative changes have increased the role that
pharmacists play in the dispensing of medication, allowing for independent generic
substitution of ethical prescriptions. There have also been revisions made to pricing
methods used in the industry, with a change from the cost plus system of mark-ups on
drugs at the pharmacy level, to a dispensing fee that is fixed at a flat rate, which has
also impacted on pharmacy practice in South Africa.
1.3.5 The South African Government
The responsibility for the development and implementation of legislation governing
the health care sector in South Mrica rests with the Ministers of Health and the
Departments of Health nationally and provincially. The government has had to
assume the responsibility of devising the infrastructure that would meet the health
care needs of the population and the area of medicines control has been its greatest
challenge. The reality is that even essential medicines remained out of reach of the
majority of the population, due to the cost factor and the situation had to be urgently
addressed, within the constraints of the resources allocated to the Health Budget.
1.3.6 The Consumer
The consumer in the private sector is usually represented by medical aid schemes in
any negotiation forum. The major medical aid schemes in South Africa include
Medscheme, which acts as administrator for other medical aids, National Medical
Plan (NMP), Discovery Health, Medihelp, Bankmed and Mx Health, which
administers Polmed. Consumers in the public sector who could not afford private
care, have had to utilize the services provided by the Department of Health
(DOH).The biggest concern about the medical insurance industry in South Africa has
been its adoption of the managed health care model, which has historically failed as a
system of cost-effective health care delivery, in other countries, like the US.
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The Consumer Council and various public advocacy groups do monitor the situation
and assume responsibility to be the voice of the consumer in South Africa. In the
health sector, there has been minimal input from these advocacy groups at the level of
legislation governing health services, except for media coverage of the major issues at
stake, relevant to mv illness and generic medication. In the antidepressant market,
there is a fairly active Anxiety and Depression Support Group that offers advice to
patients nationally via a toll-free line that is partly funded by the pharmaceutical
industry and has the support of SASOP. However, the service is mainly confined to
assisting patients and there is minimal focus on legislative policy and how it impacts
on patients' rights (Internet 2).
1.4 THE MARKET
In the year 2000, the value of drug sales in South Africa was R8,25 billion. Public
sector sales made up approximately 24%, translating to R59,36 per person without a
medical aid scheme. The per capita expenditure on prescription drugs in the private
sector was approximately R800,29, excluding over-the-counter (OTC) medicines
sales, which constituted only 6% of the total value. Dispensing doctors were only
responsible for 15% of drug sales (Internet 1).
The current value of the pharmaceutical industry lies in the branded sector of the
market, although government support for generic medication is making inroads. SA
currently uses about 20% of generic drugs compared to the United States, where 60%
of pharmaceutical sales are generic products. The generic market is expected to grow
substantially over the next few years, especially in the light of legislative support. The
alternative medicines market, which is not regulated at all, is growing at 15% per
annum. This represents a concern for all role players in the ethical drug market as
South Africa is being viewed as an open market for 'natural' products, many of which
have never undergone any testing for human consumption and have had no regulatory
responsibility in terms of standards, in their country of origin. South African
companies in the alternative health market like Herbex, have seen a sudden growth
spurt in the market, for drugs like St John's Wart, that have been advocated to have
antidepressant properties. There is also a huge market for weight loss related and
libidinal products and the Advertising Standards Authority is now investigating
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claims made by some of these companies with regard to the efficacy of their products
(Internet 1).
1.4.1 The antidepressant market
The antidepressant market has particularly been at the forefront of the current battle
for brand recognition both locally and internationally. In the US, the 20 best-selling
prescription medications in 2001 included three antidepressants: Zoloft, Paxil and
Prozac. GlaxoSmithklein's Paxil ( Aropax in SA) and rival Pfizer's Zoloft each had
about $2 billion in U.S. sales in 2002. According to a marketing-research service that
tracks consumer advertising, marketers spent $184.5 million in 10 months from
January through October 2001 (Internet 4). The South African situation is as
competitive and invested in branded products.
The government's decision to proactively support generic medication has impacted on
this market within the private sector, as most medical aid schemes now subscribe to
the essential drug list (EDL) that has been compiled by government after consultation
with the public health sector. Medical aid schemes now only pay towards drugs
registered on the Maximum Medical Aid Price (MMAP) list, which is essentially a
replica of the EDL. Should consumers request branded products, medical aids require
that difference in costs to be self-funded.
One of the difficulties with this situation for service providers is that there are only
five antidepressants listed in the EDL. All of them have generic substitutes available
and four of them may place the consumer at risk because of their side effect profile. A
further complicating factor in the private sector, for antidepressant use, is that most
medical aid schemes have annual limits on medication expenditure. Branded products
cost more for a year's treatment than these limits and consumers have historically
relied on samples, or loyalty programs from the pharmaceutical industry to meet the
lack. These samples were issued as part of structured re-imbursement programs that
rewarded compliance and were accompanied by educational information regarding
disease and lifestyle management. These programs had the support of service
providers and the medical aid industry and are now 'illegal' in that samples may not
be issued except under very specific conditions, like research (Internet 1).
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1.5 THE LEGISLATION
The Medicines and Related Substances Amendment Act, 2002, Act No. 59, 2002
(Appendix One) states amongst other things that the Act aims to:
• Provide for measures for the supply of more affordable medicines in certain
circumstances
• Provide for the generic substitution of medicines
• Provide for the establishment of a pricing committee
• Regulate the purchase and sale of medicines by manufacturers, distributors,
wholesalers, pharmacists and persons licensed to dispense medicines
• Provide for the licensing of certain persons to compound, dispense or
manufacture medicines and medical devices and also to act as wholesalers or
distributors
• Regulate the Minister's power to make decisions
The Act includes Section 12 of Pharmacy Act 90 of 1997, which included the
following amendments to the previous legislation governing this sector, Act 101 of
1965:
• Bonusing Section 18 A:
''No person shall supply medicine according to a bonus system, rebate
system or any other incentive scheme"
• Sampling Section 18 B:
"No person shall sample any medicine"
• A code ofethics Section 18 C:
"The Minister shall, after consultation with the pharmaceutical industry and
other stakeholders, prescribe a code of ethics relating to the marketing
policies of pharmaceutical companies"
In May 2002, an amendment of Section 18C of Act 101 of 1965 as inserted by
Section 12 of Act 90 of 1997 was passed with the following section hereby substituted
for Section 18C of the Principal Act:
"The Minister shall, after consultation with the pharmaceutical industry and other
stakeholders, make regulations relating to a Marketing Code relating to the marketing
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practices of pharmaceutical companies. The regulations referred to shall also provide
for: the appointment of a body comprising of representatives of trade associations,
pharmaceutical industry, consumers and health care providers to enforce the
Marketing Code together with Council, the funding of the body referred to and the
enforcement of the Code referred to" (Internet 5).
1.6 THE HEALTH PROFESSIONALS COUNCIL'S RESPONSE
The Health Professionals Council of South Africa's (HPCSA) issued a policy on
perverse incentives, which was drawn up in response to Act 90 of 1997 (Internet 7).
The South African Medical Association (SAMA) responded to the changed legislation
by providing guidelines based on Act 90 and the HPCSA's policy statement. The
guidelines stipulate that the pharmaceutical industry may not provide samples of any
medicine, supply medicine on a bonus, rebate or incentive scheme, pay commission
and provide expensive gifts and that health care professionals may not accept any of
the above (Internet 6).
Further, doctors may not advertise or encourage the use of medicines, health-related
products, hospitals or medical devices in order to promote his/her practice unfairly for
improper financial gain. Doctors may not charge fees for seeing medical
representatives or request samples, gifts, bonuses and other incentives (Internet 3).
Although the guidelines seem to be a rational approach to the dilemma facing the
industry and the profession, the issue is more complicated. The HPSCA requires that
all medical professionals participate in continuing professional development (CPD)
accreditation programs in order to continue to actively practice in South Africa
(Internet 6). The pharmaceutical industry has spearheaded the drive to organize CPD-
accredited activities as a service to its customer base. The industry has a presence at
all continuing medical education (CME) meetings, journal club meetings,
conferences, Independent Practitioner Association (IPA) meetings and symposia.
Sponsorship is usually of meals associated with these events but the medical
representatives often assume the organizational responsibility for these events
combining the marketing of the company's product offering, with CPD activities. The
boundaries have thus been consistently blurred between the educational needs of
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health care providers and the marketing strategy of the industry. SAMA has indicated
that although such sponsorship can continue strict, guidelines that include the removal
of product branding have to be abided by. The guidelines still allow for company
branding though, which is open to interpretation and hence, manipulation, as most
brands are established in the consumer base already.
1.7 THE INTERNATIONAL PERSPECTIVE
International trends in the relationship between the pharmaceutical industry and the
medical profession do lend weight to the SA government's perspective on a need to
regulate the marketing activities of the pharmaceutical industry:
• U.S. Drug spending increased by 17.1% to $154.5 billion dollars in 2001.
One-quarter of this increase was due to a shift to the use of more expensive
drugs.
• Pharmaceutical industry profits were 18.5% of revenue in 2001. For the
remainder ofFortune 500 companies, median profits were 3.5%.
• Since 1995, the research and development (R&D) staff of US brand- name
drug companies have decreased by 2%, while marketing staff have increased
by 59%. Currently, 22% of staff are employed in R & D, while 39% are in
marketing.
• 46% of physicians reported in a survey that drug representatives are
moderately to very important in influencing their prescribing habits.
• In 2000, Merck spent $161 million on advertising for Vioxx, which is more
than Pepsico spent advertising Pepsi ($125 million).
• Drug companies spent $15.7 billion dollars on promotion in 2000 including
the distribution of$7.2 billion dollars worth of free samples.
• The American Medical Association generates $20 million in annual income by
selling detailed personal and professional information on all doctors practicing
in the US to the pharmaceutical industry (Internet 7).
1.8 MOTIVATION FOR THE CASE STUDY
The Medicines and Related Substances Amendment Act was developed by the
Department of Health in 1997, however, disputes over intellectual property rights by
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the international pharmaceutical industry delayed promulgation of the Act until 2002.
The controversial areas in the Act involved mandatory generic substitution, the
licensing of dispensing doctors and the acceptance of parallel imports. The
Department of Health has supported the implementation of the policies within the
Bill, resulting in the South African pharmaceutical industry being in a state of flux. To
date there has been no evaluation of the impact these legislative changes have had on
stakeholders.
Pharmacy Act 90, Section 12 that was incorporated into the MRSCA Act, is
impacting on private practice and the marketing practices of the pharmaceutical
industry in SA. The SA government has requested input from all the stakeholders
including trade associations, the pharmaceutical industry and the medical profession.
The South African Society of Psychiatrists (SASOP) has not yet formulated a
response with regard to the impact of the legislation on its members. Some of the
knowledge gaps that exist due to insufficient data include: brand awareness among
psychiatrists within South Africa, the concept of ethical marketing and the link
between marketing activities of drug companies and the prescription habits of
psychiatrists. Certainly, it appears as if the banning of sampling and incentive
schemes will impact on service delivery to the consumer (Internet 2).
The antidepressant market in South Africa is a potential growth area for the economy
and the concerns about the Act are that regulation of the industry will be at the cost of
growth. The PMA does not have sufficient data from its client base, the service
providers, regarding its marketing mix. Existing market research in South Africa in
the antidepressant market has focused mainly on new product launches and
differences in marketing approach between the different drug companies. Data about
advertising and brand awareness among psychiatrists in SA would be invaluable to
the PMA and its members in correctly apportioning their marketing budget. Further,
South African affiliates of global companies are faced with the challenges of a single
exit price policy and fluctuating rand/dollar exchanges, so profit margins within the
industry are already pressurized. Accurately pitched marketing strategies would give
companies the edge over their competitors (Internet 1).
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SASOP's concerns have been two-fold. There is concern over the restrictions placed
on branded product usage by medical aid schemes as the consumer is not being
afforded the right to the best possible treatment option, which is in keeping with good
medical practice. South African psychiatrists also need to acquire clinical expertise
with the newer products that are available on the market internationally. In the public
sector doctors-in-training have minimal exposure to branded products, which does not
prepare them for private practice.
On the other hand, SASOP is concerned about the impact of the marketing practices
of the industry on the prescription habits of psychiatrists, especially in the light of the
trends in the US, where the industry has taken the lead role in the education of
psychiatrists and consumers alike. This has fueled the arguments of the anti-
psychiatry movement that are vociferous in their attack on the ethical antidepressant
market. The concerns about industry-driven diagnoses and management is legitimate,
however, the reality is also that psychiatry remains a discipline with the greatest
potential for research and drug discovery, as so much is still unknown. Feedback to
SASOP from its members regarding a Marketing Code would be invaluable in
determining the course that the relationship between the industry and the service
providers in South Africa should take, especially with regard to medical education
and research (Internet 2).
1.9 RESEARCH OBJECTIVES
This case study analysis therefore aims to assess the impact of legislative changes on
stakeholders in the pharmaceutical industry, by exploring the question "Will the new
legislation benefit stakeholders?" The study aims to evaluate the South African
pharmaceutical industry and consider the impact of the amendments to existing
legislation, on stakeholders, specifically with regard to the banning of sampling, the
use of generic medication and the removal of incentives. Finally, a Marketing Code
for the pharmaceutical industry will be compiled.
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1.10 METHODOLOGY
Secondary data will be used to acquire information about all the stakeholders in the
pharmaceutical industry in South Africa. Induction will also be used, as
generalizations will be made from specific observations to draw conclusions ( Babbie
1998:66).
1.10.1 Design Type
This study is exploratory in nature as an attempt will be made to understand the
impact of legislative changes on stakeholders. It is explanatory as it will try to explain
the forces that led to the legislative changes and the reason for the selection of the
factors listed in the amendments. The objective of the exploration will be to expand
our understanding of the impact of these amendments on stakeholders. One key to this
understanding would be to look at the way that other countries have addressed the
need for the regulation of the marketing activities of pharmaceutical companies.
These lessons learned from other countries with respect to a Marketing Code can be
incorporated in the design and implementation of such a code in SA.
The methodology to be adopted is one of qualitative comparison. No attempt will be
made to quantify benefits, costs or risks, as the objective is to uncover and understand
information regarding changes in legislation and its impact on stakeholders. This
method is validated by Ghauri, Gronhaug and Kristianslung (1995:85) in their
statement that "It is generally accepted that for inductive and explorative research,
qualitative methods are most useful, as they lead to hypothesis building and
explanations".
The case study methodology will be implemented, as it allows for the study of the
impact oflegislative changes on stakeholders. This method is supported by Leedy and
Ormrod (2001: 157) who suggest that a case study methodology is applicable in poorly
understood situations where the explicit purpose is to explore in greater depth the
issues. The validity of this method is confirmed by Yin (I Chetty, 1996:73) who
defines a case study as an "empirical enquiry that: investigates a contemporary
phenomenon within its real life context; when the boundaries between phenomenon
and context are not clearly evident; and in which multiple sources of evidence are
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used". Chetty (1996:73) also states that case studies are appropriate for explanatory
and exploratory research.
1.10.2 Data Collection and Sources
Patton (1999) suggests that the use of varied methods and sources of data collection
increases the reliability and validity of a study. Sources of data for a case study
methodology can include amongst others: interviews, textbooks, journal articles and
Internet web sites (Leedy and Ormrod, 2001:157).
The data collection for this study included: semi-structured interviews with five
psychiatrists from the KZN branch of SASOP (Drs V Agambaram, K Domingo, C
Maud, J Krystofiak and Dr P Miseer); informal discussions with members of the
National Executive Committee of SASOP (Dr Eugene Allers - President of SASOP
based in Pretoria, Professor Margaret Nair- Editor of Headline, Dr Mohamed
Salduker- Public Relations Officer);informal discussions with PPSA directors (Dr
Franco Colin, based in Gauteng and Dr Francois Daubenton, based in Cape Town)
unstructured interviews with representatives of pharmaceutical companies involved in
the antidepressant market (Anne Bennet - Pfizer SA, Nicole Wortmann - Lilly SA
and Cheryl Prior- Lundbeck SA) and unstructured telephonic interviews with product
and sales managers of pharmaceutical companies involved in the antidepressant
market (Akbar Wallele, based in Gauteng - Pfizer SA, Elaine Milne, based III
Gauteng- Lundbeck SA) and informal discussions with Ben Christen, based III
Gauteng - Managing Director, Lundbeck SA and Dr Frans Korb, based in Vienna, -
Medical Director, LiIIy SA, CNS Product Division. Journal and Internet articles,
textbooks, brochures relevant to the subject matter were also analyzed. The data was
collected and analyzed concurrently and was examined, compared and used for
analysis.
1.11 EVALUATION OF THE STUDY
Internal validity, external validity, reliability and objectivity are criteria that can be
used to evaluate qualitative research. Internal validity considers the degree to which a
study correctly assesses the phenomenon and external validity is the degree to which
the findings can be generalized. The degree to which findings are considered free
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from bias, assists in a study's objectivity. Multiple data sources and methods
providing corroborating evidence, increases internal validity and credibility
(Devers:1999), which is also increased by subject review. The researcher will adopt a
clear data analysis process to increase dependability and reliability and triangulation
and sceptical peer review to increase conformability and objectivity.
1.11.1 Credibility
Credibility is determined by three elements (Patton: 1999). These include:
• Credibility of the researcher, which is reliant on the experience and status of
the researcher
• The responsiveness of the researcher to the data and the capacity for
impartiality. Corroborating evidence from a variety of sources will reduce the
researcher's bias in this study.
• The validity, reliability and transferability of data is important, so techniques
and methods to ensure a high quality of data, will be used.
1.11.2 Validity
The validity of findings can be supported by triangulation of multiple data sources in
search ofa common theme (Leedy and Ormrod, 2001:106). A detailed description of
the context of the observations will be made to increase the external validity of
findings.
1.11.3 Reliability
Reliability is the degree to which findings can be replicated. Consistency of results is
fundamental to determining reliability in a study (Babbie, 1998:129), therefore the
researcher will ensure completeness and accuracy of interviews and observations.
Sceptical peer review will be used to increase dependability and reliability.
Triangulation will be used in this study to increase the reliability of findings
(patton: 1999).
1.11.4 Transferability
According to Devers (1999), the similarity of contexts is central to the transferability
of findings. In this study, there will be a clear description of the study context and the
investigator's role so that transferability is feasible.
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1.11.5 Triangulation
Qualitative research is enhanced by triangulation as "multiple methods of data
collection and analysis provide more grist for the research mill" (patton: 1999) and is
useful to understand differences in findings as it considers reasonable explanations for
differences. The reliability of findings is dependent on the consistency of the results,
which triangulation will facilitate.
Source triangulation is the examination of the consistency of different data sources by
comparing and cross-checking the consistency of information collected at different
times and by different means within qualitative methods. Observational data will be
compared to interview data and different perspectives of different points of view will
be considered for consistency over a time period. Multiple sources or perspectives to
interpret the same data, is used in perspective triangulation, the objective of which is
to determine how findings are affected by different assumptions. In this study source
triangulation and perspective triangulation will be used to determine the consistency
of results.
1.12 LIMITATIONS OF THE STUDY
The following factors were considered as limitations of this study:
• The pharmaceutical sector and its interaction with its customer base IS a
dynamic situation, so it was not possible to analyze all aspects.
• The study was done only amongst stakeholders in the antidepressant market
An assumption was made that the findings represents a fair reflection of the
issues in the industry as a whole.
• Selectivity in the sampling of people for interviews and selectivity III
document sampling may have occurred.
• Due to time constraints, relevant information about the changes that were
occurring may have been ignored in the short time period of sampling.
• The case study analysis has focused mainly on three of the stakeholders, the
pharmaceutical companies, service providers and government in its strategic
analysis, due to the vastness of the analysis that would have been required,
should all stakeholders have been evaluated.
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1.13 CONCLUSION
Chapter One has provided an overview of the issues relevant to the legislative
changes in the Medicines and Related Substances Amendment Act. It has also
identified all stakeholders in the industry. Government's role in legislation has been
highlighted and the impact on pharmaceutical companies and psychiatrists in private
practice considered. The research objectives and methodology, including limitations
to the study were also described. Chapter Two focuses on strategic theory and
undertakes a strategic analysis of the pharmaceutical industry, with a focus on three
stakeholders, the SA government, pharmaceutical companies in the antidepressant
market and psychiatrists in private practice.
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CHAPTER TWO: STRATEGIC THEORY AND STRATEGIC ANALYSIS
2.1 INTRODUCTION
This chapter outlines the strategic theory that fonned the framework for the analysis
in this case study. The principles of strategic theory will be described, including
details of the environmental analysis and strategic tools used in the analytic process.
The chapter ends with a focus on the analysis of strategic change within the
pharmaceutical industry. Even though, there are several stakeholders in the industry,
the strategic analysis was weighted in favour of the pharmaceutical companies for the
purpose of this case study. Brief comment is also made with regard to the role of
government and the service providers. This was done due to the vastness of the
subject matter, time constraints and for the purposes of clarity in the strategic analytic
process.
Before the present decade, the pharmaceutical industry generated attractive returns by
investing heavily in the discovery and development of new drugs and by vigorous
sales to a growing market of medical professionals. Patent protection decreased the
level of price competition and health insurance made consumers relatively insensitive
to price. Brands were chosen almost entirely at the discretion of practitioners, whose
preferences were greatly influenced by the marketing activities and sales coverage of
drug companies.
In the 1990's the emergence of managed health care in the global pharmaceutical
arena, threatened to 'end the party'. The managed care model bypassed the
independence of the service provider by creating a process whereby services were
rendered in return for a fixed fee via companies that contracted directly with
employees. This business model had to change in the US, when pharmacy benefits-
management companies, which helped large corporations manage the cost of their
pharmacy benefits programs, began to swing the choice of products from branded
products to low cost alternatives, in exchange for incentives. These companies
proceeded to capture part of the profits of the industry and the managed-care model
did not manage to alleviate the burden on medical insurance companies and
consumers.
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There was also a serious threat to the ethical practice of medicine as the managed care
model worked via a system authorisation for services by case workers, who were
clerks with no medical training. This compromised patient care as doctors were
allowed limited treatment options but were still held accountable for the outcome.
This day has now arrived at the door of the pharmaceutical industry in the developing
world as managed care companies looked for new markets as the concept had flopped
miserably in the US market. SA was infiltrated in the late 90's after the process of
democratic change, when the country was in a state of flux. Service providers and
pharmaceutical companies have battled to keep pace with the changing face of
medical practice in South Africa. Management of strategic change is now vital for the
pharmaceutical industry in this country, which has largely been reactive to the
process, as a survival measure. For growth to occur in the industry, a proactive
strategic approach needs to develop amongst all major role players.
Another major challenge facing pharmaceutical companies worldwide is that patents
only last for 20 years. After patenting new products it can take a decade or longer for
appropriate testing and trials to be conducted before the product gains FDA approval
and is ready for marketing. The process of discovering, testing and developing a new
drug is complex, costly and time-consuming. Pharmaceutical companies spend a huge
proportion of their turnover on research and development, as the race to develop and
patent new products
In order to analyze the trends within the SA pharmaceutical industry, SA companies
with a presence in the antidepressant market, Lilly SA and competitors, Pfizer SA and
Lundbeck SA, will primarily be used as examples. To facilitate the discussion, a brief
background to the companies is useful.
2.1.1 Pharmaceutical companies in the antidepressant market
Lilly (SA) is a pharmaceutical company that is a subsidiary of Eli Lilly, a global
player in the industry. Headquartered in Indianapolis, Indiana, USA, since 1876, Lilly
has a portfolio of best-in-class pharmaceutical products for depression, psychosis,
cancer, osteoporosis and diabetes products. Eli Lilly products have been available in
South Africa since 1937 initially through Johnson & Johnson, who were appointed
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sole distributors of Lilly products. In 1963 a plant was built to manufacture Lilly
products locally. The South Mrican manufacturing operations were closed in 1998 as
a result of a global review of manufacturing capacity and production costs and from
then on the company's research and development (R & D) has been coordinated
from Indianapolis. A large percentage of Lilly' s global clinical research is still carried
out in South Mrica (Internet 16).
Lilly SA is divided between South Africa and sub-Saharan Africa, the latter operating
out of Kenya and reporting to the South African office. Lilly SA's accounts are
consolidated with those of head office. Lilly SA turns over approximately R280
million per year. The parent company turned over $11.5 billion in 2001. Lilly South
Africa spen~s approximately R120 million per annum locally in research and
development through clinical trials. In addition to Prozac, top sellers to date include
Zyprexa, Evista, Gemzar and Lorabid (Internet 16).
Prozac has been Lilly' s best selling product for a number ofyears. Like the rest of the
pharmaceutical industry, Lilly SA faces challenges of products coming off patent.
Prozac lost patent protection in the United States this past year. The company is now
tasked with ensuring that it maintains turnover and business, in spite of losing its
biggest revenue generator ever. Not many pharmaceutical companies would have
survived losing a blockbuster like Prozac. However, Lilly's new product pipeline is
one of the richest in the pharmaceutical industry, with a number of potential
blockbuster products to be released in the next seven to eight years. The challenge for
Lilly South Africa has been to provide healthcare to a shrinking private sector and an
emerging middle class market (Internet 16).
The US-based Lilly Foundation has been extended to South Mrica. The Foundation's
premise is that the cure for many diseases centers around education. The Foundation
also provides education bursaries and access to free TB medication around the world.
One of the first projects they have concentrated on in South Africa is diabetes
education (Internet 16).
Pfizer South Africa is a subsidiary of the world market leader in pharmaceuticals,
Pfizer Laboratories. Its' latest merger with Pharmacia made it the first in every major
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world market. The Pfizer brand now represents more than 120,000 men and women.
The company has the world's largest privately funded biomedical research group,
visible around the world, investing more than $100 million every week discovering
and developing high-value medicines. Tiger Brands' subsidiary Adcock Ingram
acquired the Parke-Med generic business from Pfizer South Mrica this year. The sale
includes registrations and trademarks for a number of generic pharmaceuticals
(Internet 17).
Pfizer and the South African Ministry of Health have worked very hard together to
initiate the Diflucan Partnership Programme. Pfizer expects to contribute more than
R375 million ($50 million) of Diflucan over the course of the programme. Pfizer is
also committed to initiating discussions with other members of South African
Development Community (SADC) with a view to the possible expansion of the
programme within the SADC region. Pfizer has been very active and a dedicated
contributor to developmental initiatives and health care in South Mrica and
throughout the world. As a founding member of Medical Education for South African
Blacks (MESAB), the company provided the organization's first grant as well as
ongoing financial support over the past 15 years. Pfizer also works with the
Programme for Technological Careers (PROTEC) to improve mathematics and
science education and teacher training in disadvantaged community high schools
(Internet 17).
Lundbeck's South African headquarters are located in Randburg, Lundbeck South
Africa has around 40 employees, of which half work at the headquarters while the
other half are sales staff located throughout the country. Ten years after Lundbeck set
up shop in South Africa in 1984, it launched Cipramil®, which has now led the
antidepressant market in South Africa since 1997 (Internet 18).
2.1.2 Definitions of Strategy
Strategy is concerned with the long-term direction and development of an entity and
is influenced by the values and expectations of all stakeholders. Strategic decisions
are made at a number of levels in any industry and are about a search for strategic
'fit', in which ways could be found to match the activities within companies, to an
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external environment. This concept is well illustrated in Andrew's strategy model
depicted in Figure 2.1.
Figure 2.1: AndreM Strategy MxEI
m.Ol.Ol StnEgi 2, 2001 w...
Source: Internet 9
The model depicts four components of strategy:
• Market opportunity which involves the identification of opportunities and
assessment of risk
• Corporate competence and resources, the assessment of a company's capacity
to capitalize on opportunities and manage risk
• Personal values and aspirations that influence the choices of executives
• Stakeholder responsibility which incorporates the consideration of all
stakeholders in strategic decisions
Strategy can thus achieve advantages through its configuration of resources within a
changing environment, to meet the needs of a market and fulfil stakeholder
expectations. It may be viewed as a perspective that is shared by individuals united by
common thinking or behaviour that attempts to match organizational strengths and
weaknesses of companies and the environmental opportunities and threats (Johnson
and Scholes, 1999: 10).
It has been suggested that it is imperative to understand the turbulence in respective
environments in order to select a model for the development of strategic direction. In
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fact, Stacey (1993) advocated the creation of a climate of chaos, where existing
perceptions are challenged so that there can emerge innovative strategic direction.
2.1.3 Strategic Management
The strategic management process is one where a strategic vision is formed and
objectives are set, before crafting, implementing and executing occurs. Corrective
adjustments in the vision, objectives and strategy are then initiated over time
(Thompson and Strickland, 2001). Strategic management has three elements: strategic
analysis, strategic choice and strategic implementation. Strategic analysis is the
process of trying to understand the strategic position of a company in terms of its
external environment, internal resources and competences and the expectations and
influences of stakeholders. Strategic choice involves understanding the underlying
bases guiding future strategy and is a process whereby strategic options are generated
for evaluation and selection. Strategic implementation is concerned with the
translation of strategy into activity through structure and design, resource planning
and the management of strategic change (Internet 9).
These three main components are depicted in Figure 2.2 and Figure 2.3 summarises
all the elements ofthe process of strategic management.
Figure 2.2 : Components of the Strategic Management Process
Source: Internet 9
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Figure 2.3: A summary model of the elements of strategic management
Source: Johnson, G and Scboles, K (1984)
Different contexts thus have relevance for the process of strategic management. An
environment-led 'fit' strategic management process achieves competitive advantage
by 'correct' positioning and product differentiation that is directed by market need
and risk reduction through specific portfolio establishment (Internet 9). For instance,
small businesses are likely to operate in a single market, with a limited range of
products and services whereas multinational corporations (MNC's) face key strategic
issues that are substantially different. MNC's usually operate with diversity in terms
of products and geographical markets. An option available to MNC's because of their
capacity is to opt for resource-led 'stretch' where, the 'rules of the game' are changed
by the MNC and differentiation is based on competences suited to creating market
need (Johnson & Scholes: 1999).
2.1.4 Strategic Planning
Lynch (2000:780), considered strategic planning an essential process for growth of
any industry even though it may not always be feasible, especially in situations where
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there is too much bureaucracy and rigidity, poor directional behaviour from
management and political difficulties (Lynch, 2000: 782). This process usually
focuses on attempting to fill the gap between reality and the company's vision.
FIGURE 2.4: GAP ANALYSIS
Source: Internet 9
Gap analysis, illustrated in Figure 2.4 above, is an important part of the process of
setting strategic direction. It considers where an organisation is going versus where
they'd rather be and is a useful strategic tool as there is usually a gap between the two
points. Analyzing this gap, and developing measurable, time-bounded plans to fill it
forms the basis of strategic planning. This process assists in the definition of strategic
alternatives and creates the basis for strategic implementation. As environments
become more unpredictable, the need for innovation, flexibility and diversity in an
industry does increase.
When one considers the pharmaceutical industry in South Africa, there is a significant
difference between the current market and that which existed five years ago. There are
positive and negative aspects to this. The shift to a democratic government increased
the pool of the population that constitute the private sector. Hence, the size of the
potential market for pharmaceutical companies has increased substantially. At the
same time, there have been widespread policy shifts that have directly targeted profit
margins and the way the companies do business. This has impacted on the costs of
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achieving the same market share. Most of the subsidiaries of international companies
are faced with the reality that for them to achieve their goal to satisfy shareholder
expectations, strategic planning is imperative. Several measures in the short-term to
reduce the gap between where companies find themselves now and where they would
like to be, can be taken. These include rationalisation of staff, re-allocation of
budgets, divesting of certain products in the portfolio and development of others in
line with the market, investments in social responsibility programs, and collaboration
within the industry.
2.2 ENVIRONMENTAL ANALYSIS
Environment encompasses every aspect external to an organization: not only the
economic and political circumstances but competitors, customers and suppliers, who
vary in being aggressive to a greater or lesser degree (Lynch 2000:9). Environmental
analysis is a process whereby opportunities and threats in the environment are
identified to influence strategic direction and to develop processes whereby
sustainable competitive advantage may be maintained (Lynch, 2000: 107). Where the
environment is increasingly uncertain and central control remains possible, a more
incremental approach to strategy development is usually the sensible route (Internet
9). There is no doubt that the industry is in a state of flux with drastic policy changes,
increasing production costs, due to a world-side economic recession and increasing
pressure from the World Bank and the World Health Organisation (WHO) to address
the imbalances in health care delivery globally.
The marketing environment surrounds and impacts upon the organization. There are
three key perspectives on the marketing environment, namely the 'macro-
environment,' the 'micro-environment' and the 'internal environment' as depicted in
Figure 2.5.
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This environment influences the organization directly. It includes suppliers that deal
directly or indirectly, consumers and customers, and other local stakeholders. Micro
tends to suggest small, but this can be misleading. In this context, micro describes the
relationship between firms and the driving forces that control this relationship. It is a
more local relationship, and companies exercise a degree of influence.
2.2.1 The macro-environment
This includes all factors that can influence and organization, but that are out of their
direct control. A company does not generally influence any laws, although it is
accepted that they could lobby or be part of a trade organization. It is continuously
changing, and the company needs to be flexible to adapt. There may be aggressive
competition and rivalry in a market. Globalization means that there is always the
threat of substitute products and new entrants. The wider environment is also ever
changing, and the marketer needs to compensate for changes in culture, politics,
economics and technology (Internet 15).
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2.2.3 Assessing the nature of the environment
Evaluating the nature of an environment is a useful way of providing an initial view
of the influences within an environment. Historical analysis and forecasting are
usually sufficient in static conditions whereas scenario planning is more useful in
more dynamic conditions (Johnson and Scholes, 1999:141).
2.2.3.1 Assessing the dynamics of the environment
Table 2.1: Analyzing environmental turbulence
Environmental N.cflt'lI//\·c r \/lillld/lIg ('hill/glllg j )/\COI7lI11ll0//\ .\//rj)f"/\//7g
Turbulence
A.Complexity National National Regional Regional Global
Techno- Socio-
logical political
B.Familiarity Familiar Extrapolable Discontinous Discontinous
o/events
C.Rapidity Slower Comparable Faster
o/change than to than
response response response
D.Visibility Recurring Forecastable Predictable Partially Unpredictable
o/future predicatable surpnses
Turbulence I 2 3 4 5
Level Low High
Source: Modified from Lynch (2000:108)
When considering the strategic environment, attention needs to be directed to the
nature and strength of the forces driving strategic change i.e. the dynamics of the
environment which are depicted in Table 2.1. The nature of the environment
influences the way an organization is structured to cope with such changes and can be
assessed using two main measures:
•
•
Changeability - the degree to which the environment is likely to change. In
the table, A+B = changeability. Changeability comprises complexity, the
degree to which the environment is affected by social and political
complications and novelty, the degree to which new situations are presented.
Predictability - the degree with which changes can be predicted. In the table,
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C + D = predictability which has two components: rate of change of the
environment and visibility of the future in terms of availability and usefulness
of the information used to predict the future.
It is possible then to build a spectrum that categorizes the environment and provides a
rating for its degree of turbulence as seen in the above table. When turbulence is low,
it is possible to predict the future with certainty. When one considers the SA situation,
the pharmaceutical industry has been functioning since 1997 in a fairly turbulent
environment, where there was a lot of 'political speak' about the coming changes and
constant negotiations around political agendas. This legislation has featured
prominently in the international press which has not assisted the stability of the local
industry. Employees within the industry like medical representatives have had to live
with uncertainty also in the wake of mergers and acquisitions, which were taking
place with parent companies in the international arena. Now that the legislation has
been gazetted, there is almost a sense of relief that the waiting is over. There is
acknowledgement that the rules have changed, even though acceptance ofthe changes
is still filtering through the system. The future still remains uncertain as the rate
change has been unpredictable and the nature of change extremely complex.
2.2.3.2 Scenario-based analysis
A scenario is a model of a possible future environment, created for the purpose of
investigating the strategic implication of future situations. A scenario-based analysis
is not about predicting the future but about taking different situations with alternative
starting points and exploring a set of possibilities. A combination of events is gathered
together into a scenario and the combination is explored for strategic significance.
The starting point is normally an unusual viewpoint, from which a qualitative
description of a group of possible events is developed or a narrative listed that shows
how events unfold. The outcomes are then explored building two scenarios that can be
differentiated into 'most optimistic' and 'worst-case scenario'. The uncertainty is
included as a variable and consequences are explored. Scenario planning is useful if it
leads to new strategic thinking.
When one considers the situation that drug companies in South Africa find themselves
in, this is possible a good place to start for the company that plans to stay and sit out
the changing market. It is evident that there is no precedent for the rapidity of the
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changes that occurred in SA and the relatively unilateral way in which decisions were
made. There was also a sense of disbelief when the giant pharmaceuticals withdrew
their court action against the government as many in the industry in SA had believed
that this was not a case the industry could have lost. The way forward is for
companies to construct the best and worst possible scenarios for their management
teams in workshops so that innovative strategic planning can occur in the immediate
future.
2.2.3.3 Analyzing environmental uncertainty
Figure 2.6 Coping with different levels of environmental uncertainty
Reasonably predictable,
barring catastrophe
Source: Modified from Lynch (2000: 897)
Pharmaceutical companies have had to face an uncertain environment since 1997. The
reality is that there are more than one ways to respond to a situation of rapid change.
As is depicted in Figure 2.6, if the environment is predictable, the dynamics of the
environment can be managed more easily. If the environmental uncertainty is totally
unpredictable, there are several possibilities of how to react. Often no clear way ahead
can be seen as the possible outcomes are too many. Even if drug companies
understood the nature of the change, they may still not be able to act on it. Some of
the reasons for this may include: a distorted perception of change and the
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environment, failed creative responses from its management team, political deadlocks
with government over key issues and dulled motivation from staff who have been
kept in a state of limbo for too long.
2.2.3.4 Analyzing the Co-operative environment
There are several key role players in the SA pharmaceutical industry. Despite the
uncertainty, there are positive aspects that are core issues in the environment. As well
as competing with rivals, companies could embark on a course of co-operation with
the other stakeholders. Four possibilities of co-operation exist as seen in Figure 2.7:







Source: Modified from Lynch (2000 : 133)
The objective of this analysis is to establish the strength and nature of the co-
operation that exists between a drug company and its environment. Informal co-
operative links and networks occur when companies link together for a mutual or
common purpose, and there is no legally binding contractual relationship. In this case,
it is the strengths or weaknesses of the relationship that matters. For Lilly, Pfizer and
Lundbeck, as some of the major players in the industry with similar product
portfolios, the collaborative route has a lot of plus factors, as the combined strength
would have greater influence with government and the medical aid industry.
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Formal co-operative linkages can occur in the form of alliances and joint
shareholdings, marketing agreements and joint ventures. The strengths and
weaknesses of such linkages are assessed in terms of their depth, longevity and degree
of mutual trust. There have been several such mergers and acquisitions of parent
companies and there are joint marketing agreements between companies, especially
where there is a perceived lack of expertise.
Complementors are those companies whose products add more value to the products
of other companies than they would derive from holding their own products in a
product portfolio themselves. In South Africa, with our restricted branded product
range, such a situation does not exist. Finally, government links and networks are vital
to the process of advancement of the interests of drug companies. There are huge tax
and legal matters that government has direct influence over. Some drug companies
have cultivated this relationship through lobbying the combined interests of the
industry and the consumer. A lot of the collaboration occurs behind the scenes
however, in deals struck between governments of host countries as part of political
relationships.
2.2.4 Auditing Environmental Influences
Environmental forces vary over time and there must be an awareness of their
changing impact. Two common tools, namely the PEST analysis and Porter's
Diamond are used for auditing environmental influences.
2.2.4.1 Political, Economic, Social, Technological (PEST) Analysis
Appendix Two illustrates some of the factors that are relevant when doing a PEST
analysis. Factors that influence an industry should be prioritized as an unlimited
number of factors can impact upon strategy. In climates where there is rapid change
or a period of uncertainty, forecasting of future trends with an acceptable level of
accuracy to impact on strategic direction is not always feasible. Scenario planning
techniques, which deal with high levels of uncertainty in important macro-
environmental variables, may sometimes be a more relevant option.
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In the present context that the industry finds itself in, a PEST analysis reveals that
there is political interference in the industry world-wide, in the form of policy
changes, regional agreements, challenges to existing trade agreements, trade-ofTs
between governments for political agendas and very real threats to intellectual
property rights. With increasing political stability in some areas of the developing
world, focus is now shifting to service delivery and there is an expectation that is
being created that MNC's will come to the party. There is a sentiment world-wide that
suggests that the major companies have been profit-driven at the expense of ethical
business practice and there are increasing calls to reduce costs of branded products.
This could seriously impact on the future development of the industry and the
development of the 'product pipeline', which is essential for any company's survival
in this sector.
The technological advances that have been possible, with new product development
and time-to-market once a viable molecular product is discovered have astounded
other industries. This is now under threat and even collaboration attempts between
MNC's and private-public sector partnerships have not managed to stem the tide of
anti-drug company sentiment that threatens R& D facilities internationally. The
biggest factor influencing the drug prices of branded products is the single exit price
policy of most companies. With fluctuating exchange rates internationally, in the face
of a strong dollar and pound, there has been little room to manouver for actuaries in
determining international prices. If the policy is changed, it is possible then for
consumers in the host country to demand the right to have the medication at the same
price that it is made available internationally, which would drive the prices down
anyway. Lower prices equal lower profits equal lower R& D expenditure and
investment in social responsibility programs.
2.2.4.2 Porter's Diamond
Porter's Diamond is a model that allows the analysis of competitiveness in a nation. It
suggests that there are inherent reasons why some industries within nations are more
competitive than others. Specific factor conditions help in the explanation of the basis
of advantage at a national level. This can on to yield more advanced factors of
competition. In the case of the pharmaceutical industry, for instance, where legislative
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changes encourage the use of generic alternatives, there should be a greater impetus
towards investing in that sector of the industry. Porter's Diamond is illustrated in
Figure 2.8.












It is very important in any industry that globalisation drivers are identified. In
pharmaceutical markets, market convergence is often a low driver as there can be a
wide variation in brand names used for products in different countries especially in
over-the-counter (OTC) medications. Differences also exist between markets for
ethical (prescription) pharmaceuticals. This is because medical treatment plans and
programs differ across the world. Cost advantages in South Africa are not always
easily attainable, as the marketing budgets of most role players are geared for national
brand names, leaving little scope for global economies of scale in the OTC market.
Governments are also adopting policies of cost containment in health care, especially
in the ethical market. Although this factor and the harmonisation of clinical standards
has facilitated a globalised approach, in South Africa, other factors also impact on this
arena. There are legislative standards for instance with OTC and ethical
pharmaceuticals, like the maximum allowed dosage, that vary greatly from country to
country. This incompatibility means that there is little scope for globalisation. There is
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competitive pressure on MNC's in the pharmaceutical sector to develop globally but
because of differences in legislation governing the use of pharmaceuticals,
competition is sometimes better at the local than global level.
According to Porter the domestic rivalry and the search for competitive advantage
within a nation can help provide organizations with bases for achieving advantage on
a more global scale. At a national level, Porter's Diamond can be employed by
government to consider the policies that they should follow to encourage the
competitive advantage of their industry. Domestic characteristics of competition yield
advantages on a wider basis, therefore governments should encourage competition at
home rather than be protective regarding overseas competition. Governments can also
act to foster advantage by ensuring high expectations of product performance, safety
or environmental standards and encouraging vertical co-operation between suppliers
and buyers on a domestic level.
2.2.4.3 Analyzing Stakeholder Reactions
The importance of understanding the political context for strategic change cannot be
emphasised enough. Stakeholder mapping is a way of analysing and prioritising the
'political agenda' for an organisation and is a valuable tool in assessing the likely
reactions of stakeholders to new strategies and the company's ability to manage these
reactions. The key issue with regard to stakeholders is that the company needs to take
them into consideration when formulating objectives. The company needs to address
which stakeholders have priority by analyzing stakeholder. This involves:
• Identifying major stakeholders
• Establishing their interests and claims on the company, especially as new
strategies develop
• Determining the degree of power each group holds through its ability to force
or influence change as new strategies are developed
• Developing objectives and strategy, prioritized to minimize power clashes
between stakeholders
• Diverting trouble before it starts, possibly by negotiating with key groups
• Identifying the sanctions available and applying them to ensure that either the
company's purpose is met or a compromise is reached
Table 2.2 considers stakeholders and their expectations.
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Table 2.2: Stakeholders and their expectations
STAKEIIOLDER EXPECTATIONS
PRIMARY SECONDARY
Owners Financial return Added value
'~I- I-~
Employees Salaries and wages Work satisfaction
Customers Supply ofproducts Quality






Game theory, which is an approach to decision analysis, is one way of dealing with
stakeholder issues and how they impact on a company. This theory assumes that
groups are likely to react to the moves each other makes. It helps analyze dynamic
and sequential decisions at the tactical level. The present stand-off between
government and the industry is an ideal situation in principle where game theory can
be utilized. Key applicable areas that could be explored with this strategy include:
• New product introduction - At present government's policy at the MCC is
that generic drugs at preference for registration purposes and patent drugs
are on a waiting list that is delaying product launches in this country by up to
2 years after launches internationally.
• Licensing versus production - Government desires to see FDI and prefers
that drug companies invest in manufacturing infrastructure rather than
benefit from licensing opportunities in this country with reduced
commitment.
• Pricing - this area has been characterised by tactical moves by both parties.
Government feels that drug companies' prices are too high and out of range
ofthe majority of consumers in this country. The drug companies feel that as
originators, they have the right to determine a fair market price, without
government intervention
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• R & D - drug companies are investing in R& D facilities internationally but
are using SA patients as subjects. Government has raised concerns that this
represents an exploitation of developing countries
• Advertising- government has embarked on a legislative course to tackle this
area but the reality is that advertising is essential to market growth and there
is no reason why ethical advertising cannot be permitted as part of consumer
education initiatives
• Regulation- this is clear as government is attempting to regulate the industry
and the industry is investing time and energy in attempting to find ways
around the restrictions to service its customer base
Successful strategy therefore does not just depend on a firm's position in the industry,
its capabilities or what have you. It also depends on how others react to your moves
and how others think you will react to theirs. By fully understanding this dynamic
with government, the industry will find win-win strategies that will have a better
outcome in the long-term.
2.2.5 Industry Life Cycle
According to Porter in (Lynch, 2000: 112), there are four evolutionary phases of
growth in an industry: introduction, growth, maturity and decline as depicted in
Figure 2.9. In the development of strategy, two consequences of the industry cycle
have a significant impact on industries. One is the advantage of early entry. There is
substantial empirical evidence that the first company into a market has the most
substantial strategic advantage. The second reality is that fragmentation occurs as a
market matures. The cyclicality of a market is also relevant as it has a definite impact
on market demand. Economic or political cyclical conditions over which companies
have little control are a reality. For instance a decline in an economy can influence
cyclicality. In mature markets, as is expected, demand for a product usually slows
down, except where a product wears out, and there is replacement demand. When the
economy is low, purchases can be temporarily delayed thereby reducing demand.
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Figure 2.9: Industry Lifecycle Model
Source: Internet 11
Table 2.3: Lifecycle Model
Q
Introduction Growth Shakeout Maturity Decline
Users/Buyers Few: trial of Growing Growing Saturation of Drop-off in
early Adopters: trial selectivity users usage




Competitive Entry of May be Fight to Exit of
Conditions competitors many maintain some
competitors share competitors
Attempt to Likely price Difficulties in Selective
achieve trial cutting for taking or Distribution
volume gaining
share





Source: Johnson and Scholes, 1999
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Table 2.2 illustrates buyer behaviour and competitive conditions for the varIOUS
lifecycle stages, which is significant in understanding the competitive behaviour of
role players in a market (Johnson and Scholes, 1999:121). The global pharmaceutical
industry for ethical and generic medication is still in a growth phase. There is
consistent fight for market share in developed markets. Barriers to entry in developing
markets is low, therefore the market remains fiercely competitive. There is also
increasing demand for new product development, especially in the developed world.
2.2.6 Analyzing the role of government
At government policy level, politics and economics are linked. Governments can
stimulate national economies, encourage new research projects, impose new taxes and
introduce new strategies. A political choice by government can result in one of two
approaches, a free market approach (Laissez faire) or centrally directed approach
(Dirigiste approach).
In South Africa, in the pharmaceutical industry, there is a free market approach which
is characterized by:
• Low entry barriers
• Encouragement of competition
• Little state support for industry
• Opportunities for wealth creation
• A belief in the laws of supply and demand
• High unemployment levels
• Production and quality standards being driven by profit motivation
The SA government does exercise direct control over the economy of the country. It
is easier for drug companies to launch a growth or survival strategy when the national
economy is showing steady growth with low inflation and when the international
economy is not in a recessive pattern. Macroeconomic conditions in SA have started
to shift towards a more positive climate, with a fall in interest rates and inflation and a
favourable rand/dollar exchange. It is important as part of the strategic analysis
process to consider macroeconomic forecasts as a predictive tool in their assessment.
Key macroeconomic issues that are relevant to the pharmaceutical industry would be:
• Gross domestic product (GDP), total and per head of the population
• Growth in GDP
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• Retain and consumer price indices
• Trade flows in imports, exports and the balance of payments
• Private sector share ofGDP
• Foreign direct investment (FDI), total and as a percentage of total investment
In South Africa, the fluctuation of the rand/dollar and rand/pound exchange is also an
important variable.
2.2.7 Analyzing government and industry relations
In addition to changes in macroeconomic conditions, drug companies have to be
concerned with government changes in the economic environment specific to their
industry. These include:
• Changes in government policy on the purchase of drugs: The State is the
biggest customer base of drug companies in this country and a shift in policy
to only supply generic substitutes of originator drugs at State hospital are
reducing the profitability of the major pharmaceutical companies. Companies
have to decide whether they move their focus to non-government sales in and
outside this country or whether they engage government in a consultative
process to compromise on the situation
• Cyclicality of demand: The State as an employer for the Public Service has a
direct influence on the ceiling limits for medication benefits available. These
limits on benefits usually for the lower to middle income consumer
inadvertently create a cycle of demand, when benefits become exhausted,
usually in the fourth quarter of every year.
• Industry negotiations on conditions of work: The SA government has
introduced policy with regard to employment equity that directly impacts on
the employment of expatriates in the drug companies, who are subsidiaries of
MNC's.
• The fluctuating exchange rate has an implication for the cost of drugs in the
SA market. Most MNC's in the pharmaceutical industry have a single exit
price policy and when, there is an unfavourable exchange rate, products
become unaffordable in this country and the marketing of these products
becomes an impossible task, as cost is always raised by the service provider,
as the limiting factor.
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• Government's policy of actively supporting FDI's in this country is a positive
one. However, there is a concern about pressure upon drug companies to open
manufacturing plants in this country.
2.2.8 Analyzing the intensity of competition in an industry
Governments set the basic degree of competitiveness that they wish to see in
industries. The degree of concentration of companies in a market is important as the
total number of companies in an industry influence their ability to exert buying power
over suppliers. The mix of companies making up the industry also impact on
profitability. If there are a few companies that are roughly equal in size, there may be
a tacit understanding between them to allow profits to grow. The concentration ratio
is used to measure the degree to which turnover is concentrated in the hands of a few
firms in an industry. In SA, in the antidepressant market, there are few major players
with big marketing budgets that are able to drive the market. However, the market
leader at present is Cipramil, a Lundbeck product that has achieved its position
through consistent relationship marketing with its consumer base.
2.2.9 Competitive Rivalry
Competition usually results In a dynamic environment. Forces which affect
competitive rivalry include the extent to which competitors are in balance.. There are
several pharmaceutical giants in SA in the antidepressant market and there is a danger
of intense competition as one competitor attempts to gain dominance. The growth
stage of the market is also relevant. The antidepressant market in SA is still at the
growth stage of the life cycle for the newer branded products but as the market
matures and reaches saturation, this might change.
Further, the world pharmaceutical market is in a state of flux with mergers and
acquisitions the order of the day. If the acquisition of weaker companies by stronger
companies results in the provision of funds to improve the competitive standing of
companies, their ability to compete in the hostile SA market effectively may be
enhanced. There are low exit barriers for the major players in this market as they have
an international presence. That is a factor of concern for the industry and for smaller
companies who would not be able to withstand the assault from parallel imports.
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Collaboration between the major players may be a more sensible route to achieving
advantage especially in specific sectors, like CNS products. Such collaboration could
begin with building barriers to entry to avoid substitution by generic drugs and
parallel imports. Collaboration may also be advantageous for purposes of developing
required infrastructure such as distribution channels, information systems or R & D
activities.
Of relevance to this sector is that internationally because of the rapid scientific and
technological change, high cost of R & D, high risk of failure and increasing buyer
power, it is not uncommon for there to be collaboration through a variety of different
alliances. Companies with brands in different markets like gastrointestinal and CNS
would be able to collaborate to strengthen their individual brands. Lilly, a minor
player in the gastrointestinal market could co-operate with launching a new product
under another company with a strong presence's brand, to displace smaller
competitors like Glaxo, in this market. The Human Genome Project is a classic
example of how collaboration between companies and academia allowed more
effective targeting ofR & D efforts.
The major role players in CNS products differ in terms of:
• Product and service diversity
• Extent ofgeographical coverage
• Number of market segments served
• Distribution channels used
• Marketing effort - advertising spread and size of sales force
• Product and service quality
• Technologicalleadership
• R & D Capability
• Cost position
• Pricing policy
• Relationship to influence groups
• Size of organisation
• Extent of vertical integration
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2.3 IDENTIFYING COMPETITIVE POSITION
One of the problems in analysing competition is that the boundaries of industries are
not always clear. Strategic group analysis considers the extent to which companies
differ in terms of various characteristics. One strategic tool available for this process
is that of market segmentation.
2.3.1 Market Segmentation
A key advantage for any company is the ability to dominate a sector of the market and
then target benefits that will sustain the position. The three stages of market
segmentation are:
• The identification of the market segments
• The evaluation of segments
• Positioning within a market segment
Of relevance to the pharmaceutical industry, markets can be segmented according to
the following strata in South Africa:
• Geographic: this has relevance specifically for rural versus urban areas
• Demographic: there are marked differences between the adolescent and
geriatric market, in terms of value and affordability.
• Socio-economic and income: this is of relevance in the private sector
especially for customer profiling.
• Ethnic group: there are significant differences amongst SA's ethnic
groupings of attitudes to medicines and medical diagnoses.
• Benefits sought: There are segments of the population that are extremely
health conscious who require safe drugs with minimal toxicity
• Usage rate and brand loyalty: Compliance and brand loyalty is probably a
feature of the female and young adult market respectively
• Attitudes: there is a big difference between the genders with regard to
attitudes to illness
For these factors to be taken seriously as segments, they have to be easily
distinguishable, of sufficient size and reachable as a target market by drug companies.
Certain segments would have more relevance than others for the marketing of
products especially in situations where higher prices are paid for better quality.
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An added advantage in a market that is so large is that a company's competitive
advantage may be stronger in a segment than in the broader market. Closer matching
of customer needs and the company's resources through targeting one segment can
enhance sustainable competitive advantage. The reverse is also true. Concentration of
marketing effort on smaller areas so that the company's resources are employed more
effectively, may give smaller companies the edge.
In a market segmentation analysis, similarities and differences between groups of
customers are identified (Johnson and Scholes, 1999:129). Relative market share is an
important consideration and there is definitely a relationship between market power
and performance. The pharmaceutical industry is a highly specialised sector, with
established market leaders globally that have facilitated market entry into new
developing markets and maintain a presence, even if market potential is a low
percentage of the global market. These conglomerates have used their market power
to secure the State health market in developing countries and have thus entrenched
themselves in every new market. This is not just because of scale benefits of size but
also because of 'experience curve' effects. The company that has built up most
experience in the CNS market would have lower costs but also stronger relationships,
hence having the edge in market share.
The following should be considered in the analysis of the industry's involvement in
the public (State) and private sector:
• Buyer behaviour or purchase value e.g the investment government makes
• The attractiveness of each market segment in terms of return on yield, future
growth prospects
• Relative market share in relation to competitors within market segments. This
is of importance in the CNS products market as there is stiff competition
amongst the leaders with little overall growth but changes in market share
from month to month
• Market segments should suit competences therefore, pharmaceutical
companies should consider their marketing budget allocation, if the State
sector pursues its course with generic versus branded products
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Porter and Ohmae (Lynch 2000), recommend that compames take the route of
exploring where there are gaps in the segments of an industry. The starting point of
any company wishing to sustain a competitive advantage is to map out the current
segmentation position and then place companies and their products, in an industry
into segments. It will become clear which segments are served or poorly served by
current products. Table 2.4, illustrates this using three antidepressants.
Table 2.4: New or underutilized segment gaps
Psych 1 Psych 2 Psych 3






The steps to analysing perceived value is as follows ( Johnson and Scholes, 1999: 133):
• Identifying relevant market segments within which customers and competitors
can be identified
• Defining the characteristic of the product or servIce most valued by the
customers. This is usually done by market research.
• The third step is to rate how important these dimensions are to customers.
Reputation and the need to provide good service and reliability are valued.
World leaders in this industry have traded on their reputation for creating shareholder
wealth and have managed to stay off the recessive nature of the world economy. From
1992-1997, Lilly and Pfizer created enormous shareholder wealth: 40 % a year for
Lilly by taking the transformational route and engaging the pharmacy management
benefits program in-house, and Pfizer, 35% by taking the operational approach and
building on its traditional strengths in research and sales. This was against an industry
average of28% (Internet 13).
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2.3.3 Competitor Analysis
Pearce and Robinson (1997:86) stated that competitor analysis has three objectives: to
identify current and potential competitors, to identify potential moves by competitors
and to assist in devising competitive strategies.
According to Pearce and Robinson (1997:87) competitors are those firms that:
• have similar levels of commitment in the industry
• have similar definitions of the scope of their market
• provide similar benefits to customers and their products have a high level of
substitutability
The pharmaceutical industry globally has a few major players that have entrenched
themselves as market leaders that are highly competitive with each other. The smaller
companies compete for the lesser share, at the same pace of competitiveness. The
experience of the bigger companies sets the standard in that their respective skill sets
have determined their chosen strategy and success over the years. Pfizer's style has
been hard-driving and pragmatic, with aggressive investment in R & D, whereas Lilly
built a strong management team and divested most of the non-core entities from its
business portfolio.
Lilly's organisational team excelled at making timely portfolio decisions and tough
strategic choices about first-mover investments to enter markets, investments in
technology, make versus buy decisions and strategic alliances and relationships that
fostered the development of a powerful drug portfolio. The functional structure was
streamlined to five areas in which the company had a strong presence as well as
unmet medical needs. The initiatives were driven from the top and this innovative
vision to change jumpstarted their transformational strategy.
Pfizer focused its energies on its area of expertise. It exercised discipline in managing
projects at every stage of development and used efficient management processes,
including early input from marketing and a ruthless commitment to delivering
practical results, to spearhead its initiatives.
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2.4 ANALYSING THE COMPETITIVE ENVIRONMENT: FIVE FORCES
ANALYSIS
A framework developed by Michael Porter known as Porter's five forces model can
be used for industry analysis. It is an analytical model for assessing the nature of
competition in an industry that is illustrated in Figure 2.10.
Figure 2.10: Porter's Five Forces Model









d pled fl'OiI'I M.E. Porter: Co petith'e lrat~l', Frre P .. , 1980.
Source: Internet 15
This model is a means of identifying the forces which affect the level of competition
in an industry. The analysis is most valuable when the influence on the immediate or
more competitive environment is examined, rather than the more generalised level,
where the value of the analysis is reduced.
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2.4.1 Threat of New Entrants
Threat of entry to an industry largely depends on the extent to which there are barriers
to entry. With the pharmaceutical industry, barriers to entry were historically high R
& D costs, which required access to large amounts of capital. Other factors included
clinical standards and regulations in different markets with increased development
costs by duplicating the regulatory approval process. In recent yeas, governments
have sought cost containment and drug companies have had to show that the benefits
of new branded drugs are clinically desirable and quantifiable. The drugs have to
perform better than existing drugs to ensure that they appear on 'approved








Economies of scale where in sales and marketing or production ofgoods and
distribution, this factor assumes relevance
Capital requirement of entry which varies according to technology and scale.
The pharmaceutical sector is a capital-intensive industry.
Cost advantages independent of size is related to early market entry and the
established operators whose experience enables them to overcome market and
operating problems. The increasing globalisation of markets and South
Africa's change to democratic rule is facilitating market entry at present.
Access to industry distribution channels, which may be a limiting factor as in
most developing countries, infrastructure is poor leading to monopolies among
logistic companies.
Expected retaliation is a factor where there are established brand leaders.
There are several world leaders in the pharmaceutical sector with a presence in
South Africa and entry for smaller firms with restricted budgets may prove to
be a costly exercise.
Legislation or government action is of relevance to this sector. Legal restraints
on competition are a reality in South Africa as there have been attacks on
patent protection with parallel imports and regulation via legislation to control
markets.
Differentiation would be difficult for any entrant as there is resistance at MCC
level to the development and launching of new branded products because of
cost issues. Companies that have a reputation for reliability and quality,
underpinned by product and quality specification at supplier level and strong
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corporate values supportive of the quality image may be able to impact on the
private sector.
2.4.2 The Power of Buyers and Suppliers
The forces of buyers and suppliers are linked and the relationship can have similar
effects in constraining the strategic freedom in any industry. Buyer power is likely to
be high when there is a concentration of buyers, especially if the volume purchases of
the buyers are high. The public sector in SA at the moment uses this to leverage for
cost reductions in pharmaceuticals supplied to the State hospitals. This has a
detrimental effect on the private sector development if branded products are available
for less in the public sector. This power is further increased when there are alternative
sources of supply as is the case with parallel imports. This is even where there is
product differentiation because of deregulation spawning a host of entrants into the
generic market.
The high cost of branded medication due to the single exit price policy of major
pharmaceuticals means that the cost of switching to generic medication is low and
involves little risk. There is the constant threat of backward integration by
government if satisfactory prices or quality from the drug companies cannot be
obtained.
There are factors that can boost supplier power in this industry. The pharmaceutical
companies need to ensure that there is a concentration of suppliers rather than a
fragmented source of supply, therefore joint ventures with regard to government is a
possibility to be considered. There may be hidden costs to 'switching' which may
become more obvious with time as effectiveness of parallel imports and generic
medication still has to be established. Companies have to become innovative and
develop unique, strong brands that are effective such that switching is not an option.
There is always the possibility of the supplier integrating forwards if it does not obtain
the prices and hence the margins, it seeks. As the socioeconomic status of South
Africans improves, there is the possibility that the bargaining power of the consumer
would be reduced with fragmentation of the consumer base.
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2.4.3 Threat of Substitutes
Substitute products lower industry attractiveness and profitability as they limit price
levels. At present, with the focus on generic medication, there is product-for-product
substitution that has been enforced by legislation. This places a ceiling on prices for
the industry and makes inroads into the market, reducing its attractiveness. This
represents a serious threat to branded products which need to be thwarted by focusing
on representation to the consumer of the higher benefit or value of branded products.
Companies need to strengthen the perceptions of the consumer that branded is better.
Costs remain an issue and companies need to examine the extent to which the risk of
substitution can be reduced by building in switching costs through added product or
service benefits meeting consumer needs.
2.5 ANALYZING CORE COMPETENCES AND STRATEGIC CAPABILITY
Core competences are those capabilities that are critical to the achievement of
competitive advantage (Johnson and Scholes, 1999:160). Competition between
businesses is a race for market position and market power as well as competence
mastery.
2.5.1 Assessing competences
Table 2.5 illustrates the changes in functional capabilities that are associated with
each of the four basic phases in an industry lifecycle. Shakeout is the phase between
growth and maturity and requires a mixture of functional capabilities.

























































































Finance Resources to Ability to Ability to Ability to
support finance rapid generate and reuse or
higher net expansion; to redistribute liqUidate
cash overflow have net increasing net unneeded
and initial cash cash inflows; equipment;
losses; ability outflows but effective cost advantage in
to use increasing control cost of
leverage profits; systems facilities;




Personnel Flexibility in Ability to add Ability to cost Capacity to
staffing and skilled effectively; reduce and
training new personnel; reduce work reallocate
management; motivated force and workforce;
existence of and loyal increase cost




Engineering Ability to Skill in Ability to Ability to
make quality and reduce costs, support
engineering new feature develop other grown
changes, development; variants and areas orto
have ability to start differentiate apply
technical developing products product to
bugs in successor unique
product and products customer
process needs
resolved
Key functional ... Engineering Sales; Production Finance;end strllbtgy focus and market consumer efficiency and maximum
penetration loyalty and successor investment
market share products recovery.
Source: Pearce and Robinson, 1997
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The goal for senior management is to focus attention on competences that really affect
competitive advantage. Most service industries are currently experiencing the need to
innovate in relation to innovative ways of redesigning services and their delivery from
'direct-line selling' to exploitation of the Internet.
Companies develop key areas of expertise which are distinctive to that company and
critical to the company's long- term growth over time (Prahalad and Hamel: 1990)
However, core competences change over time. Companies have a responsibility to
develop areas of expertise in the critical, central areas of the company where the most
value is added to its products and should change in response to changes in the
company's environment and evolve over time.
Three factors assist in the identification of core competences in any business and
include that which:
• Provides potential access to a wide variety of markets
• Makes a significant contribution to the perceived customer benefits of the end
product
• Is difficult for competitors to imitate
The management of the linkages between a primary and support activity forms the
basis for core competence and drug companies need to make key investments in
systems or infrastructure or in the processes of innovation which provide the basis on
which the company outperforms competition. The ability to coordinate the activities
of specialist teams creates advantage by improving value for money in service
delivery. Investment in manufacturing in Africa would be a huge competitive
advantage for a major player as FDI is a vital key to government.
2.5.2 The BCG Growth Share Matrix
The BCG Growth Share Matrix is a portfolio approach to strategic analysis based on
two key variables: market share and market growth. The entities within the portfolio
e.g. market segments can be positioned within the matrix, and strategies developed
based on their relative position. The four quadrants of the matrix, derived by
categorising the two variables into "high" and "Iow", allow businesses to be
categorised. Figure 2.11 shows the various quadrants of the matrix.
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Figure 2.11 : BCG Matrix
Relative arket Share


























In the case of the pharmaceutical companies operating in SA, this matrix could be
used to assess the different CNS products in the product portfolio into:
• Stars which represent the best long-term prospects in a portfolio that should be
nurtured and invested in for long-term benefit.
• Question Marks are those products that could be turned into stars if invested in
or divested of if need be.
• Cash Cows represent those products that are yielding high returns in a stable
environment that can be 'milked'.
Dogs represent those products/businesses which have to be divested, that are draining
the resources of a company.
2.5.3 Identification of key issues
An analysis of Strengths, Weaknesses, Opportunities and Threats (SWOT) can give
an indication of strategic capability. This can also be done by assessing the extent to
which resources and competences relate to critical success factors (Johnson and
Scholes, 1999:193).
2.5.3.1 SWOT Analysis
Internal analysis identifies strengths and weaknesses and external analysis reveals
opportunities and threats. The SWOT analysis is an important tool for auditing the
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overall strategic posItion of a company and its environment and can be used in
conjunction with other tools for audit and analysis. Each of the companies involved in
this sector needs to re-visit their product portfolio, re-assess their human capital and
its' goodness of fit to the South African market, develop innovative ideas to deal with
the legislative changes and consider benchmarking and competitor profiling to assist
them with developing a sustainable competitive advantage. Developing a relationship
with providers of service is now going to be challenging without the benefit of
marketing activities that the industry was accustomed to. Warding off the threat of
generic substitution is probably the biggest threat facing the industry since the new
legislation and companies with branded products have to find a way to increase
market share for their products. Consumer advocacy remains an untapped area of
resources available to the companies and that needs to be harnessed. The industry has
been fairly closed to a few players whose strengths are their established market leader
positions internationally, their reputation for innovation and their market power.
These strengths need to be built on to include building relationships with government
in private-public sector partnerships that will ensure that the existing market for
branded products remains in this country.
The public sector could also be analysed using a SWOT analysis especially in the
light of government's desire to streamline the low to middle income groups' health
care via public-private sector partnerships. Appendix Three is a brief analysis of the
strengths and weaknesses of services at a State facility.
2.5.3.2 Critical Success Factors
Critical success factors are those components of strategy in which an organisation
must excel to gain competitive advantage (Johnson and Scholes, 1999: 192). The
major players are experienced at this in the international arena. Smaller companies
can use benchmarking to develop their own edge in the market.
2.6 INTERNAL ANALYSIS
Johnson and Scholes (1999: 149) stated that successful strategies are dependent on
strategic capability to perform at the level required for success that is linked to three
main factors. These include the resources available to the organisation, competence
with which activities are undertaken and the balance of resources and activities. The
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resources and competencies must fit the environment 10 which the organisation
operates and the opportunities and threats, which exist.
2.6.1 Resource Audit
The resource audit identifies the resources available both within and outside an
organisation to support its strategies. The quality, nature and extent of resources to
support the strategies should be assessed. (Johnson and Scholes, 1999: 153). In view
of the changing rules of the market, most companies have embarked on a process of
rationalisation of business practices, resource allocation and human capital
investment. A significant factor in the South African industry, would be to ensure that
the company is compliant with the employment equity requirements of government.
2.6.2 Value Chain Analysis
The value chain is a systematic way of examining all activities an organization
performs and analyzing the interaction to determine sources of competitive advantage.
The value chain is all of the information and physical activities that flow within and
between an industry and its suppliers, distributors and customers. The industry's value
chain is also described as a system of interdependent activities, which are linked
together. Vertical integration is the way forward as co-operative measures are
undertaken by stakeholders on the same side of the equation. Co-payments from
consumers is one way forward for the branded product market in SA.
2.7 STRATEGIC CHOICE
Strategic options have to be compared both logically and politically and aligned,
acceptable, and feasible in the process of a strategic choice for the way forward in this
country. The legislative changes are here to stay and government's pressure to reduce
the costs of branded products is unlikely to abate, hence companies have to develop
strategies that are flexible and adaptable to the new South African business climate.
2.7.1 The SWOT Matrix
In the SWOT Matrix key external opportunities and threats are systematically
compared with internal strengths and weaknesses (Pearce and Robinson, 1997: 170).
Figure 2.12 is a diagrammatic representation of a SWOT matrix.
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Cell I is the most favourable situation as there are many environmental opportunities
and strengths that encourage the pursuit of the opportunities. This situation favours
growth oriented strategies. Companies that wish to increase their market share need to
aggressively discover innovative ways to not only retain their customer base but also
actively make inroads into new markets to counteract the negative impact of the
growth in the generic and alternative medicine market.
Cell 2 illustrates a situation where there are major environmental threats and
substantial internal strengths. Strategies should encourage the use of current strengths
to build long-term opportunities in a more favourable environment. The major threat
comes from parallel imports and companies need to constantly engage government in
a process of mutual co-operation to shift this policy.
Cell 3 displays numerous market opportunities but firms are constrained by their
internal weaknesses. This needs to be eliminated before they can effectively pursue
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market opportunities. Smaller companies that are stifled by structural problems and
limited budgets, need to rationalise services, develop a niche for their products and
focus on service delivery as a core competence.
Cell 4 is the least favourable situation as there are major environmental threats and
critical internal weaknesses. Strategies that reduce or redirect involvement in the
products or markets examined by the SWOT analysis should be encouraged (pearce
and Robinson, 1997: 172). At present, a case can be made that SA is a hostile market,
however, this is a pessimistic view ofthe situation.
2.7.2 Generic Strategies
Michael Porter suggested four "generic" business strategies that relate to the extent to
which the scope of a business's activities could be differentiated in order to gain
competitive advantage. The four strategies are summarised in Figure 2.13 below:














The differentiation and cost leadership strategies seek competitive advantage in a
broad range of market or industry segments. The differentiation focus and cost focus
strategies can be adopted in a narrow market or industry. At present, the market in
South Africa is narrow for branded products and product differentiation and cost
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reduction is the only way that companies would be able to sustain competitive
advantage.
2.7.3 Grand Strategies
Basic directions for strategic actions are provided by the grand strategies which are
the basis of efforts directed at achieving long-term business objectives (pearce and
Robinson, 1997:218). Fourteen principal grand strategies include: concentrated
growth, market development, product development, innovation, horizontal
integration, vertical integration, concentric diversification, conglomerate
diversification, turnaround, divestiture, liquidation, joint ventures, strategic alliances
and consortia. The principle purpose of the grand strategy to overcome weaknesses or
maximise strengths is compared to the choice of an internal or external emphasis for
growth and profitability (pearce and Robinson, 1997:265).
2.7.3.1 Market development
Figure 2.14 Ansoff's ProductlMarket Matrix
~ Present NewMarket
Present Market Penetration Product De elopment
New Market Development Diversification
Source: Internet 15
Ansoff's model in Figure 2.14 describes four different ways that companies can relate
to markets via market penetration and development, product development and
diversification. Three ways of developing a market involves: extension into other
market segments which are not currently served; developing new uses for existing
products and geographic expansion (Johnson and Scholes, 1997:292). All of these are
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feasible options for the major role players who have the internal capacity to develop
the market within the SADC region and Africa. The world market leaders have an
opportunity to increase the market for their range of products in SA, which is still
regarded as a developing market.
2.7.3.2 Product Development
Product development involves the marketing of new and modified products to
existing customers via the existing distribution channels, developing new product
features, quality variations and additional models and sizes (pearce and Robinson,
1997:225). The success of this strategy would depend on the ability to analyse and
understand the changing needs of customers. Strategic development should be built
around such a core competence. The major players already have this as their core
competence internationally. What would be vital is the location of a manufacturing
plant in this continent. Government is suspicious of the R & D plans of the major
companies as patient subjects are easy targets for clinical trials but an actual plant,
would address this by indicating a commitment to stimulate the local economy.
2.7.3.3 Concentric Diversification
Concentric diversification involves the acquisition of businesses that are related to the
acquiring firm in terms of markets, products or technologies. In the ideal scenario
profit potential is high, exposure to risk is reduced and resource demands are minimal
(Pearce and Robinson, 1997:229). There have been widespread changes
internationally and in South Africa where there have been mergers of smaller
companies with the major players, divesture of generic divisions and acquisitions of
generic companies.
2.7.3.4 Conglomerate Diversification
Conglomerate diversification refers to a situation when a large business acquires a
business where the sole reason for the acquisition is profit considerations (pearce and
Robinson, 1997:230). Pfizer Laboratories has embarked on this in the last two years
to become the largest pharmaceutical company in the world.
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2.7.3.5 Horizontal Integration
Horizontal integration is a form of related diversification. The intention is to eliminate
competitors and to gain access to new markets (pearce and Robinson, 1997:227).
Collaboration between stakeholders in the SA market is the way forward.
2.7.3.6 Vertical Integration
Vertical integration is a form of related diversification. It involves the development
into activities, which are concerned with inputs into current business to allow
organisations to grow their market share, improve economies of scale and increase
efficiency of capital use (Johnson and Scholes, 1997:294). This has already been
commented on and it is a viable option for suppliers of service and the industry.
2.7.3.7 Strategic Alliances
In a strategic alliance the companies do not take an equity position in one another
(Pearce and Robinson, 1997:237). An example ofa strategic alliance includes:
• Licensing which involves the transfer of property rights. Patents or
trademarks is granted to licensee for a specified time in return for a royalty
and for avoiding tariffs or import quotas. This is one option open to
companies that do not want to lose their intellectual property rights.
Companies like Pfizer SA and Lilly SA have competitive advantage that can be traced
to one of these three roots: superior resources, superior skills or superior position. As
a result, the companies have a positional advantage in the global market over
companies like Lundbeck. Once attained, a good position is defensible. The
companies return enough value to warrant continued maintenance and would be so
costly to capture that rivals are deterred from full-scale attacks on the core of the
business. This positional advantage is associated not just with size or scale but with
the ownership of strong product pipelines and having a global geographical presence.
Smaller R & D companies like EISA! enter into strategic alliances with the R & D
division Pfizer for the purpose of developing their molecules. The reality is that it
costs a fortune to bring a drug to market and these companies only way forward is to
engage these market leaders in strategic alliances. For Pfizer, it represents the
possibility ofadding a new molecule to its database of possibilities.
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2.7.4 McKinsey Model
The McKinsey model looks at how businesses should develop their growth strategies
as summarised in the Figure 2.15 below:
Figure 2.15: The McKinsey Model
Gene 'c options and investment strod res for a growth strategy
Acquisitions
Source: Internet 12
Growth in individual companies can be achieved by looking at business opportunities





In the SA pharmaceutical industry, growth will only be achieved, if the market leaders
actually invested in local manufacturing companies. The growth in the industry
remains below the industry average internationally as there are more companies,




Strategies can be assessed against three evaluation criteria: suitability, acceptability
and feasibility.
2.8.1 Suitability
Johnson and Scholes (1999:319) describe suitability as a broad assessment of whether
a strategy addresses the circumstances in which an organisation is operating. This
involves establishing the rationale for each strategic option and establishing the
relative merits of each one.
Establishing the rationale consists of assessing the extent to which a strategy:
• exploits the opportunities in the environment and avoids threats
• capitalizes on the organisations strengths and core competencies and avoids or
remedies the weaknesses
• addresses the cultural and political context (Johnson and Scholes, 1999:322)
Tools used to test for suitability include: lifecycle analysis, value chain analysis,
portfolio analysis, positioning and business profile (Johnson and Scholes, 1999:321).
It would be very important for drug companies to assess the portfolio of their SA
subsidiaries to assess whether they are strategically positioned in this market. The
political context is changing, but this is a universal phenomenon and so drug
companies need to revisit their business portfolio and tailor it to the changing world
market. In the developed world, like Europe and the UK, the market us fairly mature
but in the developing countries, the lifecycle stage is still at a growth phase.
2.8.2 Acceptability
The acceptability of a strategy is concerned with expected performance outcomes and
the extent to which they fit the expectations of stakeholders (Johnson and
Scholes,1999:319). This is assessed according to three issues: the expected return
from a strategy, the level of risk and the likely reaction of stakeholders. Drug
companies face increasing pressure from their shareholder base to meet performance
goals and in SA, government is facing an election soon in which its ability to translate
policy into action will be critically assessed.
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2.8.3 Feasibility
Feasibility is concerned with whether an organisation has the resources and
competencies to deliver a strategy (Johnson and Scholes, 1999:319). Fund flow
analysis, break-even analysis and resource deployment analysis can be used to assess
feasibility (Johnson and Scholes, 1999:350). Most of the players in the SA market are
global leaders who are profit-driven. The attack on patent rights may seriously impact
on the companies' bottom-line and is a situation that has to be addressed. The
companies should also assess the feasibility of entering the African generic market,
specifically with a manufacturing facility.
Markides (2000) stresses that the process of developing superior strategies is part
planning and part trial and error. He argues that analysis and planning will not
produce a fully-fledged strategy ready for implementation but will help narrow the
options. Hamel (2000) claimed that the current environment is hostile to industry
incumbents and hospitable to industry revolutionaries who radically reconceive
products and services, not just develop them, redefine industry boundaries and
redefine market space.
2.9 STRATEGIC CHANGE
Gemini's framework for planned strategic change is a useful starting point to consider
this aspect of strategy. Business transformation is seen as a four-dimensional process
of re-framing, i.e. questioning what the organisation is and what it can achieve so as
to open up new possibilities and challenges. Companies need to achieve mobilisation
before creating a vision and building a measurement system to assess response to
change. Restructuring deals with a company's structure and is usually associated with
cultural change. A company would have to construct an economic model before
aligning the physical infrastructure to ensure strategic fit. A redesign of the work
architecture or processes would ensure that the process added value. Revitalising is
about achieving a goodness of fit with the environment by achieving market focus
first and then inventing new business. Companies would have to change the rules of
competition to provide new bases for it through product or process differentiation.
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Finally, renewal creates a reward structure to ensure a culture of acceptance of change
and encourages individual learning to develop the organisation (Lynch, 2000).
2.9.1 Enforced Choice
There are some circumstances where the strategic development of an organisation is
largely imposed from outside. This may be because major changes in the environment
overshadow other considerations. In this scenario, the organisation may be seen as a
'victim of circumstance'. The danger of enforced choice is that the risk profile of a
company increases. Scenario planning becomes a vital tool in developing
contingency plans. The regulatory changes that have been imposed onto this sector by
government represent exactly this scenario. The reality is that change is here to stay
and companies need to adapt to manage the change process. In fact the environmental
rule change by government may have acted as an unfreezing mechanism in an
industry that was ready for change. Managing the unfreezing process is not easy as
the whole situation is in a state of flux. Diagnosing strategic change needs,
information building and strategy workshops to facilitate a change in tactics, to
communicate change, change routines and define roles in the change process, are
important steps in the process of accepting change (Lynch, 2000).
2.9.2 Expansion strategies
Innovation cannot be institutionalized so strategic planning is not a replacement for
intuition and creative thinking. In the current world climate, companies have to do
more than just develop new products and enter new markets to maintain their
competitive edge. Companies have to consistently come up with ideas that
differentiate them from others for there to be growth.
2.9.2.1The Market Options Matrix
This model is a useful way to start considering strategic options for expansion in a
climate of change as it presents the product and market choices open to a company. It
considers the possibility of launching new products and moving into new markets and
explores the possibility of withdrawing from markets and moving into unrelated
markets.
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Withdrawal is considered when the product life cycle is in the decline phase with the
possibility of retrenchment a valid option. Over-extension of product range is
occurring worldwide and holding companies are selling their subsidiaries, as funds are
needed for investment elsewhere. De-mergers are also not unusual but it is usually a
strategy used to realize the underlying asset value in publicly quoted companies.
Privatization in SA is a positive way to realize real value as state-owned assets have
inherent value. Government is looking for private-public sector partnerships and for
models from industry with regard to an NHS system.
Market penetrating strategy should begin with existing customers. Existing companies
with low relative market share in a growing market can attack aggressively the market
or a segment. Companies with smaller market share need to take charge of this
process. Where there is a high relative market share, there is risk of loss so predatory
price cutting sometimes keeps out smaller new entrants. GlaxoSmithKlein has
consistently taken this view in SA and kept Aropax as the lowest price of the ethical
antidepressants in the serotonin class of drugs.
Market development strategy has allowed compames to move beyond immediate
customer focus and attract new customers from existing product range by seeking new
segments, new geographical areas or new uses for products. A classic example is
Aropax which has now been registered in SA for about five more indications than
when it was first launched. Product development for the existing market is really in
the territory of the big R & D players who use this to counter competitive entry,
maintain the lead as product innovators, thereby protecting overall market share.
Diversification into related markets in the SADC regIOn and Mrica is a real
possibility and can include: Forward integration in the company's outputs via
distribution, transport and logistics, or backward integration by extending activities to
the provision of inputs like raw materials. Acquisitions have been popular in this
country and it is probably because this method of market expansion is associated with
gaining assets of a company: its brands, market share, core competencies and
technology. This route is also chosen for competitive reasons.
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2.9.3 Strategic change in government agencies
Profitability and shareholder value are the drivers behind private sector planning.
Government agencies struggle with defining and measuring the 'bottom line'. Even a
focus on service delivery to 'customers', is not really helpful in this situation. Strategy
in public organizations is governed by broader public policy issues like politics,
where the political policy of government guides strategic development and monopoly
supply as public authorities often have the monopoly as suppliers of a service. Part of
the problem is that they are under pressure to operate efficiently but are unable to
spend any surplus profits they generate. They are also subject to changes in
government policy direction and lack the consistency of private organizations. The
lack of choice for consumers at these agencies means that suppliers of service are not
really subject to the market pressures that affect business strategy in the private sector.
(Lynch 2000:31). Faced with pressure for change from politicians who need to see
health care service delivery improve, managers often resign and enter the private
sector.
Subsidiaries of MNC's are not very far off from the same level of frustration as
leaders in the public sector. They are subject to restrictions with funds, headcount, and
limiting factors at a policy level. The parent company shows them the field to play on
but do not allow them to take the initiative in the local market. In the public sector it
is similar as whatever the government says, has a massive effect on where policy goes
as there is always an overlay of the party political position.
2.10 STRATEGIC OPPORTUNITIES FOR PROVIDERS OF SERVICE
With the changes in legislation, especially the licensing of dispensing doctors, the
removal of incentives and sampling and the flooding of the market with generic
medication, healthcare providers have embarked on ambitious, cost-reduction
initiatives in an attempt to improve their financial position. Some have mounted
significant attempts to optimize payment for healthcare services, revised coding
procedures, implemented more thorough charge-capture mechanisms, reviewed terms
oftheir managed care contracts and ensured payer compliance with contract terms.
66
Strategic planning will uncover new revenue-generating opportunities for health care
providers including:
• Increasing market share by expanding the breadth and depth of service
delivery
• Filling gaps in the continuum of services by partnering with other providers or
developing new services not currently provided for in the area e.g. 3D
ultrasound at obstetric practices
• Developing niche services that are not sufficiently available in the area
• Re-packaging existing services to address specific market segments
2.11CUSTOMER-DRIVEN STRATEGY
Customer-driven strategy is concerned with meeting the needs of the company's
actual and potential customers, and as a result, delivering the objectives of the
company. The customer-driven concept argues that only by attracting and retaining
customers will long-term profits be maintained (Lynch 2000:201). SA companies
have begin to realize that simple financial measures of profitability are not enough to
ensure the growth and survival of a company. There has to be a link with customer
satisfaction and loyalty. Lynch (2000) stated that there is empirical evidence to
suggest that loyal customers are more profitable as they tend to account for the
majority of sales and their loyalty means they are less sensitive to price increases and
may even encourage new customers, attracting new customers costs organizations
more than retaining loyal customers and retaining existing customers can drastically
increase profits.
There are three main strands to this strategic approach:
• Understanding the customer: By directing customer contact at many levels,
widely disseminated research on key customer findings e.g. on segmentation,
knowledge of why customers choose the company's products
• Responsiveness of the company to customer needs: The company regularly
receives and acts upon customer satisfaction surveys versus competitors, is
responsive to customer complaints and suggestion and tracks key customer
data on company image versus its competitors
• Provision of real value for money: The company needs to monitor quality
relevant to the positioning of products in the market place, conduct
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comparative surveys of competitors' prices and service offerings and rewards
inside the company based on performance with customers.
Five possible elements ofcustomer added value include:
• Differentiating capabilities: a unique location of servIce outlet will tie
customers to the company, product differentiation in a niche market
• Channel power: Develop real dominance in the delivery of service to the
customer
• Company reputation: The knowledge and trust of years of trading in the
market bonds customers to a company
• Brands: The names of the products or services that distinguish the company
from others
• Customer relationships: formal and informal relationships that link customers
with their suppliers
2.11.1 Customer profiling
Customer profiling is clearly related to the sustainable competitive advantage of the
company as it helps to identify why some customers choose one product over another.
Customer profiles describe the main characteristics of the customers and how they
make their purchase decisions. Customers can be profiled according to:
• Domestic customers who buy products and services for themselves or their
families. This is called primary demand that is influenced by the industry
itself. The product must work however and give customer satisfaction.
This group of customer can be persuaded to purchase products by pricing,
branded goods and advertising and by quality and service levels; these
elements form the basis of the sustainable competitive advantage between
compames.
Large business customers tend to buy for more rational and economic
reasons. Demand is often derived demand: influenced by factors in another
industry
• Not-for-profit charity consumers will involve servIce, focused benefits,
and value for money
There are three areas where customer profiling supports competitive advantage:
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• Customer switching costs: This is the cost to the customer of changing its
purchase from the company and moving to another supplier. If costs are high,
then switching may not occur
• Customer bargaining power
• Customer cooperation
2.11.2 Branding
Branding is a specific name or symbol used to distinguish a seller's product or
service. It allows a product to be at a higher price than a functionally equivalent non-
branded version. Reputation is a broader concept, which refers to the sum of customer
knowledge developed about a company over time and is based on:
• Product performance: customers experience forms their basis for their
judgement about a product
• Quality: customers expect certain levels based on pncmg, positioning,
advertising and built-in performance levels
• Service: customers may be offered differing levels of delivery, advice or other
forms ofcustomer experience
• Marketing support: advertising, packaging and promotional activity





Does the product have a reputation?
Does it have continuity?
Does it have a distinctive formula that is difficult for others to replicate?
Does it communicate the company's position as an established player in the
market?
2.11.3 Communicating with customers




Inform them about their products
Persuade them to purchase or continue buying their products or services
Establish and secure the competitive advantages of their products
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In most situations, personal persuaSIOn IS the most cost effective method of
communication because the message can be tailored to the individual customer. Mass
marketing is required and would involve: advertising, branding and promotion. The
key criterion is cost effectiveness which is measured by the cost of obtaining an
effective communication with the customer which is measured by the sale of the
product.
Communications can include:
• Branding: powerful way to retain customer loyalty in mass market products
• Personal selling: personal relationship and individually tailored message for a
single customer to purchase the product
• Technical promotions: the use of technical presentation of data on the product
• Consumer promotions: devices that promote the product without building any
relationship. Effective where customer loyalty is low or a new product is
being introduced
• Public relations and sponsorship: lobbying of government and other
stakeholders
Communications directed at customers will be seen by other stakeholders like
employees, shareholders, government, trade unions, suppliers and consumer groups.
2.11.4 Strategic pricing and value for money
In the longer term, pricing strategy can be a major factor in competitive advantage
because it significantly alters the basis on which companies can compete. Pricing is
important because of the impact of prices on profitability, positioning of the product
in the marketplace and value-for-money impression created. Price changes have more
than twice the impact on earnings compared with volume changes (Lynch 2000: 224).
The pricing decision is a balance between two factors:
•
•
Costs: setting the price above the marginal cost ofproduction
Competition: pitching the market price significantly above competition even
if product differentiation doesn't help sales
70
The strategic role of price is involved in price discounting .For some customers
quality, availability of stock, product performance, after sales service and brand
value are as important.
Government purchases are made on the basis of competitive price comparisons.
Products that perform to acceptable industry standards and are available are
negotiate with over: the size of the order, the importance of the customer in terms
of annual sales, the costs of production and the prices and terms offered by
competitors. Traditional practice is that of cost plus pricing where the costs are
added up, a percentage profit is applied and the final price is determined. Target
pricing occurs where the price is set primarily on the basis of the competitive
position of the company rather than the costs. So, the overall process in pricing
decisions of companies should include: evaluation of competitor's pricing,
establishment of price objectives and consideration of competitors and the
product life cycle and set prices.
2.12 CONCLUSION
This chapter discussed the strategic theory and strategic analysis that can be used to
evaluate stakeholders, mainly pharmaceutical companies. The next chapter will
discuss the South African pharmaceutical industry in greater detail, evaluating the role
each stakeholder plays in it. It is important to for all stakeholders to recognise that the
legislative changes are here to stay. The choices open to the pharmaceutical industry
are to:
• Do nothing, that is continue with present strategies
• Withdraw by leaving the market
• Consolidate by attempting to hold market share in the existing market.
It is important that drug companies, even if they are market leaders:
• Have senior leadership who "own" their strategic planning processes
• Employ a consistent, well-understood and structured planning process across
all levels of the company
• Use effective internal communication to link planning to practice
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• See planning as a continuous process and view the process as more important
than the product
• Tie performance measurement to incentives that require accountability for
results
• Understand that customer-driven strategic planning has to be linked to culture
change for it to be successful (Lynch:2000).
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CHAPTER THREE: THE SOUTH AFRICAN PHARMACEUTICAL
INDUSTRY AND THE LEGISLATIVE CHANGES
3.1 INTRODUCTION
The stakeholders in the South African pharmaceutical industry, specifically in the
market for CNS products, include international giants like Pfizer Laboratories, Eli-
Lilly, GlaskoSmithklein and Jansen-Cilag, whose investment in South Africa
represents approximately I% of their US market and less than a percent of their global
turnover. The South African subsidiaries are locally registered as companies,
however, their strategic direction is decided by senior management in the parent
company, usually in the United States. South Africans are employed at regional and
national level in positions including those of marketing representatives and sales and
product managers, however, the chief executive officers are usually expatriates, who
serve terms of office ranging from between two to five years in this country. There is
however, a commitment to the development of the market in South Africa as it is seen
as a springboard into Africa and most companies are co-operative with the goals of
the South African Government in making health care affordable for most South
Africans.
3.1.1 Historical Background
The relationship between the SA government and pharmaceutical companies came
under the spotlight of international attention in the last five years over the issue of
availability of products to the majority of the population at affordable prices. It
reached a head to head confrontation over the issue of anti-retroviral drugs and the
parallel importation of generic substitutes from other countries into South Africa,
which undermined the branded market. The issue was resolved when the companies
withdrew their class action suit against government, regarding patent rights and
attempts were then made to facilitate a process whereby a consultative process would
result in legislative changes that would benefit all stakeholders.
The pharmaceutical industry was initially consulted during the development of the
National Drug Policy and in January 1998 proposals were made to the industry to deal
with some of their concerns about developing regulations under the Act. However,
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because of the senousness of the issues at stake and the implications for the
international pharmaceutical industry, litigation was the preferred choice by the
industry. Provisions of the Medicines Act that related to intellectual property rights
were at the heart of the court case.
The pharmaceutical companies first brought this action in 1998. At that time, they
obtained an interim interdict which prevented the Government from implementing the
contested sections of the Medicines Act, pending the outcome of the forthcoming
case. At virtually the same time, the United States Trade Representative put South
Africa on the Special 301 Watch list in May 1998, acting in terms of the United States
Trade Act of 1974. Eighteen months later it dropped South Africa off the 301 Watch
List. This followed talks between the two governments that led the White House to
release a statement declaring that "the two governments have identified common
ground with respect to South Africa's implementation of its so-called 'Medicines Act'"
(Internet 5). The United States had accepted the South African government's
assurance that it would honour its international commitments that fully protected
intellectual property rights. The basis for this belief was that the provisions of the Act
were not inconsistent with the Trade Related Intellectual Property Rights (TRIPS)
Agreement.
3.1.2 The Issues Involved
The drug companies had contended that numerous sections of the Medicines Act






The extent of the powers conferred on the Minister ofHealth.
Deprivation of intellectual property in a manner that amount to expropriation
without compensation
Various forms of discrimination against sections of pharmaceutical industry
Restriction of freedom oftrade
Failure to comply with legislative procedures set down in the Constitution
(Internet 6).
The South African Government's drug policy was driven mainly by domestic factors,
but the international dimension was also relevant and the dispute became part of the
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larger international debate on access to affordable health care for developing countries
and for the poor in wealthier nations. The SA government saw the withdrawal of the
action as a victory as it was able to stand by its policy of affordable health care
without having to sacrifice the international trade treaties that it was party to. It was a
hollow victory though in that the issues that were at stake were central to a free
market economy. The withdrawal of the action allowed the SA government to pursue
its policies and the MRSCA Bill was promulgated in 2002.
The prohibition on sampling and the removal of incentives and bonuses by the
pharmaceutical industry automatically kicked in with promulgation. The Government
moved speedily to set up the Pricing Committee whose job it was to include the
gathering ofpharmaceutical intelligence in order to advise the Minister ofHealth on a
transparent pricing system for medicines. It also activated the system of generic
substitution which had been endorsed by all medical aid schemes.
The SA government pledged to engage the pharmaceutical industry in the local
context and in the international arena as there was a growing realization
internationally that governments could not tackle the major public health problems of
developing countries without concentrating all available resources. This demanded a
new style of commitment by government to venture into partnerships with the private
sector and a joint working group with the pharmaceutical industry was formed to
consult on and consider broader issues in the area of health care. Government felt that
this was the way forward in holding multinational companies accountable for the
markets they dominate.
3.2 THE ECONOMICS OF PRICING IN THE PHARMACEUTICAL
INDUSTRY
Any government wishing to pursue equity as a policy goal will commit itself to
improving access to quality health care. Economic factors that constrain this access are
usually related to the costs of services. In South Africa, out-of-pocket expenditure is
high, as is the case in the rest of the developing world. In sub-Saharan Africa figures
range as high as 65% of total drug expenditure, in Asia 81 %, while it is less than 40%
in established market economies (Internet 9). Drug prices can therefore be considered a
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crucial element in determining access to health care therefore drug costs impact directly
on policy choices of government especially in the public sector. The cost of drugs is a
prime consideration in whether or not they are included in Essential Drugs Lists, both
internationally and in South Africa. Cost alone does not determine access as depicted in
Figure 2.1 (Internet 9).




3.2.1 South African public sector expenditure and prices
Drug acquisition costs either to patients or health care systems are a major part of
recurrent costs. In the South African public sector, drug costs are second only to
personnel costs. Data on actual consumption in the State sector is patchy but historical
data available to the Department of Health Chief Directorate: Pharmaceutical Services
is shown in Table 2.1. The industry estimate of total public sector purchases in 2000
was R1.96 billion (Internet 9)
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Table 3. 1: Provincial expenditure on drugs per financial year
11199409511995-96 11996-971997098 1199&-99\::::0 12000-01
~::m 11111I1
IFree State IN/A IN/A IN/A IN/A IN/A 1104.607 161.390
IGauteng IN/A IN/A 1380.418 1451.274 1468.430 1352.314 1453.499
~::UIUo 1111111
IMPumalangalN/A IN/A IN/A IN/A IN/A 1103.000 IN/A
~::= 11111I1





IN/A IN/A IN/A IN/A IN/A IN/A IN/A
11157.401 1170.35811900977 r090544 12160209 1201.411
Notes: Actual expenditure IS stated, where available. Where only budgets were available, these are
indicated in italics. North West reported that drug expenditure could not be separated from the other
items under Standard Item C (Stores and Livestock), but that payments to the Gauteng depot for 1998-
2000 totaled R72.647 million, and to other suppliers for the period 1997-1999,R13.164 million. The SA
Military Health Services also budgeted Rl00 million for drugs in the 1999-2000 financial year.
N/A=not available
Sources: National Department of Health and individual provincial Heads ofPhannaceutical
Services
3.2.2 Private sector spending: medical aid expenditure
In the private sector, drugs are the single biggest cost driver. The Registrar of Medical
Schemes reported that out of expenditure of a total of R18.745 billion paid out by
medical aid schemes in 2000, medicines accounted for 27%. However, of the 28.5% of
payments that were made to private hospitals, some were also for drugs used by
inpatients and those that were issued as discharge medication. Per capita expenditure on
drugs in the public and private sectors are thus markedly different. The sales figures for
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2001 quoted by the Pharmaceutical Manufacturers Association (PMA) put the total
value of anticipated drug sales to be R12.25 billion of which public sector sales were
24%, which implied a per capita expenditure of about R 60.00. In contrast, the per
capita expenditure on prescription drugs in the private sector was R800.29, excluding
sales of over-the-counter (OTe) medicines, which constitute only 6% of the total value.
This includes sales via private pharmacies, private hospitals and dispensing doctors,
who are responsible for 15% of drug sales. If the dispensing doctors are servicing only
indigent patients on behalf of the State as is claimed, the private sector per capita
expenditure would still be R641.69, which translates to more than 10 times the amount
spent per person in the public sector (Internet 9).
3.2.3 The cost of drugs in South Africa
The cost of drugs in South Africa relative to other markets has long been a contested
issue. In 1997 government statements on the matter were the subject of a complaint by
the PMA to the Public Protector. One of these alleged "offending statements" was that
"South Africa rated in the top five most expensive countries in the world for medicine".
The final ruling by the Public Protector is perhaps indicative of the complexity of the
subject. He stated that it was "not possible to say that the Minister ofHealth was able or
unable to prove or substantiate the statement". However, he went on to record his view
that "pharmaceutical profits are substantial in this country; that the cost and price of
pharmaceuticals in South Africa is high; and that the amount spent on medicine, is
nearly double to triple that of other major countries". This area of policy has also been
seen as part of a greater struggle, one that pits the health and economic interests of the
South against those ofglobal free trade (Internet 9).
The National Department of Health does not routinely collate price comparisons over
time. However, in preparation for the tender adjudications in 2001, a comparison was
made of a selected basket of high expenditure items. According to DOH figures, for 31
of the 36 items, prices for the same pack sizes could be compared between 1997 and
1999. The median price change was an increase of 7.8% per annum. While the largest
increase was 93.2% pa, the item with the greatest price decrease dropped by 7.5% pa.
For the 22 items for which a 2001 price was available, the median change from 1997
was an increase of 7.4% pa. The largest increase was 62.1% pa, and the item with the
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greatest price decrease had dropped by an average of 13.9% pa (Internet 9).
The Hospital Association of South Africa monitored the prices of a basket of 1 000 high
cost/high volume items, which were compared to the prevailing consumer price index
(CPI), and tracked against the Rand-US dollar exchange rate. Against a January 1997
index of 100 for each parameter, the all products basket reached 145.9 in May 2000,
whereas the CPI was only 120.4. The rand had weakened to 154.1 by the same point.
The close tracking ofthe exchange rate and the basket price is shown in Figure 2.2.
Figure 3.2: Prices of a basket of 1 000 drugs used in private hospitals, plotted
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It should be noted though that expenditure is a result of both unit price and volume of
consumption. As a reference point, the United Kingdom, with the highest prices in
Europe, managed to keep drug expenditure to about 10% of total health care costs
(Internet 9).
3.2.3.1 Price surveys
The PMA and the Minister of Health's price comparisons are clearly at variance with
each other. This is because the entire area of pricing assessments is fraught with
methodological difficulties. Among the issues shown to have considerable effects on
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the results of surveys that attempt to compare prices over time or between countries are:
• Sample selection :it may be necessary to include generics and aTC drugs that
might substitute for the branded items being compared
• Units of measurement for price and volume: often pack sIzes vary
considerably, and direct comparisons between bulk and patient-ready packs
cannot be made on the basis of unit dose prices
• The relative weight given to consumption patterns in the different settings
• The use of exchange rates or purchasing power parities for currency
conversions (Internet 9)
Despite methodological concerns, policymakers continue to act on studies that display
weaknesses. A study that sought to compare South African prices with those in known
high price countries like USA, UK, Germany, Denmark, Netherlands, is still used by
the PMA today to ratify pricing decisions. Price comparisons between countries and the
public and private sector continue to make headlines. At present there is no
internationally acceptable reference pricing system. The current International Drug
Price Indicator Guide produced by Management Sciences for Health has been attacked
from various quarters. It is a listing of prices from supply organizations that service
non-profit humanitarian projects and government bulk-purchase structures but lacks
quality of data with regard to the suppliers (Internet 9).
In South Africa, there are considerable differences between private sector prices and
those offered on State tender. Claims are made that the difference is on average 10-fold.
It is alleged that the lower prices offered to the State are responsible for higher than
usual prices in the private sector, in other words that higher private sector prices are
used to offset revenue losses and that this constitutes cross-subsidization. There are no
accurate data to support either contention. There is also evidence of discriminatory
pricing practices between different purchasers in the private sector (Internet 9).
An in-depth Competition Board investigation concluded that such discriminatory
practices existed, that they constituted a "restrictive practice", and that this was not in
the public interest (Internet 9). Some of these practices, such as the selling of stock by
dispensing practitioners to so-called "short-line" wholesalers have been dealt with by
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the Medicines and Related Substances Control Amendment Act (Act 90 of 1997). The
Act prohibits wholesalers from buying drugs from anyone other than a manufacturer or
importer. This type of in-country market segmentation is not unique to South Africa,
and has also been demonstrated in the United States (Internet 9).
3.3 THE DOH'S DRUG POLICY
The DOH's drug policy is founded in the National Drug Policy that was developed in
1996. As early as mid 1994, the then newly constituted Drug Policy Committee was
tasked to "develop a pricing plan for drugs in South Africa in the public and private
sectors" (Internet 5). The resulting drug policy's stated aim was to ensure the
availability and accessibility of essential drugs to all citizens with the added economic
objective of lowering the cost of drugs in both the private and public sectors. It also
aimed to promote the rational use of drugs, thus targeting both parts of the expenditure
equation. As a national development objective, the Committee supported the
development of the local pharmaceutical industry and the local production of essential
drugs (Internet 9).
Specific cost containment measures that were part of the policy development included:
• A pricing committee, to "monitor and regulate drug prices"
• Total transparency in the pricing structure at all points of the distribution chain
• A non-discriminatory pricing system
• Replacing the wholesale and retail mark-up system with one based on a fixed
professional fee







Regulation of price increases
Provision, in certain circumstances, of public sector stock to the private sector
Promotion of generics products including the policy of generic substitution,
while maintaining a negative list where the prescribed brand had to be supplied
Measures to improve rational drug use, including establishing Pharmacy and
Therapeutics Committees (PTCs) in all hospitals and
Control of pharmaceutical marketing practices (Internet 9).
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International tendering, competitive negotiation for state supplies and price preferences
for local manufacturers was included in the DOH's procurement policy. Export of local
products to neighbouring countries was supported. Many of these measures have been
promulgated with the MRSCA legislation.
3.3.1 The economics of drug policy options
Medicines are not ordinary articles of trade. Specifically, their demand and supply
characteristics do not follow classic market principles. There is a three-tiered demand
structure: prescribers, including physicians and others, as the actual demanders, the
patients as the consumers and the health care system frequently the payer in both the
public and private sectors. There is often limited competition between suppliers,
especially in the case of patented products. Medicines also have both positive and
negative externalities as is the case with treatment of TB, which benefits that patient
and reduces the spread to the community ( Internet 9)
A case can be made then for government intervention with policy in that information
available to prescribers and consumers is often selective, unbalanced or incomplete,
further demonstrating the supply-driven nature of trade in medicines. Also, market
forces rarely reflect true social costs and benefits, and cannot meet social objectives
such as equity. The factors mentioned above could constitute a situation of market
failure, where drugs can therefore be considered to be "meritorious" goods, worthy of
government intervention (Internet 9).
The pharmaceutical industry begs to differ. Industry groups claim that the market is
working, that interventionist policies don't work and actually increase health-care
expenditures, and stifle innovation. The global industry would prefer a situation of
market pricing for all medicines, less dependence on national social security systems,
more private/insured purchase, and competitive purchasing systems operating in a
price-deregulated environment. In fact, there have been calls to adopt US standards
even to the point of having direct-to-consumer advertising (DTCA) of prescription
drugs. A recent policy analysis ofDTCA options for South Africa commissioned by the
DOH has suggested retaining a European rather than US standard (Internet 9).
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3.3.2 Government interventionist policies
Governments that choose to intervene in drug policy can be characterized in a number
of ways. They can be either direct via primarily legal measures that have an immediate
effect on suppliers or consumers or indirect using usually market-related measures,
which entail financial implications for the players. Governments may also either target
prices themselves with supply side measures such as price controls, positive or negative
lists, and promotion of generics or consumption via demand side measures such as
exclusion from positive lists, reclassification to OTC status, introduction of patient co-
payments and caps on pharmaceutical budgets (Internet 9).
Policy options exercised by governments have resulted in either a total control situation
like in Ecuador and Honduras, a mixed system similar to that of Canada, monitored
freedom like in Brazil or total freedom as in the US. Price control policies are more
common in developed than in developing countries, even though price sensitivity might
be greater in countries with poorer social security systems (Internet 9).
While the South African government's policy commitment to some form of
intervention is clear, the exact mechanics of the proposed system are still being
formulated. Policy instruments available to government include:
• Producer price control measures with direct price controls, reference pricing
systems, equity pricing and generic policies
• Distribution chain cost controls of mark-ups and fixed professional fees
• Bulk purchase measures using tender and negotiation strategies and regional
initiatives in the SADC region
• International trade agreement relief measures with compulsory licensing and a
policy allowing parallel imports
• Demand side measures that involve rational drug use and co-payments by
consumers (Internet 9).
3.4 THE RELATIONSHIP BETWEEN STAKEHOLDERS
In the above discussion, policy options available to the South African government have
been explored. The reality is that this is a dynamic environment that involves a
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relationship between all stakeholders, the pharmaceutical comparues, government,
suppliers of service and consumers represented by medical aid schemes. It is important
to consider then the pros and cons of policy options and their impact on the various
stakeholders.
3.4.1 Producer price control measures
The imposition of direct price control is in conflict with South Africa's national trade
and industrial practices, which are influenced to a large extent by global trends. The
balance of evidence from other countries would seem to indicate that such practices,
while commonly used, are complicated and easily circumvented by transfer pricing via
inflation of the prices of imported raw materials. This policy is also open to political
interference, and relies to a great extent on industry transparency. Further, production
costs are not often easily determined, while the use of a landed costs plus system is
open to manipulation by transfer pricing (Internet 9).
A more transparent system is that of reference pncmg. Internal reference pncmg
systems involve a national authority setting local prices for a drug by comparison with
similar drugs on the national market. External reference pricing systems use the prices
of drugs sold in other countries as well, as part of the comparison. In South Africa, a
form of this system is already in effect in the private sector, where many medical aids
use a maximum medical aid price (MMAP) system for drugs that are no longer
controlled by a patent and are therefore available from many sources. Patients who wish
to receive a branded version that costs more than the MMAP have to pay the difference
in price themselves. However, it is unclear whether any such system is applied when
adjudicating State tenders. International experience in the Netherlands and Germany
has been that reference pricing is not effective, and is out-flanked by changes in
prescribing habits. It also shifts the load to the patient, by way of the additional co-
payments that are necessary. Innovator drugs are usually not covered by reference price
systems, as no comparator products exist. If applied internationally, this might result in
convergence of prices at higher levels, hurting current low price countries (Internet 9).
Equity pricing may be a favoured option, where manufacturers agree to subsidize lower
prices in developing countries by levying higher prices in wealthier countries. Two
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potential problems with this approach are that prices might not drop sufficiently or
consumers in the Northern hemisphere might insist on either lower prices or the right to
import drugs from low price countries. Legislative attempts to allow such parallel trade
are already underway in the US. Equity pricing is the basis for the UNAIDS
negotiations with major AIDS drugs manufacturers, and also underlies offers of drug
donations to developing nations. Neither approach is without problems. Donations in
particular are difficult to accept when accompanied by demands for additional
monitoring and systems costs and restrictions, as was the case with the Pfizer offer of
fluconazole to South Africa in early 2000 (Internet 5).
Efforts to promote the production and use of generic medicines, while unpopular with
the research-based industry, are effective. They stimulate competition and promote the
development of local manufacturing concerns. Two policy instruments to facilitate this
process are however lacking in South Africa. The first is an unambiguous legal
framework for generic substitution, which is already practised in the public sector, and
is often necessary in order to comply with MMAP restrictions in the private sector and
secondly policy that will allow prospective generic manufacturers to complete scientific
and regulatory processes before the expiry of the patent, allowing for quick entry of the
generic product onto the market and fair competition with both the originator product
and any "generic" versions made by that company or its subsidiaries. Such provisions
are not in conflict with international trade agreements but this practice is not welcomed
by industry groups. The most dramatic evidence of the impact of generic competition
on drug prices has been provided by Brazil where anti-retrovirals that were only
available from innovator companies reduced in price by only 9% from 1996 to 2000,
whereas the prices of those that did face such competition dropped an average of 79%
over the same period (Internet 9).
3.4.2 Distribution chain cost controls
PMA contentions are that South Africa's distribution chain costs are among the highest
in the world, adding more than 100% to the manufacturer's factory gate price (Internet
1). This is vehemently denied by the Pharmaceutical Society of South Africa (PSSA).
Direct control over mark-ups has been abandoned by government, but is still exercised
indirectly by the reimbursement policies of the medical aid industry. The traditional
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distribution route for pharmaceuticals in the private sector is illustrated in Figure 3. 3.
Figure 3. 3: Traditional distribution chain for medicines
11__ 1
Note: the "retailer" is either a pharmacist in a retail pharmacy or private hospital or a dispensing
doctor. SOURCE: www.napm.co.za
At each step a percentage mark-up is applied, but this is also often accompanied by a
discount. The actual mark-up might therefore be lower than the theoretical figure.
However, each stage starts from a presumed price resulting from application of the
theoretical mark-up by the previous player. In most cases, patients do not pay directly
for their medicines. Payment is rendered by the medical aid, which is therefore a third
party to the transaction between the seller (pharmacist or doctor) and the supposed
buyer (the patient). The mark-ups are to a large extent the result of acceptance of the
system by the payers, the medical aids. This acceptance is formalized in the
Pharmaceutical Scale of Benefit published by the Board ofHealthcare Funders (BHF),
which is a voluntary association of medical aids. Most medical aids make use of
intermediaries, medical aid administrators like Medscheme, to manage the payments for
claims submitted by their members (Internet 9).
The start of the process is the manufacturer's selling price, also called the factory gate
or exit price. Theoretically the pharmaceutical wholesalers add a mark-up of 21.2%.
However this is brought down by the practice of giving retail clients discounts, either
on bulk purchases or as reward for loyalty based on the total of that client's purchases
over a period of time. These discounts average 10-11%. The retail pharmacy sector
adds a 50% mark-up on the theoretical wholesale exit price. This results in a maximum
81% mark-up from manufacturer to patient (Internet 1).
Additional dispensing fees (R1.20 per item), broken bulk (10%), container and copy
fees add negligible amounts to the final bill. However, third party payers demand
discounts from the retailer, varying from 20% for acute medication to 30% for chronic
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medication. This can be confirmed by looking at the average cost difference between
gross amounts claimed and net values paid by medical aid administrators. In 2001, this
difference amounted to an average of23.8% for one such administrator (Internet 1).
In order to understand the net result of these mark-ups and discounts, it is easier to
consider a product leaving the manufacturer at a nominal R100.00. This product would
therefore be sold by the wholesaler at R121.20, but the discount offered would on
average reduce the actual cost to the retailer to R109.80. The retail pharmacist would
then add the 50% mark-up to the theoretical purchase price of R121.20, selling the
product at R181.80. In turn, the retail pharmacist would be required to discount this
price to either R165.25 (20%) or R145.08 (30%) depending on whether it was claimed
against the patient's acute or chronic benefit. Value added tax would be levied at 14%.
If the actual amounts retained by each actor in this chain after applying discounts are
expressed as percentage contributions to a final amount (100%), for each of the two
discount scenarios described above, then the "contribution" of each step to the final cost
can be seen Table 2.2 (Internet 9).
Table 3.2: Relative contributions to the final selling price of a medicine to the
private sector patient in South Africa
Discount scenario Manufacturer Wholesale Retail VAT




60.5 15.5 121 .7 F
130% (chronic medicines)
1
68.9 /6.3 112.5 F
Source: www.napm.co.za
The greatest proportion of drug costs is accounted for by the manufacturer's exit price,
with less than 40% being constituted by the entire distribution chain costs. There has
been significant vertical integration in South Africa. As much as 55% of wholesale
trade now goes through direct distributors owned by consortia of manufacturers, like
Direct Medicines (Internet 1).
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The situation in South African private hospitals is different, where a 0% mark-up on
wholesale list price is levied. Private hospital pharmacies have however been able to
use their collective buying power to extract rebates from manufacturers of up to 20%.
In effect therefore, they make a profit on medicines despite levying no mark-up. When
the 0% mark-up was introduced, an agreement was reached between the hospitals and
the medical aids that prices should not rise more than 20% between December 1998 and
April 2000. They had in fact only risen by 13.2% over that time period, as can be seen
in Figure 3.2. Nonetheless, a steady increase in private sector drug prices is evident
from the data (Internet 9).
The DOH objective of replacing mark-ups with a fixed professional fee has not been
realized, despite intense negotiations between the PSSA and BHF. Current proposals
include a professional fee ofR20.00 per item, plus the disclosed non-discriminatory net
unit exit price from the manufacturer, plus inventory related costs (5%) and practice
costs (R4.00). No discount would be given to the medical aid, and VAT would be
levied as before. However, as this fee would be applied regardless of the cost of the
medicine, current very low cost items might actually increase in price. The logic behind
the policy is that removing the profit motive will mean that the pharmacist earns the
same amount, regardless of whether there is dispensing of an expensive branded
product or a cheaper generic. One effective cost containment measure that is in place is
that for anti-retrovirals under the "Aid for AIDS" programme operated by Medscheme.
Such drugs are paid for by the medical aids at factory gate prices plus R50.00, without
any mark-ups at either wholesale or retail level. However, this does not apply to other
AIDS-related drug needs, such as drugs for opportunistic infections and palliative care
(Internet 1).
3.4.3 Bulk purchase measures
The State already uses the most basic measure, that of competitive bidding by a tender
system, as the major mechanism to ensure maximal price leverage. However, tenders
are only open to locally-registered firms. It is possible that better prices might be
obtained on the international market. This does have implications for the reach of the
Medicines Control Council (MCC).
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Manufacturers abroad should either be cleared by the inspectorate for Good
Manufacturing Practice (GMP) standards, both before and during the tender period, or
foreign regulatory systems or international certification schemes must be relied upon to
guarantee the quality of goods purchased. Recent indications are that competitive
bidding alone is not assuring the State of sufficiently competitive prices. A number of
products were identified where the price offered by a local tender was more than double
the median price in the International Drug Price Indicator Guide (Internet 1).
Post-tender negotiations have been successfully used to further reduce prices in some
instances. A growing demand is for regional bulk purchasing arrangements, particularly
with other member states of the Southern African Development Community (SADC).
These are crucial if African countries are to overcome their historical disadvantage in
negotiating power with the global pharmaceutical market. Such arrangements can also
be used to bolster local production. Africa still imports more than 90% of its
pharmaceutical needs, and the African share of global production value has slipped
from 1.3% in 1975 to 0.7% in 1995. Three successful regional schemes are available for
comparison. Bulk purchasing by countries of the Union Maghreb Arabe (Libya,
Mauritania, Tunisia, Algeria, and Morocco) achieved price reductions ranging from 15-
20%. The six-nation Gulf Cooperation Council (Bahrain, Kuwait, Oman, Qatar, Saudi
Arabia and the United Arab Emirates) achieved savings averaging 30%, compared to
purchasing by individual countries. A trial by the African Association of Central
Medical Stores for Essential Drugs (ACAME) involved 5 essential drugs procured by
three countries (Guinea, Mali, and Niger), compared to bulk purchasing tenders. The
costs obtained by the bulk scheme were 7-27% lower than the individual countries had
been able to obtain for the previous 3 years (Internet 9).
Perhaps the most telling evidence of the power of collective bargaining comes from the
recent MSF price comparison study which noted that far greater reductions had been
obtained by international agencies with regard to drug price reduction offers to African
agencies. The Pan American Health Organization (PAHO) supplies vaccines at
discounts of between 86 (Haemophilis inf/uenzae type B) and 99% (oral polio vaccine)
compared to US public sector (Centers for Disease Control) prices. The United Nations
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Population Fund (UNFPA) is able to supply contraceptives at between 97%
(injectables) and 99% (condoms and oral contraceptives) discounts compared to US
wholesale prices (Internet 9).
3.4.4 International trade agreement relief measures
A fundamental way to address prices would be to weaken the monopoly-like powers
afforded the manufacturers by the patent system. In essence this would involve either or
both of the following measures:
• Compulsory licensing by giving a local firm the right to make a copy of an
expensive patented drug at a lower price, while compensating the patent holder
• Parallel importation by buying drugs from countries where prices are already
lower, and so trading in parallel with the local seller of the same drugs.
Patent rights are underpinned by international trade agreements, in particular the
Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). For
example, by 2006 all signatories to the Agreement, which means all members of the
World Trade Organisation, must give drug companies 20 years' patent protection on
their inventions. Much attention has therefore been focused on attempts to soften the
potential access-denying impacts of these agreements. The WHO and other
commentators have produced guidelines on the safeguards available to nation states
under the TRIPS agreement. Opposing views on such measures include the view that a
patent is not an absolute right (Internet 5).
Included in the relief measures outlined by the WHO, and in line with the international
agreements, is the right to issue compulsory licenses. This right may be used where a
patent holder can be shown to be abusing its monopoly position, or in cases of national
emergency. Such licenses may only be used predominantly for supply of the domestic
market, but both entire imports and partial exports are permissible. This could allow
South African decisions to be made to the additional benefit of our SADC neighbours.
A compulsory license issued in South Africa could be used to allow importation of the
drug that was the subject of the license from a manufacturer outside of South Africa.
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However, while the TRIPS agreement only allows this strategy to be used to mainly
satisfy our own needs for the drug, there is some flexibility allowed. Some of the stock
procured under the license, by local manufacture or importation, could in turn be
exported. Such flexibility is important if South Africa is to export needed drugs to
neighbouring countries, which perhaps lack the infrastructure to engage in manufacture
under compulsory licenses. South Africa has recourse to the 1978 Patents Act, which
includes a compulsory license provision. The Medicines Amendment Act (Act 90 of
1997) introduced health-specific measures to exploit the safeguards provided by TRIPS
(Internet 5).
Parallel importation is based on the principle of exhaustion of rights, a patent holder's
rights are said to be "exhausted" once the product is first placed on the market, allowing
the purchaser to resell the product without offending the intellectual property rights of
that patent holder. Specific mention is necessary in national law of where rights are
considered to be exhausted, so that parallel trade can occur within that area. Industry
groups have contended that even where regional exhaustion of rights does occur, as in
the European Union, price reductions to the consumer have been modest. It is alleged
that profits are generally retained by the parallel importer. This might not be the case
where the State is the importer, but might blunt the impact of parallel trade in the
private sector. There is a concern that parallel trade and price regulation based on
international comparisons might lead to price convergence at higher levels (Internet 9).
Many developing nations assume that innovator products are patented in their countries.
It is important to note that international patents do not exist. Patents are only issued in
terms of national law or regional agreements. Some countries and regions have
mistakenly enacted patent measures in excess of the minima set by the World Trade
Organization (WTO). This is particularly true of the West African signatories to the
revised Bangui Agreement. South African health authorities have also not made a
systematic search for unpatented products, which might be available cheaper from
generic manufacturers such as those in Brazil and Thailand. A major feature of the
global pharmaceutical industry is that of voluntary licensing, to a greater extent than is
seen in other manufacturing sectors. Cross-licensing between firms that have shared
R&D costs is also common. This experience can be put to good use in technology
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transfers between major multinationals and local manufacturers, without unduly
impacting upon global returns on investment (Internet 9).
3.4.5 Demand side measures
Coercive rules to force rational prescribing behaviours on prescribers have rarely been
successful without considerable "buy-in" by the prescribers. This remains a neglected
area in both the private and public sectors in South Mrica. The SAMA has attempted to
address the situation by developing minimum treatment guidelines for medical
professionals, to set a minimum standard of cost-effective care in South Africa. The
dispute over licensing of dispensing doctors has not helped the situation as medical
professionals felt marginalized in favour ofpharmacists, by government.
3.5 THE MEDICINES AND RELATED SUBSTANCES CONTROL
AMENDMENT ACT, ACT 59 OF 2002
This Act provides for the supply of more affordable medicines to the people of South
Africa, and for the tightening up of safety regulations concerning the manufacture,
preparation and dispensing of medicines in South Africa.
3.5.1 The Supply ofMedicines in South Africa
Under the previous legislation, only medicines registered in South Africa could be
imported and supplied to pharmacies, hospitals and patients. It was not possible for
pharmacies to obtain or dispense 'generically equivalent' medicines - medicines which
contain the same active ingredients and are identical in dose or concentration and
dosage form to the registered, branded medicines, but which are usually considerably
cheaper.
3.5.2 Parallel Importation
The Act allows the 'parallel importation' of medicines, which means buying an
identical product made by the same company, but from a location other than where
the South African distributor purchases it, and at a lower price. It is also permissible
to import medicines not currently registered in South Africa if they are generically
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equivalent to medicines already registered in South Africa. The South African
government justified this position by stating that it recognizes the intellectual property
rights of manufacturers of patented medicines and will only parallel import from
countries and companies which also recognize patent rights and which include the
accepted patent cost in the overall price ofthe generic equivalent medicine.
3.5.3 Prescribing Generically Equivalent Medicines
Doctors and other health professionals issuing prescriptions are encouraged to
prescribe generically equivalent medicines, instead of branded medicines. Moreover,
whenever a person takes a prescription to a pharmacist, the pharmacist will have the
following obligations:
• to inform the person of the benefits of substituting the prescribed medicine
with a generically equivalent medicine
• to dispense a generically equivalent medicine, instead of the medicine
prescribed, unless expressly forbidden to do so by the patient.
A pharmacist will not be permitted to dispense a generically equivalent medicine if:
• the person prescribing the medicine has written 'no substitution' in his/her own
handwriting on the prescription
• the retail price of the generically equivalent medicine is higher than that of the
prescribed medicine
• the product has been declared unsuitable by the Pharmacy Council of South
Africa.
3.5.4 Pricing Committee
A pricing Committee was established to advise the Minister on a transparent pricing
system for all medicines, to monitor the pricing of medicines and advise on an
appropriate dispensing fee.
3.5.5 Bonusing and Sampling
Bonusing is an incentive system used by pharmaceutical companies to encourage
pharmacists or other licensed dispensers to supply their medicine in preference to
another. Sampling is a system under which manufacturers, wholesalers or agents
supply free medicines to pharmacists or other licensed dispensers.
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Both bonusing and sampling was banned, as is any other rebate system or incentive
scheme. This is an attempt to eradicate any perverse incentive schemes which have
impacted on ethical health care delivery.
3.5.6 Code of Ethics
A code of ethics is to be implemented by the Minister relating to the marketing
policies of pharmaceutical companies after a consultative process with all
stakeholders.
3.5.7 Safety Regulations
With the change in legislation, the SA government aimed to improve safety and time
efficiency, therefore it now:
• requires that medical practitioners, dentists, practitioners, nurses and any other
registered person be licensed before being allowed to dispense medicines with
the exception of an emergency bag containing medicines to treat patients in
emergency situations, which will not require a dispensing licence
• requires that manufacturers, wholesalers and distributors of medicines or
medical devices to apply to the Medicines Control Council for a licence before
being allowed to manufacture or supply such medicines or medical devices
• increases the powers of inspectors to enter any premises in which medicines
are manufactured, stored, compounded or dispensed; and to enter any
premises, place, vehicle, vessel or aircraft if there is reason to suspect that an
offence has been or is being committed or attempted.
3.6 THE HEALTH PROFESSIONALS COUNCIL'S RESPONSE
The HPCSA responded to the legislative changes by issuing guidelines regarding
perverse incentives that supplemented its existing policy. These policy guidelines
were translated by SAMA
into a Code of Ethics that should govern the relationship between the medical
fraternity and the pharmaceutical industry.
The HPCSA stated that "health care professionals should always try to avoid potential
conflicts of interests and maintain professional autonomy and independence. Any
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conflicts of interests or incentive or form of inducement which threatens such
autonomy, independence or commitment to the appropriate professional and ethical
norms or which does not accord first priority to the clinical need of a patient, is
unacceptable" (Internet 7).
In this policy statement, the Medical and Dental Professions Board identified those
incentive schemes and forms of inducement which it finds unacceptable but
acknowledged that this should not in any way be regarded as an exhaustive list. The
principles underlying the listed perverse incentives however, would be will applied in
every case of alleged unprofessional conduct on the part of a health care professional
in the private or public sector and where applicable would form the basis for an
investigation by an appropriate health care authority or the Board (Internet 7).
The HPCSA acknowledge that historically, there has been a close collaboration
between health professionals and the pharmaceutical and health supply industry which
extended particularly to continuing professional development. However, it felt that
health care is to a large extent self-governing and practitioners were encouraged to
ensure that their participation in such collaborative efforts was in keeping with their
duties towards patients and society. Although the decision on content and choice of
continuing professional development activities, as well as funding arrangements lay
ultimately with the health care provider, organisations such as professional
associations, its branches and groups, should not be put in a position of conflict of
interest by virtue of any relationship with the funding body. The organisers may
acknowledge financial or other aid received, but should not identify any specific
products. Generic names of products should be used rather than trade names in the
course of continuing professional development activities. Funds for continuing
professional development activities should preferably be in the form ofan educational
grant payable to the health care provider organisation arranging the activity (Internet
7).
The HPCSA felt that no travel or lodging costs or other expenses should be paid by
the industry for individual health care professionals to attend a continuing
professional development event. Scholarships, grants or other special funding, to
permit students and other deserving health care professionals to attend continuing
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professional development activities are permissible, provided the funds are paid to the
organizers for disbursement. The organizers may extend reasonable honoraria and
imbursement for travel, lodging and meal expenses to speakers. The principal event
should at all times centre around education and not around meals, entertainment or
other hospitality, the cost of which should not exceed that level which the recipients
might reasonably be expected to incur for themselves under similar circumstances
(Internet 7).
The HPSCA supported the established practice that health professionals should
benefit from being exposed to new knowledge and insight into their respective
professions and/or disciplines by the attendance of international conferences, either
locally or overseas. It was regarded of utmost importance that young and upcoming
health care professionals and educators and those from disadvantaged backgrounds be
given an equal opportunity to expand their knowledge and understanding with regard
to their respective professions and/or disciplines by the attendance of such
international conferences. It was therefore permissible for companies to sponsor
delegates to attend international conferences, either directly or through professional
associations/societies, with the proviso that a fair and transparent process should be
followed in the election and sponsoring of delegates to attend such events, especially
with regard to the attendance of such conferences by young and upcoming health care
professionals and educators and those from disadvantaged backgrounds. Such
sponsorships were to be earmarked for specific educational events/conferences and
not for holiday purposes (Internet 7).
It was stressed that a distinction should be made between education and training on
the one hand and product promotion on the other as practitioners could not be seen to
be earning continuing professional development points for attending product launches
or other product promotion events.
3.7 THE IMPACT OF NEW LEGISLATION ON PHARMACY PRACTICE
The Pharmacy Act came into effect on 2 April 2003. This deregulated pharmacy
ownership in South Africa. Pharmacies could now be owned by non-pharmacists so
long as a qualified pharmacist is employed to run them. This mirrored the situation in
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the United Kingdom and it opened the door for multiples and other retailers to
increase their representation. For example, mixed supermarket style retailers like Pick
n' Pay could enter the market.
Under the new act the South African Department of Health (DOH) will have
responsibility for the licensing of pharmacies. All persons wanting to own a
pharmacy, including registered pharmacists, have to apply for a licence. By having
control of pharmacy licensing, the DOH obtained a more rational distribution of
pharmacies. There was no guarantee that, should a pharmacist wish to sell an existing
business, a licence will be transferred to a new owner. It depended on whether the
DOH found it favourable or not and the DOH was likely to consider the siting of the
existing pharmacy in its decision.
The South African Pharmacy Council continues to have responsibility for the
registration of pharmacists. This includes maintaining acceptable standards in
pharmaceutical education and pharmacy practice. With regard to pharmacy premises,
the pharmacy council's role is limited to inspection and record keeping only.
United South African Pharmacies, which represents about two-thirds of independent
community pharmacies in South Africa, has expressed concern about the possibility
of large retail firms stepping into pharmacy. It has suggested that large retailers
should only be permitted to open up pharmacies in areas that do not currently have
pharmaceutical services. There appears to be some uncertainty about the DOH
intentions with regard to this.
In the Medicines and Related Substances Control Amendment Act, Act 90 of 1997,
pharmacists are required to offer customers a generic substitute, regardless of what
the prescriber has written. This is assuming that the drug is off-patent and a generic is
available. The aim of this according to the director-general of health, Ayanda
Ntsaluba, is that Act 90 will bring down drug costs.
Concerns have been raised that this legislation, although aimed specifically at
amending practice in community pharmacy, will have implications for hospital care.
Norman Weltman, director of the Hospital Association of South Africa, has
questioned how pharmacists are expected to deal with an unconscious person since
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the new legislation specifies that patients must be asked whether they would like to
receive a generic substitute.
3.8 DEFENDING THE MEDICINES CONTROL AMENDMENT
This Act was enacted during the term of President Nelson Mandela who was cited as
the first respondent. It was a critical instrument seen by the SA Government as a way
ofachieving its National Drug Policy (NDP).
The SA government's motivation for the changes in legislation were:
• The legislation was viewed as a major step forward in the drive to improve
South Africa's access to cheap, safe, quality medicines.
• The cost of medicines to patients, hospitals and medical aid providers was
being cut.
• It was felt that the pharmaceutical companies opposed the Bill, because it
reduced their scope for profits, however, the South African medical aid
industry welcomed the Bill, because it reduces costs to patients.
• The discredited practice, employed by some pharmaceutical companies, of
providing free samples, bonuses, perks and even free holidays to medical
professionals for prescribing and dispensing their drugs was dealt with.
• The DOH would be able to use savings on the cost of medicines to improve
other aspects ofhealth care delivery.
• The Bill, for the first time, gave patients a real choice in what medicines they
are being prescribed.
3.9 PHARMACY ACT 90
Pharmacy Act 90 is a progressive piece of legislation that aimed to regulate the
pharmaceutical industry while offering the SA government some comfort that the
people of South Africa were going to benefit in terms of affordability of
pharmaceutical products. After 1994, South Africa was viewed as a positive market to
enter for most multinational companies, however, there was also the reality that a
'black market' in trading of most commodities was also open and the pharmaceutical
industry was not immune to the attack from cheap, parallel imports from developing
countries. Section12 ofPharmacy Act 90 has two controversial areas.
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3.9.1 Sampling
Prior to Pharmacy Act 90, pharmaceutical companies could provide suppliers of
service with 'free' samples that were distributed as trial packs to patients. Sampling
itself is a common marketing practice that allows products to be made available to a
customer base. The SA government's perspective was that this practice was
vulnerable to bribery and corruption and was being abused to by suppliers of service
and pharmacies to circumvent VAT and taxation. Sampling is not allowed under the
new legislation, however, the wording of the new legislation is unclear as to whether
sampling is allowed on compassionate grounds.
3.9.2 Generic Substitution
With the goal of affordable health care in mind, the SA government came out in
support of generic substitution and actively supported the concept. It has therefore
been incorporated into the legislation so that the consumer is given the choice at the
level of the pharmacy of a generic substitute, even if a branded product is scripted. A
duty is placed on pharmacists who dispense to ask the patient if a generic substitute is
preferred.
The difficulty facing the pharmaceutical industry is that branded products incur huge
research and development costs that have to be recouped from product sales before
the patent expires. These costs do not apply to companies producing generic drugs,
who only have to provide the Medicines Control Council with bioavailability studies
for generic drugs to be allowed registration. Further, even though most multinational
companies have their own generic division in South Africa, stiff competition is faced
from 'illegal' parallel imports from developing countries. There is poor regulation and
control of what is available in the SA market and this represents a major threat to
growth of the industry. The SA government's position with the industry has been that
generics drugs are here to stay.
3.10 CONCLUSION
This chapter focused on the impact that legislative changes in the pharmaceutical
sector have already had on the industry. There are several unresolved issues. The
pharmaceutical industry has been concerned about the implications of the legislation
for the market in South Africa and clarity is required on the confusing aspects of the
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legislation. Even though an industry task group was formed to address the
controversial areas of donations and sampling of pharmaceutical products, there have
been no guidelines issued for the provision by pharmaceutical manufacturers of
registered medicinal products for compassionate use or for a marketing code. Chapter
Four will consider lessons from the international arena.
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CHAPTER FOUR: LESSONS FROM INTERNATIONAL EXPERIENCE
4.1 INTRODUCTION
The pharmaceutical industry globally has been in a state of flux with mergers and
acquisitions involving some of the largest conglomerates internationally. The leading
pharmaceutical company in the world Pfizer Laboratories recently acquired two major
pharmaceutical companies to become the world leader. Simultaneously, there has
been a flurry of activity from activists who maintain that giant pharmaceutical
companies are solely driven by profit margins, with little social responsibility, hence
the high cost of health care. Large conglomerates do invest billions of dollars in
research and development, however, there are questions being raised about whether
the pharmaceutical industry is in fact driving the swing to evidence-based medicine,
so that its products can be utilised by increasing numbers of the population. Lipitor,
the drug with the highest sales internationally, marketed by Pfizer Laboratories is an
anti-cholesterol drug and many question whether its prescription is necessary in such
large numbers. Antidepressants, like Glaxo's Paxil and Lundbeck's Cipralex are listed
in the top 10 of drugs sold in the US. There is concern expressed about the cost of
these medications, which are justified by the drug companies, as being due to R & D
costs (Internet 7).
Worldwide, there is an increasing focus on endorsing the use of generic medicines as
a means of saving costs to the health care system. In the UK, generic medicines
account for almost 52% by volume of all prescriptions whereas in South Africa, it is
estimated that generic usage is of the order of 20% on the market. The economic
importance of increasing use of generic medicines was highlighted in the US when
new regulations were proposed to limit the ability of drug companies to prolong
patent protection. It has been estimated that this change will create savings of some
US$3billion for consumers (Internet 4).
Chile faces similar challenges to South Africa, with very similar stratification between
a private sector serving some 20% of the population and an overburdened and under-
resourced public sector servicing the remaining 80%. A report on their policy choices
concluded that it was not clear that the process of privatization of health care or the
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financing of health services, and the complete liberalization of drug prices, are the
best ways to achieve equitable and rational coverage in respect of drugs in Chile. The
state urgently needed to devise mechanisms to exercise its normative functions in
regard to drugs in order to prevent the present freedom from degenerating into
anarchy (Internet 8).
Both a WHO review on health reform and drug financing and the Austrian Health
Institute review of market controls in Europe point to a "pendulum" effect. As
governments act on an unfavourable situation by either tightening state control or
relying on market instruments, so the local situation reacts, initiating a swing in the
opposite direction. The challenge is therefore to minimize the amplitude of the
swings, by finding an adequate but flexible mix of interventions. That different
countries may be at different parts of the pendulum's swing might go some way to
explain the apparent paradox that while developing countries are generally moving
towards market-driven policies, developed nations are increasingly resorting to direct
interventions. The policy instruments included in most countries' national drug policy
(NDP) seem to vacillate between intervention and what has been termed "monitored
freedom". This latter course has not been shown to be particularly effective. There are
also potential conflicts with overall trade policies as some may also be in conflict with
each another. For example, higher levels of price control may inhibit the development
ofa generic market (Internet 8).
4.2 THE GENERIC DEBATE
Rising pnces of medicines are putting essential medicines and other drugs like
antidepressants beyond the reach of many people, even in rich countries. In less-
developed countries, millions of individuals do not have access to essential drugs, let
alone CNS products and drug development is failing to keep up with the major health
needs of these countries. The prices of patented medicines usually far exceed the
marginal costs of their production. The industry maintains that high prices and patent
protection are necessary to compensate for high development costs of innovative
products. There is controversy over these claims, as has already been discussed
(Internet 8).
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Concerns about the harmful effects of the international system of intellectual property
rights that are protective towards large conglomerates have led the World Trade
Organization to relax the demands placed on least developed countries, and to
advocate differential pricing of essential drugs. How these actions will help countries
that lack domestic production capacity is unclear. Better access to essential drugs may
be achieved rather through voluntary licensing arrangements between international
pharmaceutical companies and manufacturers in developing countries and South
Africa is no exception (Internet 8). Generic medication seems to be a rather obvious
solution to a pressing problem. The controversy is that governments of developing
countries are using parallel imports to service their generic market.
4.2.1 The World Health Organisation
A major challenge facing the governments in Mrica, including South Africa, is how
to provide affordable health care to the majority of the population that cannot be
catered for in the private sector. The South Mrican government has stood its ground
against the major players in the pharmaceutical industry with regard to the issue of
generic medication and parallel imports as their view has been that this is the only
feasible option of meeting the need (Internet 5).
There is rising concern that the WHO has permitted a handful of large pharmaceutical
companies to exercise undue influence over its polices and programs, and that in
particular, the WHO has been intimidated and deterred from exercising leadership on
a wide range of trade related issues, and has shrunk from its traditional role in
promoting the use ofgeneric drugs in poor countries (Internet 14).
In the area of AIDS, the WHO has been collaborating with big pharmaceutical
companies on an ill-advised public relations effort, called the "Accelerating Access
Initiative", which is designed to:
• undermine the legitimacy of national campaigns for compulsory licensing of
patents on mv drugs
• pressure poor countries to adopt overly restrictive intellectual property
policies in return for extremely limited and unsustainable donation strategies
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• undermine the success of Southern African generics producers, who have been
the most effective agents in bringing down the prices of mv drugs (Internet
14).
The central message of the WTOIWHO appears to endorse a model of restrictions on
parallel imports on medicines and negotiated discounted prices by big pharmaceutical
companies, as it has failed to come out in support of the broader use of parallel
imports of medicines and compulsory licensing as sound policy goals (Internet 8).
The WHO has obviously not accepted the objective analysis that one of the factors
that drove down the prices of mv drugs in poor countries was the availability of
generic medicines or it would have been more proactive with regard to efficient
procurement and competitive tendering from generic suppliers.
The WHO needs to direct the process with regard to:
• WHO trademark provisions, an issue of very large importance in generic drugs
• the costs of patent litigation
• the capacity of poor countries to resolve patent disputes
• the implications for poor countries if they lack the practical ability to reject
overly broad or non-novel patent claims;
• the costs of "ever-greening" strategies for patents, involving cases where
companies seek endless extensions of market exclusivity by filing new patents
on old drugs
• the implications of WTO TRIPS restrictions on the export of medicines
produced without permission of a patent owner. Specifically, while the WTO
TRIPS gives countries fairly broad authority to issue compulsory licenses or
authorize government use of patents, for most cases this is predominantly for
domestic use, making it problematic for smaller market countries to benefit
from such measures, when economies of scale would make it impractical to
produce drugs locally. The WHO needs to spell out in practical terms exactly
how a rigid interpretation of restrictions on such exports would affect the
health care of the poor in smaller market countries.
• Pro-consumer strategies for implementation of TRIPS, Article 39.3 which
honours obligations for protecting pharmaceutical drug registration data
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• The public health concerns with respect to TRIPS Article 27.1, which requires
that patent rights not discriminate on the basis of the field of technology, and
in particular, the concerns that a one size fits all patent system will hamper
efforts to protect public health interests.
• The extent to which patent exceptions for research serve the public interest,
and the policy instruments needed to address problems of excessive
intellectual property claims on research tools.
• The need to develop simplified and easier to administer systems for
compulsory licensing of patents and the development of model legislation.
• New models for treatment of health care in trade agreements that focus on
funding R&D, rather than on the protection of property rights (Internet 8).
4.3 PRIVATE SECTOR DEVELOPMENT IN LOW INCOME COUNTRIES
In recent years there has been a considerable growth of interest in the activities of
providers in the private health sector in low-income countries, and in how policy-
makers might best capitalize on the accessibility and popularity of this sector. There
have been many references to social marketing, accreditation, franchising and
contracting as a way forward to developing this market (Internet 8).
4.3.1 Characteristics of the private health sector in low-income countries
The private health sector may be defined as comprising all providers who exist
outside the public sector, whether their aim is phiJanthropic or commercial. In Africa,
they include large and small commercial companies, groups of professionals such as
doctors, national and international nongovernmental organizations, and individual
providers and shopkeepers. The services they provide include hospitals, nursing and
maternity homes, clinics run by doctors, nurses, midwives and paramedical workers,
diagnostic facilities, e.g. laboratories and radiology units, and the sale of drugs from
pharmacies and unqualified static and itinerant drug sellers, including general stores
(Internet 13).
In practice, there is a considerable overlap between the public and private sectors.
Staff employed in the public sector in most countries also practice privately, either on
their own account or working for owners of private facilities. This may be legal or
may not be strictly legal or controlled. Public hospitals often operate their own private
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wards and manage the income from them, or allow work for private gain on their
premises, as when doctors admit private patients and are paid directly by them. This
situation needs monitoring because if public services become heavily dependent on
fee income, there may be little to distinguish them from private enterprises that
operate in the interest of their owners rather than in that of the general public (Internet
13).
The private sector therefore represents a resource that is available and used even in
the poorest countries and among lower income groups. However, the effectiveness of
private services is often very low, even though they are popular because they are
accessible and cheap because there is often adjustment to the purchasing power of the
consumer. The use of the more expensive private services, or treatment for chronic
conditions, however, can result in households being unable to afford other vital
requirements. Over 10% of the income of the poorest quintile of the population is
often spent on medical care. The other concern is that rapidly growing private services
compete with the public sector for trained human resources. There are pros and cons
to the situation as it weakens the public service but opens up the possibilities of using
private sector resources to promote public health objectives (Internet 13).
How can the operation of the private market be improved in developing countries?
The current situation is the result of interaction between consumers and providers.
Consumers make their decisions on which providers to use on the basis of price,
available income, their knowledge of different providers, and their preferences for
services with different characteristics, particularly relating to quality. Providers are
influenced by what it costs them to provide services, what they can charge, their own
knowledge, and the regulatory environment. Efforts to improve the current situation
should influence demand or supply directly or should seek to restructure the overall
environment (Internet 8).
4.3.2 Influencing Consumers
Consumers in low-income countries face a number of problems in relation to the
private sector. They often lack knowledge about appropriate means of treating and
preventing illness. This translates into low levels of demand for effective disease
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control measures. They are dependent on providers for information and this can make
them vulnerable to self-interested behaviour by providers. Consumers are usually
unable to assess the technical quality of services, with the result that they place more
weight on aspects of perceived quality, such as the interpersonal skills of providers
and the comfort of the environment in which treatment occurs, both of which may be
unrelated to technical competence. They may, therefore, be more exposed to
inadequately qualified practitioners providing care of very poor quality. Consumers
with low incomes may choose to use practitioners in the informal sector, such as
unqualified providers and drug sellers, rather than higher-quality private providers.
However, very little is known about the patterns of health-seeking behaviour in
different socioeconomic groups in developing countries or about the extent to which
the poor rely more than the better-off on low-quality private providers. Relatively few
approaches to supporting consumers in their use of the private sector have been tested
(Internet 13).
4.3.3 Social marketing
Social marketing is increasingly being used to tackle lack of consumer information. It
uses commercial marketing techniques to stimulate demand for effective public health
interventions that are then sold, often through the private sector. Social marketing
organizations are often non-profit firms or associations, but the products tend to be
distributed through various for-profit outlets and nongovernmental organizations.
Social marketing has been applied to such diverse interventions as family planning,
the treatment of sexually transmitted infections, the use of insecticide-treated
mosquito nets, hand-washing and water purification. Although important increases in
coverage have been achieved for a wide range of socially marketed interventions,
there remains much debate about whether social marketing strengthens the private
sector by creating new demand that spills over into demand for full-priced
commodities or whether, instead, it crowds out the private commercial sector. The
lack of evidence is exacerbated by the fact that social marketing projects tend to
measure their success in terms of sales of their own branded products rather than by
the development of the market as a whole (Internet 13).
By providing subsidized commodities, social marketing also helps to increase
affordability. The level of subsidy differs enormously between projects and types of
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intervention; however, the price of a product often covers its cost, leaving the
promotion and distribution costs to be covered by public, usually donor, funds. This
form of subsidy is usually untargeted, raising the possibility that a substantial share
leaks to people who would otherwise have purchased the product at the full price.
Furthermore, other measures are needed to ensure access for very poor people who
cannot afford even the subsidized product (Internet 13).
There is limited experience with the branding of services and the use of social
marketing to promote them. Increasing demand for commodities is likely to be met
with an increase in supply, but qualified staff are in short supply and long periods
inevitably elapse while new personnel are trained. This means that an increase in
demand is likely to result in higher prices and/or staff being drawn from the public
sector. In both cases the overall effect on utilization is diminished. To the extent that
the social marketing of services succeeds in reorienting demand towards the suppliers
of services of higher quality, the incentives to provide high quality can be expected to
be strengthened in the long run. In the meantime, however, there is a risk that the
tendency for markets to be segmented along income/quality lines will be reinforced,
with the usual consequences for equity (Internet 13).
4.3.4 Use of vouchers
Targeted distribution of vouchers that are exchanged for services or products from a
private provider is an alternative to an untargeted subsidy at the point of purchase.
Vouchers interfere less with the supply side, since providers continue to sell at the
market price. They also allow consumers to exercise choice over where they receive
services: the money follows the patients, and providers therefore have to compete for
business, making them more sensitive to the preferences of patients. A voucher
system nevertheless needs a mechanism for determining who qualifies for subsidy,
and vouchers can be traded among individuals, making it more difficult to ensure that
subsidies reach the target group. Voucher systems have been used for targeting some
lower income groups, but their potential remains underexploited (Internet 14).
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4.3.5 Consumer protection
Consumers often lack the institutional structure to seek redress when they have been
victims of medical malpractice or negligence. One example of the creation of such a
structure was the incorporation of private medical practice into the Indian Consumer
Protection Act of 1986. A number of improvements followed, but other
complementary measures are needed in order to confront the poor quality of care in
the private sector (Internet 13).
There are other potential approaches to strengthening the position of consumers in
private medical markets. Direct consumer education could help to inform patients
about what constitutes care of good quality for a range of common medical
procedures; information about prices could help patients when they choose providers;
and social marketing approaches could prove useful in publicizing such information.
Although regulation and accreditation are, strictly speaking, provider-side
interventions, they play an important role in sending clear and transparent signals to
consumers about which providers are registered and meet minimum requirements in
terms ofstructure, equipment and staff (Internet 13).
4.3.6 Influencing private providers
Governments of developing countries could use a range of approaches when working
with private providers rather than relying on single strategies.
4.3.6.1 Training
The improvement of knowledge and skills is a necessary starting point. Most private
providers receive no guidance from the public sector on diagnosis and treatment.
Consequently, their practices are determined more by biased information from
pharmaceutical companies. Although imaginative ways of disseminating evidence-
based information to private providers are insufficient on their own to change
behaviour, they offer a potentially affordable strategy that has been little explored.
Training is central to most approaches. However, improvements attributable to one-
off training may be short-lived, and follow-up and supervision in the private sector is
difficult for an under-resourced public sector unable to supervise its own health
workers (Internet 13).
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4.3.6.2 Regulatory and participative approaches
The private ambulatory sector can be highly competitive, so that success in meeting
users' perceived needs and retaining clientele is vital to the economic survival of
providers. Private providers may use treatments they know to be ineffective because
of actual or perceived user demand. The involvement of service users in the training
of providers has successfully reinforced improvements in practice. However, private
providers may engage in what they know to be unethical practices in order to
maximize income. Regulatory approaches, including consumer protection legislation,
have helped to highlight these practices but have done little to control them. An
approach that could have great impact in the longer term is for the public sector to
work with providers' representative organizations in order to promote professional
ethics, building on non-financial incentives such as the desire of providers for social
recognition and prestige. Such organizations could also be used to support measures
promoting rational drug prescribing, which have mainly been applied in the public
sector (Internet 13).
4.3.6.3 Resourcing providers
Private providers may lack access to essential diagnostic services and treatments. One
approach has been to provide them with prepackaged drugs for common conditions.
However, perverse outcomes can occur, so such strategies require a high level of
monitoring.
4.3.6.4 Comprehensive approaches
Some successful projects have adopted a comprehensive approach, improving
providers' knowledge and skills, assisting users to recognize and demand good care,
and helping providers to apply what they have learnt. In these projects the quality of
clinical care was monitored by external assessment, and the project brands were
promoted among potential service users: functions that weak public sectors would
find difficult to replicate on a national scale. This approach runs the risk of further
segmenting the market along income/quality lines though.
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4.3.7 Restructuring the market
Recognizing the importance of the private sector in health system outcomes does not
imply that the public sector has a diminished role to play. Rather, attention is drawn to
the often neglected governmental role of stewardship, without which the private
sector operates unchecked and unguided. Governments should regulate the private
sector not just in the sense of legislating and administering formal rules but also by
intervening to alter the incentives available to private sector institutions and thereby
their activities and performance outcomes.
4.3.8 Government stewardship
The concept of stewardship relates not only to the role of government vis-a.-vis the
private sector but also to a realignment of governmental functions in the public
system, which is often both inadequately regulated and inadequately steered towards
serving a public health interest. By focusing on the purchasing rather than the
providing side of the health services market, government may seek to achieve similar
ends in the public sector to those pursued through contracting out policy in the private
sector. Formal regulation can influence the number of providers through licensing, but
the development of purchasing may create a significant new market to which private
providers respond. The separation of purchasers and providers involves the creation of
public provider institutions with increased autonomy. These can be expected to
compete more vigorously with private sector alternatives (Internet 13).
4.3.9 Contracting out services
Over the past decade, many countries have moved towards greater contracting out to
private providers, largely for non- clinical services but also for clinical services, much
of the latter having been reported in the unpublished literature. Formal contracts are
more common for services that are relatively easy to specify and monitor, e.g. hospital
catering and the provision of commodities, whereas less formal, more trust-based
relationships are commoner for services that are less easy to specify, e.g. most clinical
services. Long-term relationships have traditionally dominated in primary care. This
suggests that the development of competition may not be a common outcome of
increasing reliance on contractual relationships for clinical services, whether or not
the market would otherwise be contestable, or potentially competitive. Indeed, very
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little is yet known of the nature of the relationship between purchaser and provider
and how this affects the care provided (Internet 13).
4.3.10 Regulating the market
Regulation that primarily aims to intervene strategically in the health service market
appears to be relatively rare. In any case, the major issue in regulation is
implementation., which has typically been extremely weak, especially in sub-Saharan
Africa. This implies that regulation is unlikely to have had a major impact on private
providers or on market structure and explains the widespread development of the
informal private sector. Growth of the private sector is largely determined externally,
even when enabling measures intended to support the sector are in place. Experience
gained in a middle- income country suggests that important opportunities to regulate,
before the private sector becomes both politically and economically strong enough to
resist, should not be missed by low-income countries. Regulation seems to be a
function ofthe market as well as, potentially, an influence on it (Internet 13).
4.3.11 Comprehensive restructuring
Comprehensive attempts to fully restructure the health service market are relatively
rare, especially in the very poorest countries. In Zambia the Central Board of Health
has been created to perform the purchasing role at national level. It contracts with
district health authorities and referral hospitals, both public and nongovernmental.
The volume of contractual business with hospitals run by nongovernmental
organizations represents a significant departure from a standard integrated public
sector approach and alters the demand side of the market considerably. It also offers
the opportunity for public coordination of non-profit providers, whereby, for example,
the geographical equity of service provision can be increased and the planning of
coverage of preventive interventions can be improved. Other effects of reform are
constrained by the under-exploitation of the new structures. For example, contract
mechanisms permit the relationships between purchasers and providers to mimic
those of integrated systems, and health ministry officials continue to intervene directly
in the affairs of provider institutions instead of focusing on regulatory and other
functions of stewardship. The restructuring approach has yet to be fully tested in a
low-income context (Internet 13).
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4.3.12 Conclusions regarding developing countries
A fair amount of experience has been gained with private providers in low-income
countries. This has not been translated into information about influencing consumer
behaviour and restructuring the market. Although some successful efforts to influence
private providers have been identified, they are problems. Should South Africa seek to
implement some of these measures, it may imply that government is sanctioning
treatment practices that are contrary to current policy and there may be strong
opposition from powerful professional groups. The monitoring function although
vital, would be difficult to sustain in the long term. Consequently, careful judgement
has to be made concerning the relative return on investment in improving private
sector activities as opposed to investment in a strengthened public sector.
Working with the more organized formal private sector, i.e. doctors, nurses and
pharmacists, is a more feasible starting point for the South African government.
Training and investment in a stronger formal sector, both private and public, and
restructuring the market so as to strengthen the purchasing and regulation functions of
government, can go a long way to addressing imbalances, but this is likely to be a
very long-term process.
4.4 THE US MARKET
The message that many people are suffering with anxiety and depression and in need
of medication has found the spotlight in the US after 9/11. Advertisements for a
depression and anxiety campaign have been widespread in TV Guides, Reader's
Digest, Time and House and Garden magazines. Pfizer, the world's largest drug
maker, spent $5.6 million on TV and magazine ads in October to tell consumers about
the benefits ofZoloft for post-traumatic stress disorder (Internet 7).
US statistics for the year 2001 for marketing activities for the following branded
antidepressants are included in Table 4.1:
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Total for Jan. to Oct. 2001.
Source: Internet 12
$184,464,126
Concerns have been raised that the diagnosis of psychiatric conditions and medication
prescription is being driven by the drug companies. These concerns have been raised
at the APA's annual congress where the sentiment was expressed that a lot of what is
considered evidence-based medicine represents a collation of data from industry-
sponsored conferences where 'research data' is presented to influence prescription
habits of psychiatrists. On closer examination, most of the research is sponsored by
drug company grants and represents mere meta-analysis of statistical data from
various studies (Internet 7).
This has also raised ethical issues about whether the pharmaceutical industry should
have any role to play in the continuing medical education programs of medical
doctors. It is felt that the education of physicians is too important to be left to the
pharmaceutical industry and is a cause of great concern to the American Psychiatric
Association that has been faced with the challenge of finding the right balance with
regard to the ethical involvement of the pharmaceutical industry in medical education.
There is a growing disquiet about the level of influence that the industry has on the
prescription habits of psychiatrists especially in the anti-depressant market, as new
uses are found for older products that are nearing the end of their patent in the US
(Internet 12).
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There are several consumer-based organizations that are fighting back. A new
organization, No Free Lunch has been set up to counter pharmaceutical company
marketing. It has developed a variety of resources, including a "pen amnesty
programme" in which practitioners are invited to send drug company pens to the
organization, which will replace them with their own "No Free Lunch" pens. Drug
company pens are then donated to charity (Internet 14).
The website home page features a questionnaire to ascertain "drug company
dependence". It asks: "Have you ever prescribed Celebrex? Do you get annoyed by
people who complain about drug lunches and free gifts? Is there a medication logo on
the pen you're using right now? Do you drink: your morning eye-opener out of a
Lipitor coffee mug? If you answered yes to two or more of the above, you may be
drug- company dependent" (Internet 14).
It has initiated a "drug-free practitioners" listing, which is made up of health care
providers who have pledged to be "drug company free". The listing aims to provide a
mechanism for patients to find health care providers who are ethically practicing
medicine, and to raise awareness of this issue both among the public and the medical
profession (Internet 14).
4.5 THE UKMARKET
The recent publicity involving the creation of the "super-pharmaceutical" company,
with the recent spate of mergers and acquisitions has left feelings of concern within
the UK and Europe, about drug companies monopolizing the market. It has
highlighted the need for health care professionals to be equipped with skills to
appraise pharmaceutical industry marketing materials critically. According to the
National Prescribing Centre, in the United Kingdom, the pharmaceutical industry
spends about 1.5 per cent of its revenue from sales to the National Health Service on
information and 9 per cent on promotion. It can sometimes be difficult to differentiate
between industry-sponsored information as a form of education and industry-
sponsored information as a form of promotion. Such information is not always
accurate and should not be seen as a reliable source of medicines information
(Internet 7).
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Pharmaceutical marketing has become more sophisticated in recent years. The
industry has generally moved on from using advertisements showing dodgy graphs
with split axes. However, although direct promotional material must comply with the
terms of a product's marketing authorization, evidence to support claims made in
advertisements is not always robust. A number still refer to "data on file". When they
do refer to published papers these often turn out to be short abstracts for posters
presented at an industry-sponsored conference and consequently are unlikely to have
been subjected to rigorous peer-review (Internet 7).
Much pharmaceutical advertising relies on highlighting a drug's effects on surrogate
markers like lowering cholesterol levels. This is particularly true for antidepressants,
the marketing of which frequently relies on empirical evidence (Internet 8) .
4.5.1 Selectively reported results
When trial evidence is available results are often reported selectively to exaggerate
the effects of the product. The most commonly used method is to report results as
relative risk reduction (RRR), where the percentage reduction in events in the treated
group event rate is compared with the control group event rate. Reporting RRR
appears to inflate small differences in effect. A more meaningful measure, preferred
by proponents of evidence-based medicine (EBM), is absolute risk reduction (ARR),
where there is an arithmetic difference in absolute risk between study and control
groups. The reciprocal of ARR is the number-needed-to-treat (NNT), which is useful
for translating trial results into meaningful figures. Pharmaceutical industry
promotional material rarely refers to either ARRs or NNTs (Internet 7).
The National Institute for Clinical Excellence (NICE) guidance in the UK has
attempted to counteract some of the marketing strategies of the industry, especially in
the case of the marketing of the COX-2 selective inhibitors which are aggressively
marketed by Pfizer Laboratories as a breakthrough in anti-inflammatory drugs,
however, studies indicate that non-steroidal anti-inflammatory drugs (NSAID's) are
still regarded as first-line therapy in a number of situations. NICE guidance has been
either used selectively or ignored in the marketing situation (Internet 7).
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Companies still market their drugs directly to the consumer in ways that contradict
NICE guidance, and there is little that can be done as advertising in the UK only has
to comply with the terms of the product'S marketing authorization. In addition to
direct advertising, a lot of pharmaceutical marketing now employs "infomercial"-type
promotion. Some infomercials are quite blatantly promotional; others are subtler and
use an "expert" to review information about a product or therapeutic area. Such
reviews are supported by educational grants from the pharmaceutical industry and
invariably include a statement which says that the views expressed in the publication
are those of the author and not necessarily those of the publisher or the
pharmaceutical company. They are often provided free of charge either as articles in
"free" journals, or as special supplements. Such journals are paid for by advertising
(Internet 7).
4.5.2 The Backlash in the UK and Europe
There is a concerted effort being made by concerned parties within the industry to
counter the marketing strategies employed by the pharmaceutical industry. A multi-
faceted approach is being implemented. Undergraduate and postgraduate training
programs are now incorporating the skills needed to appraise pharmaceutical
advertising critically. Primary care trusts and other NHS organizations are setting up
robust and enforceable policies for managing the entry of new drugs and for dealing
with NICE guidance (Internet 7).
This has led to the development of interface formularies, which are formularies across
primary and secondary care and more widespread use of clinical decision-making
support tools, for objective diagnosis. Organizations have been asked to develop
guidelines and policies for working with the pharmaceutical industry, including the
setting up registers of interests, in academia (Internet 7).
4.6 A MARKETING CODE FOR THE US
In April 2002, the Pharmaceutical Manufacturer's Executive Committee (phrMA)
which represents the country's leading research-based pharmaceutical and
biotechnology companies, adopted a new Marketing Code that governed interactions
with healthcare professionals. The voluntary code outlines guidelines for how sales
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representatives and others involved in marketing pharmaceuticals should interact with
healthcare professionals (Internet 4).
The main points of the new code are as follows:
• General Interaction: Interaction should focus on informing the healthcare
professional about scientific and educational information and supporting
scientific medical research and education to maximize patient benefits.
• Entertainment: Interaction should not include entertainment. Interaction
should occur at a venue conducive to providing scientific or educational
information. Specifically, this means no "dine and dash", no entertainment,
and no recreational events, like sporting events or spa visits.
• Continuing Education: Companies can provide support to the conference
sponsor but should not fund individual participants. That means, a company
should not pay an individual's tuition, but could provide support to the event
sponsor. That sponsor may in turn provide grants to individuals to participate,
or to reduce the overall registration fees for all attendees.
• Consultants: Legitimate consulting or advisory arrangements are appropriate
but token consulting arrangements should not be used to justify payments to
healthcare professionals. Characteristics of legitimate consulting
arrangements include the retention of professionals based on their expertise,
not as a reward or inducement for prescribing, and retaining no more
consultants than needed for the specific program. It would be inappropriate to
retain 10,000 physicians for a program that requires no more than 1,000, or to
select them as a reward for high prescribing.
• Educational and Healthcare Practice-related Items: Educational and
practice-related items may be provided to healthcare professionals, but should
be for the healthcare benefit of patients and of less than substantial value (100
dollars or less). Items for the personal benefit of the healthcare professional
should not be offered or distributed. In short, nothing should be offered or
provided that would interfere with the independence of the healthcare
professional's prescribing practices (Internet 4).
The PhRMA Code on Interactions with Healthcare Professionals permits
informational presentations and discussions that provide valuable scientific and
educational benefits by industry representatives and others, speaking on behalf of a
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company. The code says, "In connection with such presentations and discussions,
meals, but no entertainment or recreational events may be offered so long as they:
(a) are modest as judged by local standards;
(b) occur in a venue and manner conducive to informational communication and
provide scientific or educational value" (Internet 7)
Inclusion ofa healthcare professional's spouse or other guests is not appropriate. And
offering "take-out" meals or meals to be eaten in the absence of a company
representative is inappropriate. The code provides that token consulting or advisory
arrangements should not be used to justify compensating healthcare professionals for
their time or their travel, lodging, and other out-of-pocket expenses. In addition, the
code specifies that items primarily for the benefit of patients may be offered to
healthcare professionals if they are not of substantial value, however, an anatomical
model for use in an examination room primarily involves a patient benefit, whereas a
VCR or CD player does not (Internet 7).
The new code also provides that no grants, scholarships, subsidies, support,
consulting contracts, or educational or practice-related items should be provided or
offered to a healthcare professional in exchange for prescribing products or for a
commitment to continue prescribing products. Nothing should be offered or provided
in a manner or on conditions that would interfere with the independence of a
healthcare professional's prescribing practices. The code also contains 10 frequently
asked questions and answers to those questions. One question, for example, is
whether golf balls and sports bags may be provided if they bear a company or product
name (Internet 4).
4.7 IS A MARKETING CODE NECESSARY?
There has been much discussion in the US in response to the PhRMA's decision to
develop the new marketing code about whether such a code is necessary and whether
there is sufficient infrastructure to implement the monitoring of pharmaceutical
companies' relationships with service providers. The medical profession is plagued by
perverse incentives from all spheres and this quarter is no different. Advocates of the
marketing code point out that some form of regulation is necessary as the situation is
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conducive to an unethical, enmeshed relationship between the two industries (Internet
4).
4.7.1 Interactions with representatives
A study by B Hodges (1999) of the University of Toronto into the attitudes of
psychiatric residents and clerks to the pharmaceutical industry, using self-report
questionnaires, examined the type of interactions with pharmaceutical representatives.
105 residents, interns and clerks training in psychiatry at seven teaching hospitals
participated. Less than one third felt that pharmaceutical representatives were a source
of accurate information about drugs; however, 71% disagreed with the statement that
representatives should be banned from making presentations. Although only 15% felt
they had sufficient training about meeting with pharmaceutical representatives, 34%
felt that discussions with representatives would have no impact on their prescribing
practices, and 56% felt that receiving gifts would have no impact on prescribing.
Fewer than half said they would maintain the same degree of contact with
representatives if they did not receive promotional gifts. The study found a significant
confidence level in the finding that the more money and promotional items a
physician-in-training had received, the more likely he or she was to believe that
discussions with representatives did not affect prescribing. Supervisors of
postgraduate medical training programs were asked to provide instruction concerning
potential conflicts of interests inherent in these interactions (Hodges: 2000).
4.7.2 Sampling
Pharmaceutical companies often use drug samples as a marketing strategy in the
private sector. There is insufficient information about how the availability of drug
samples affects physicians' prescribing practices. A study by Chew and O'Young et
al (2000) assessed under what circumstances and why physicians dispensed drug
samples, if drug samples lead physicians to use medications other than their preferred
drug choice, and the physician characteristics that were associated with drug sample
use. 154 general medicine and family physicians were included in the study which
involved physicians' self-reported prescribing patterns for 3 clinical scenarios,
including their preferred drug choice, whether they would use a drug sample and
subsequently prescribe the sampled medication, and the importance of factors
involved in the decision to dispense a drug sample. Avoiding cost to the patient was
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the most consistent motivator for dispensing a drug sample for all 3 case scenarios
that were presented to the doctors. The study concluded that the availability of drug
samples led physicians to dispense and subsequently prescribe drugs that differ from
their preferred drug choice.
4.7.2.1 Misuse of sampies
One of the concerns about the distribution of samples by pharmaceutical companies to
suppliers of service is the possibility of bribery and corruption. Tong & Lien (1995)
used a voluntary questionnaire survey to determine whether pharmaceutical
representatives misused their samples. The study was undertaken over a period of 3
months and 27 representatives were surveyed. 59% had provided prescription drug
samples to friends or relatives, the most commonly sampled drug being non-steroidal
anti-inflammatory drugs.
4.7.3 Detailing by representatives
Pharmaceutical companies in industrialized countries generally view detailers as the
most crucial element in the promotion of their products, with the result that over 50
percent of expenditures on promotion are devoted to detailers. In the United States
there is one drug representative for every 15 practising physicians. The standard sales
pitch is rife with information on a drug's effect on cellular receptors, its in-vitro
inhibitory activity, or its effect on serum concentrations. Companies make claims that
the detailers have the scientific knowledge for their role in passing on information to
physicians, however, the validity of information presented by drug representatives
varies with their level of knowledge and their zeal in conveying their message. A
recent analysis of the accuracy of information from representatives found that one in
10 statements, all of which favoured their product, were at odds with the company's
own literature. The main purpose of detailers then is to sell their company's products.
This emphasis on sales is evident from statements of detailers themselves, from
advertisements for detailers, from company documents, and by looking at the groups
of physicians that companies specially target for visits by detailers. A variety of
explanations are offered as to why physicians see detailers, but on examination none
of the reasons is justifiable. Studies from a number of industrialized countries have
shown that over 90 percent of physicians see detailers and a substantial percentage
rely heavily on detailers as sources of information about therapeutics. Detailers are
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higWy successful in altering physicians' prescribing habits, but almost all the literature
available shows that the more reliant doctors are on commercial sources of
information, the less appropriate they are as prescribers (Internet 13).
4.7.3.1 Detail Aids
The detail aids used by pharmaceutical companies to present information to doctors is
also the branded material presented to the doctor regarding the company's product.
Stryer & Bero (1996) evaluated the characteristics of material distributed by
pharmaceutical companies to physicians to determine whether the material complied
with Food and Drug Administration (FDA) regulations and whether it contained
promotional and educational characteristics. Forty-two percent of the items failed to
comply with at least one of three FDA regulations assessed, including 17 items that
discussed unapproved uses for drugs. Advertisements, as well as items that were not
obviously promotional, contained promotional characteristics. Thirty-nine percent of
the items offered scientific support for their claims. The study concluded that little of
the material distributed by pharmaceutical companies to physicians conveyed
information about important therapeutic breakthroughs and some of it failed to
comply with FDA regulations. The material always contained both educational and
promotional characteristics.
4.7.4 Prescription Habits
The consistent argument for the regulation of interactions between the pharmaceutical
industry and the medical profession is that the relationship would be one of undue
influence where the practitioners' prescription habits would be altered. A study by
Orlowski and Wateski et al (1992) examined the impact on physician prescribing
patterns of pharmaceutical firms offering all-expenses-paid trips to popular sunbelt
vacation sites to attend symposia sponsored by a pharmaceutical company. The
impact was assessed by tracking the pharmacy inventory usage reports for two drugs
before and after the symposia. Both drugs were available only as intravenous
preparations and could be used only on hospitalized patients. The usage patterns were
tracked for 22 months preceding each symposium and for 17 months after each
symposium. Ten physicians invited to each symposium were interviewed about the
likelihood that such an enticement would affect their prescribing patterns. A
significant increase in the prescribing pattern of both drugs occurred following the
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symposia. These changed prescribing patterns were also significantly different from
the national usage patterns of the two drugs by hospitals with more than 500 beds and
major medical centers over the same period of time. These alterations in prescribing
patterns occurred even though the majority of physicians who attended the symposia
believed that such enticements would not alter their prescribing patterns.
4.7.5 Journal Advertising
The pharmaceutical industry spends a significant proportion of its marketing budget
on advertising in leading medical journals. The larger companies with the bigger
budget are able to hog this space and see this as a competitive advantage. A study by
Wilkes, Doblin et al (2000) assessed both the accuracy of scientific data presented in
print pharmaceutical advertisements and the compliance of these advertisements with
Food and Drug Administration (FDA) standards. A cross-sectional survey of 109 full-
page pharmaceutical advertisements appearing in 10 leading medical journals, along
with all available references cited in the advertisement were sent to three reviewers:
two physicians in the relevant clinical area who were experienced in peer review and
one academic clinical pharmacist.
Reviewers were asked to evaluate the advertisements using criteria based on FDA
guidelines, to judge the educational value and overall quality of the advertisements,
and to make a recommendation regarding publication. In 30% of cases, reviewers
disagreed with the advertisers' claim that the drug was the "drug of choice."
Reviewers felt that information on efficacy was balanced with that on side effects and
contraindications in 49% of advertisements but was not balanced in 40%. Reviewers
agreed with advertisements' claims that the drug was safe in 86% of the cases but
judged that headlines in 32% of the advertisements containing headlines misled the
reader about efficacy. In 44% of cases, reviewers felt that the advertisement would
lead to improper prescribing if a physician had no other information about the drug
other than that contained in the advertisement. Fifty-seven percent of advertisements
were judged by two or more reviewers to have little or no educational value. Overall,
reviewers would not have recommended publication of 28% of the advertisements
and would have required major revisions in 34% before publication.
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The study concluded that in the OpInIOn of the reviewers, many advertisements
contained deficiencies in areas in which the FDA has established explicit standards of
quality. It recommended that new strategies be employed by the pharmaceutical
industry to ensure that advertisements comply with standards in order to promote
proper use of products so as to protect the consumer.
4.7.6 Promotional Gifts
Another area of investment by pharmaceutical companies is in the distribution of
promotional gifts to its customer base. While this is an acceptable marketing practice
in other sectors of the economy little is known about the factors that influence medical
professional attitudes toward pharmaceutical industry promotions or, how such
attitudes correlate with physician behavior. A study by Steinman, Shlipak et al (2001),
investigated the attitudes of 105 interns, using confidential surveys. The majority of
respondents considered seven of nine types of promotions appropriate. Residents
judged the appropriateness of promotions on the basis of their cost. Most respondents
stated that industry promotions and contacts did not influence their own prescribing,
but only 16% believed other physicians were similarly unaffected. The study
concluded that although generally positive attitudes were present toward gifts from
the pharmaceutical industry, there is a belief that behavior is not influenced by the
companies even though report behaviors in the study were often inconsistent with
their attitudes.
4.8 CONCLUSION
The international experience of the relationship between the pharmaceutical industry
and the medical profession lends support to the South African government's stance on
regulation of the marketing activities of the pharmaceutical industry. In every aspect
of contact between the two sectors, there exists the potential for unethical influence on
the prescription habits of practitioners for the purpose of sales figures. The final
chapter will discuss recommendations for the South African situation, with specific
reference to generic substitution, parallel imports, and Section 12 ofPharmacy Act 90
with regard to issues of sampling, removal of incentives and the constitution of a
marketing code.
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CHAPTER FIVE: RECOMMENDATIONS AND CONCLUSIONS
5.1 INTRODUCTION
This case study was undertaken to evaluate the impact of legislative changes on
stakeholders in the pharmaceutical industry. In the preceding chapters we have
discussed the stakeholders, described the legislative changes and strategically
analyzed the industry. Exploration of the international experience of the regulation of
the pharmaceutical industry appears to hint at pros and cons to the stance of the South
African government. In this chapter, we will comment on the impact of the
restrictions with regard to sampling, removal of incentives and generic medication on
psychiatric practice. This evaluation makes the assumption that the issues are
translatable to the industry at large in South Africa. Further, recommendations
regarding the constituents ofa marketing code will be highlighted.
5.2 GENERIC SUBSTITUTION
Statistics of the South African anti-depressant market (TPM: Total Private Market)
for the year 2001 are reflected in Graphs 5.1 and 5.2 below (Internet 7).
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These figures of the South African antidepressant market are similar to the statistics
of the US and indicate that the trends in the South African market follow those of the
US quite closely, even to similarities between the market leaders (Internet 7). There
are several reasons why this may be the case:
• Diagnostically, SA psychiatrists use the DSM-IV system of classification of
mental illness that is US-based. This is versus the European classification of
mental illness that is based on the ICD-l0 classification.
• The market leaders in the US have local subsidiaries in South Africa
• There is aggressive marketing of branded products in the South African
market
• There is aggressive marketing ofbranded products in leading publications
• There is investment in R & D in the area of CNS products and there have been
new product launches yearly
• The level of contact between the pharmaceutical industry and psychiatrists is
high
As is the case in the US, branded products are still the preferred products in private
practice, despite legislation to the contrary. There is still suspicion among private
practitioners about generic medication. Concerns are raised about the efficacy and
tolerability of the substitutes. There is also a lack of experience in the use of generic
medication as the private practice market has bee focused mainly on branded
products. As a nation South Africans are very brand conscious in general and this
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expectation that 'branded is better' also rings true for medication. The health provider
is not the only pro party in the equation as the consumer also feels that generic
medication is less potent than the 'real stuff'. With regard to efficacy, it is then
impossible to determine, either for the practitioner or the consumer, whether the
perception that branded products are better, influences response or whether there is a
significant difference in efficacy. Certainly at the level of the MCC, there appears to
no disbelief in the tolerability of generic drugs, as no other data is required other than
bioavailability studies for registration. Branded products are actively being bypassed
in the queue so that generic medications can be supported by government agencies.
SASOP'S position IS clear. Although there is the reality of problems with
affordability, it is a concern that the EDL has been constituted with so few of the
branded products that genuinely represent a breakthrough in treatment. The field of
psychiatry IS rapidly advancing and there are new developments III
psychopharmacology. There are also serious concerns about the safety and tolerability
of some of the older preparations that have made the EDL. SASOP has indicated that
it would not oppose the EDL but it has indicated its reservations regarding some of
the treatment options available.
The second area of restriction on the use of branded products comes from the
administrators of health care in the private sector, who impose limits on medication
use. Certain medical aid schemes like Mx Health have designed their accepted
formulary on the EDL and will not pay for certain branded products, even if the
patient wishes to use his entire annual limit for that prescription. This can be
construed as an infringement on the consumer's right to privacy. Further, there are
also restrictions as to what constitutes chronic medication, which is defined as life-
saving medication. Here again, administrators have guidelines and limits and patients
who belong to the Schemes have little flexibility. The Schemes have now introduced
specialist verification of scripts for longer than six months, thereby necessitating a
visit to a specialist, which does not help in the reduction ofcosts.
In the public sector, generic medication is the treatment of choice and branded
products are rarely available. Concerns have been raised about the training of health
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professionals with limited exposure to a range of medication before they are licenced
to practice in the private sector.
5.2.1 The NAPM's Perspective on Generic Medication
The National Association of Pharmaceutical Manufacturers (NAPM) welcomed the
implementation of the Medicines Control Amendment Act which came into force at
the beginning of May 2003, as it opened up opportunities for investment in the local
generics sector.Generic substitution is viewed as a direct benefit to consumers by the
NAPM and the Association is in the process of implementing a marketing campaign
which will educate consumers and healthcare professionals on the advantages of
generic medicines.
In terms of the legislation, introduced in May, it is mandatory for pharmacists or other
dispensers to inform patients of the benefits of Interchangeable Multi-Source
medicines (!MM). !MM is defined as 'medicines that contain the same substances
which are identical in strength or concentration, dosage form and route of
administration and meet the same or comparable standards which comply with the
requirements for therapeutic equivalence as prescribed' (Internet 1).
The NAPM is satisfied that the therapeutic equivalence determined from comparative
bioavailability, pharmacodynamic, clinical or in vitro studies, meet the requirements
and criteria for bioequivalence as determined by the Medicines Control Council. The
legislation states that !MM must be dispensed unless expressly forbidden by the
patient and the dispenser must take all reasonable steps to inform the prescriber of
such substitution. This has implied that unless the prescriber writes no substitution on
the prescription, there is no guarantee that the consumer would receive what was
scripted.
There are safeguards that in that generic substitution is not permitted if expressly
prohibited by the prescriber, or !MM is more expensive, or the original medicine has
been declared 'non-substitutable' by the Medicines Control Council. The NAPM feels
that in South Africa, generic medicines currently account for about 20% of the South
African market, which indicates that there is considerable room to improve the
affordability of medicines through increased use of generics. It is no secret that the
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agenda of the organisation is that this represents a maSSIve opportunity for the
manufacturers of generic medicines. The NAPM has therefore urged its members not
only to promote the use of generic medicines but also to actively seek to work as
closely as possible with the Department of Health by proposing affordable solutions
for pharmaceutical care that will be in the best interests of the patient (Internet 1).
5.3 THE NATIONAL DRUG POLICY
The South African legislation is aimed at lowering drug pnces by allowing
importation of generic substitutes and imposition of compulsory licensing. At stake
however, are the sovereignty of patent law and World Trade Organization rules on
Trade in Intellectual Property and international power relations between developing
countries and the pharmaceutical industry. In reviewing the ongoing debate, the
situation raises concerns about contemporary imperialism, the role of the profit
motive as an incentive in vital pharmaceutical products, and the depth of "democracy"
in the US where international drug firms have sufficient clout to dictate policy against
the life-and-death interests of millions of consumers of essential drugs in South Africa
and other developing countries (Internet 5).
What is clearly needed in South Africa is action on some of the NDP steps that
closely match those suggested by the WHO as general advice to all countries:
• More detailed data on price trends in both the private and public sectors
• More analysis of the impacts of policy decisions, with emphasis on
indicators of equity, affordability and availability
• Finality on those policy choices which seem to hold clear advantages such as
fixed professional fees and non-discriminatory exit pricing based on volume
• Finality on the legal struggle to introduce generic substitution, to regulate
marketing practices and to exploit the safeguards provided by the TRIPS
Agreement
• Consideration of regional options, including bulk purchasing across the SADC
regIOn.
In South Africa, crucial to the success of these options will be strengthening of the
national Departments responsible, the Directorate of: Pharmaceutical Programmes
and Planning and the Directorate: Medicines Administration, the secretariat to the
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Medicines Control Council. Significant strengthening of the inspectorate functions of
the MCC will also be necessary if the potential pitfalls of parallel trade and
compulsory licensing are to be avoided. Strengthening the entire system will ensure
that the populace is not exposed to counterfeit and sub-standard medicines and will
demonstrate that such exposure is not an inevitable consequence of the policy choices
outlined in this chapter. In this regard, South Africa still remains a test case, one
watched closely by the international community (Internet 5).
5.4 A CODE OF CONDUCT FOR THE PHARMACEUTICAL INDUSTRY
It is clear that a framework of good practice to audit companies' behaviour on issues
relevant to patient care needs to be formulated. However, there are bigger ethical
issues than the industry's relationship with providers of service. The biggest issue is
whether the companies are prepared to be socially responsible, by reducing prices
systematically for poor countries and directing some of its enormous drug
development capabilities to neglected health needs.
Ensuring social responsibility from the industry in the long term depends on socially
responsible government policies at the country level. An international convention
could be developed to ensure that new medicines are developed according to global
health needs, and equitable drug pricing can be ensured through a mandatory
framework. However, such policies are unlikely to be forthcoming while the
pharmaceutical industry continues to influence governments to the extent it currently
does.
5.5 THE PLACE OF PRIVATE PRACTICE IN SOUTH AFRICA
The use of private health care providers in low-and middle-income countries (LMICs)
is widespread and its implications are the subject of continuing debate. One view is
that private providers are likely to be more efficient than the public sector and hence
that government should contract out services to the private sector. An alternative view
is that private providers are often not superior in quality or efficiency to the public
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sector, and that contracts are not straightforward to design and implement. Finally,
there is increasing recognition that neither public nor private providers have uniform
characteristics, and that this distinction might overlook more important issues, such as
the extent to which a provider uses public funds efficiently and serves the goals of
public health (Internet 8).
A new model of private primary care provision could be developed in South Africa, in
which private companies provide standardized primary care services at a relatively
low cost. Drawing on data from other low-income countries where there is service
delivery, this represents the most likely alternative for patients on a low income with
no access to health care.
The fact that public sector primary care is free in South Africa, yet around 30% of
people without medical insurance still choose to payout of their own pocket to attend
facilities in the private sector, is a telling statistic. Even in the lowest income quintile
this proportion is estimated to be 20%. The market for private patients is lucrative and
most general practitioners are in private practice. The private sector is a feasible
option in urban areas as patients appreciate the service delivery because of
perceptions of greater privacy, speed of service, and quality of diagnosis, prescribing
and counseling (Internet 2).
Currently, there are more 100 private, branded, primary care clinics in South Africa
owned by a handful of companies. Larger companies are achieving widespread
coverage and brand recognition. Some company managers have also expressed an
interest in contracting with the government to deliver services on their behalf, but as
yet they have had no clear response from the South African Department ofHealth.
Patterns of use differed markedly at the private clinics compared with the public
sector. Patients appeared to "shop around" between different providers for different
services, tending to use the public sector for treatment of chronic conditions and
private clinics for curative care.
What are the implications of this new model of primary care for the current debate
about the role of the private sector in public-private partnerships, and how will the
public health care system react to the possibility? For the public sector, in its current
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mode of operation, this model of private provider presents threats and opportunities.
One direct threat is competition for primary health care nurses who are in short supply
and who traditionally have been employed largely by the public sector.
Other possibilities posed by this new model relate to its probable impact on the shape
of the health care system. The low-income segment of the population could be
serviced by the private sector, while the public sector concentrates on its role as
regulator and providing services to the poorest. Potentially, this could remove some of
the burden on the public sector, and the task of regulation might be made easier by the
strong hierarchical control exercised within the private sector. One drawback is the
desirability of encouraging any low-income group to pay for primary care services is
also debatable.
An alternative form of cooperation would be for the government to contract with
these companies to provide services to the whole population. Clinic chains can deliver
services that are very acceptable to users and which are at a similar cost to the public
sector, and they are attracted by the market expansion that contracting with
government would offer. In addition, contracts with a hierarchically structured
company might be easier to manage than with a series of self- employed professionals
such as general practitioners, because the internal management systems and
standardized procedures of the former would lessen the variation in service delivery
and give greater control. In addition, contracts could secure access for the poorest
section of the population and draw the clinics into the framework of public sector
service delivery, offering a similar range of services, rather than allowing them to
remain largely as complements to the public sector.
However, many real-life constraints, of market structure, information and capacity,
would need to be taken into account in designing and implementing such a system.
The South African experience of contracts for district hospital provision and curative
primary care services emphasizes the crucial prerequisite of adequate public sector
capacity to manage these constraints effectively, especially when dealing with agile
and creative private companies, although positive experiences of contracting out have
been recorded in a variety of settings. Scepticism among some policy makers and
managers about the desirability of working with the private sector, and of their
motivations, is a further potential hurdle (Internet 5).
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5.6 PARALLEL IMPORTS
Several large pharmaceutical companies have asked US trade officials to put pressure
on the South Africa government to modify the country's policies with regard to the
regulation of pharmaceutical drugs. The South African government, however, is
working closely with the World Health Organization (WHO) to adopt policies which
may serve as a model for other developing countries in Africa and elsewhere. One of
the issues in dispute concerns the matter of parallel imports for pharmaceutical drugs.
The South Mrican government has lowered regulatory barriers for the importation of
registered pharmaceutical drugs as it believes its consumers will benefit if hospitals
and other health care providers can seek the procurement of pharmaceutical drugs in
the broader world market. Parallel imports are legal within the European Community
and account for 8 percent of the UK pharmaceutical drug market, and 5 to 10 percent
of the Netherlands market. The SA government is committed to its stance and is
swinging world support its way.
5.7 CLARITY OF LEGISLATION
Section 18B (1) of the Medicines and Related Substances Control Amendment Act
No. 90 of 1997 prohibits the sampling of any medicine by any person. However
Section 18 (2) clarifies this by defining what is meant by "sample" i.e. The free
supply of medicines BY a manufacturer or wholesaler, or its agent to a pharmacist,
medical practitioner, dentist, veterinarian, practitioner, nurse or other person
registered under the Health Professions Act 1974. It goes on to clarify that this ban
does NOT include the free supply of medicines for:
a) the purposes of clinical trials
b) donations of medicines to the State and
c) quality control by inspectors.
Presumably the supply of a sample of a medicine to the Medicines Control Council
for registration purposes would fall under c) above (Internet 5).
It has been the practice in South Africa for many years for companies to donate
medicines to the many private charities which offer medical and clinical services to
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the indigent and unemployed in areas where the there are no State services or where
these are inadequate to meet the needs of the public. This is also the case in certain
private hospitals run by various religious orders or missionaries in which doctors and
nurses offer a wide range of medical care. There are also many clinics run by NGO's
which are staffed by part-time medical practitioners, nurses and other health care
practitioners who have benefited from "donations" or "samples" supplied by
pharmaceutical companies as part of their social responsibility programmes ego
Alexandra Clinic.
An alternative designation could be that the products are donated or made available
for "compassionate" reasons given the urgent need for such programmes in this
country. Such products are not donated or given away as samples for promotional
purposes since the limited budgets of the various clinics and hospitals would not
allow for the purchase of these products. Stocks are properly controlled and used
under the supervision of registered heath care professionals.
Donations such as these described above are now illegal according to Section 18B of
Act 101 of 1965 as amended, since they do not fit into any of the categories for
exemption described in the Act. The medicines are supplied free of charge but they
are not promotional samples. However, they are also not one of the sample categories
that are permitted. The medicines donated are not for use by the State; they are not
samples for tender, quality control, analytical purposes or to go to the MCC with
applications for registration ofnew medicines.
Through the Industry Task Group [ITG], the South African pharmaceutical industry
should propose to government that a special category of "compassionate use"
donations of REGISTERED medicines, should be permitted for distribution to
designated charities running clinics, hospitals, or providing medical services for the
indigent, and unemployed in areas where there are inadequate or no State services, or
where the State services cannot not offer the treatment needed, as in the case of the
daily medicine needs for a home for abandoned or orphaned babies with mv /AIDS.
The current provision of "compassionate use" samples generally relates to new
unregistered medicines for patients who do not respond to the standard treatment
available or for whom such treatment is not suitable.
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At the moment,
a) Section 21 does not cover the supply of registered medicines for
compassionate use;
b) the current prohibition on the sampling of medicines is contained in Section
18B of Act 101 of 1965 as amended, and that a change in this Section of the
Act would require returning to Parliament for an amendment to the legislation.
c) However it is not clear if a "no charge" supply of medicines for compassionate
purposes would be regarded as "samples" or "a donation" as listed in the Act
and if a change in the legislation is in fact required at all.
Should a change in legislation be required, an additional statement in clause 18B(2)
could read:
"18B(2): For the purposes of this section "sample" means the free supply of
medicines by a manufacturer or wholesaler or its agent to a pharmacist, medical
practitioner, dentist, veterinarian, practitioner, nurse or other person registered under
the Health Professions Act, 1974, but does not include the free of supply of medicines
for
a) the purposes ofclinical trials,
b) donations of medicines to the State,
c) donations to a registered charity or NGO approved by the Minister or a
designated State official,
d) tendering to the State and
e) quality control by inspectors."
In addition, Guidelines outlining conditions for the free supply of medicines for
Compassionate Use for individuals or for patients at designated private clinics or
hospitals could be issued. The current provision of "compassionate use" medicines
under Section 21 of Act 101 of 1965, generally relates to new unregistered medicines
for patients who do not respond to the standard treatment available or for whom such
treatment is not suitable.
This guideline covers the supply of registered medicines by manufacturers, or
wholesalers, free of charge to non-governmental organizations or individuals for
compassionate use. This would include registered charities, which run clinics, or
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hospitals, and NGO's which assist the indigent and unemployed who might not be
able to afford medical treatment, in areas where there are inadequate or no State
services or where the State services cannot offer the treatment needed. Donations of,
medicines for such people should be made directly to a health care professional
registered with one of the relevant Statutory Health Councils and the control and
issuing of such donated medicines should be done by personnel with the appropriate
qualifications and authority. All required records must be kept by the responsible
health care professional.
Applications for approval of any donation of a registered medicine to other than
registered charities, could be made to the Minister or a designated official of the
Department ofHealth [or the MCC].
5.8 A MARKETING CODE
Sales and marketing compliance IS clearly becoming a major industry issue as
companies strive to undertake internal reviews to ensure compliance with "anti-
kickback" laws and avoid unwelcome publicity. However, as marketing potential
reaches saturation, the industry needs to extend its promotional influence while
remaining within the confines of regulatory law.
Clearly, the industry is under pressure to review sales and marketing practices as
increasing flaws are found in the influencing strategies that pharmaceutical companies
currently apply to prescribers. The World Medical Association is also reviewing the
relationship between the medical community and pharmaceutical marketers to
determine the extent of alleged influence. Practices such as product sampling,
educational sessions aimed at physicians and sponsored research are under review.
In an attempt to boost prescription volumes, companies are under pressure to match
the promotional spend of competitors to maintain their sales force share of voice.
Detailing is still viewed as the key way to reach doctors and companies have
increased the size of their sales force by about 75% over the past six years (Internet
7).
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The principles behind a Marketing Code should be based on legislation relating to
medicinal products, consumers and competition and on the International Code of
Advertising Practice. The Code of Conduct should cover marketing activities in
medical journals, promotional and educational materials used by medical
representatives, trade displays, medical education, and supply of information to the
general public and healthcare professionals.
An independent Code of Conduct Committee, made up of representatives from the
medical profession, government, industry, and consumer groups could investigate
complaints about breaches of the Code and impose sanctions such as fines or
publication of corrective advertising.
The purpose of this code would be to ensure that the marketing of medicines by all
pharmaceutical companies to health professionals and the general public in South
Africa is carried out in a responsible and ethical manner. All pharmaceutical
companies supplying drugs in South Africa will be subject to this code by virtue of
registering their products with the Medicines Control Council. Punitive measures will
be applied against a company ruled in breach of the code.
The code could be divided into three parts: Part I dealing with the promotion of
medicines to health professionals, Part 11 dealing with the promotion of over-the-
counter medicines to the general public and Part ID relating to the Authority that will
monitor the Code and administer the complaints procedure.
All pharmaceutical companies would be expected to assume responsibility to know
the parameters of the code and to ensure that appropriate personnel within their
companies and their advertising agencies have a comprehensive understanding of the
code. The Code could include the following constituents:
•
•
Media advertising, detail aids and other promotional material should include a
considerable amount of prescribing information and may only appear in
professional publications.
Each company should have a standard operating procedure for the certification
process for promotional material which must be available for audit by the








without any subsequent amendments after it has been certified by two persons
on behalf of the company. One of the two persons should be a registered
medical practitioner or a responsible. The other signatory could be an
appropriate senior official of the company.
Certification should be maintained also for promotional material and meetings
being organized for health professionals that involve travel outside South
Africa. Certificates and the relevant accompanying information must be
preserved for not less than three years.
Medical representatives should have a mInImUm standard of training that
could be decided on by the industry.
No gift, benefit in kind, rebate, discount, kickback or any other pecuniary
advantage should be offered or given to health professionals or administrative
staff or government officials or to the general public as an inducement to
prescribe, supply, stock, dispense, administer or buy any medicines.
The only exceptions to the code are inexpensive gifts in the form of
promotional aids or prizes. Competitions are permissible but must be in good
taste and appropriate for the promotion of medicine.
Hospitality may include the payment of reasonable, actual travel costs for
delegates to attend meetings in South Africa but such payments should only be
made to the professional associations organizing the event.
Sponsorship of meetings could be permitted but the meeting must have a clear
educational content and the hospitality associated with the meeting must be
secondary and not out of proportion. Hospitality should not be extended to
spouses or other persons unless that person is a member of the health
professions or qualifies as a delegate in his/her own right. Meetings for groups
of health professionals or administrative staff that are wholly or mainly of a
sporting or social nature should not be acceptable.
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5.9. CONCLUSIONS
This case study attempted to evaluate the impact of the legislative changes on all
stakeholders in the pharmaceutical industry. Gap analysis revealed that all
stakeholders had perceived a real difference between the industry five years ago and
now. With the legislative changes being so fundamentally different from the old
legislation with regard to significant areas of the industry it is clear, that the impact of
the legislation would cause a further gap between where the stakeholders perceive the
industry is at present and where they would like it to be.
The SA government would like to be in a position of offering affordable health care to
its people and the region and continent and would like to be seen as a regional leader
in the fight to have the costs of medication reduced. The legislation has begun a
process whereby that could be a reality in the next decade. For the pharmaceutical
industry, which has been a global leader as an industry, this Act represents a major
challenge to retaining its profit margins in a global economy that is in recession. What
is required of the industry is to become innovative in its strategy, to be collaborative
in its approach with government and to pursue horizontal and vertical integration
actively. Social responsibility and establishing sustainable competitive advantage
would be invaluable to the major role players in the industry, as the demand from
governments increase for reduction in drug costs. The justification of high R & D
costs is falling on deaf ears and the industry has to move quickly to address the
negative drift it is experiencing even in the developed world. For the providers of
service, the Act represents a difficulty in providing adequate care to a section of the
population that needs it the most. Sampling was a valuable way of allowing low
income groups to have access to branded products. With regard to incentives,
especially in this country with its history of imbalance, there is some support among
professionals for the equitable distribution of sponsorship for educational events. The
issue of generic substitution and managed health care is more relevant as a factor that
could impact significantly on private practice in South Africa.
Presently, it is clear that the changes with regard to promotion of generic substitutes,
removal of samples and the banning of perverse incentives would impact largely on
the private sector. It is also clear that the changes in legislation were a necessary 'evil'
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if South Africa was going to meet its commitments to provide affordable health care
to its citizens. Its policy on generic substitution and parallel imports has been
supported within the country and outside, in the developing world and Europe.
The development of a code of conduct that would regulate the relationship between
the industry and health providers is long overdue and in keeping with international
trends. However, clarification regarding legislation with regard to sampling is a factor
that needs urgent attention. There is a percentage of consumers in both the private and
public sector that were benefiting from this practice, that have been marginalized. The
government also needs to consider private-public sector partnerships as a way forward
in addressing its objectives in providing effective, affordable health care.
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The term "exhaustion of rights," describes the termination of patent rights following
the legal sale of a good. This is sometimes called the "first sale doctrine." A patent
grants a party a monopoly on the sale of a good. Under the first sale doctrine, once a
good is sold by the patent owner, the purchaser is free to resell the good, even if the
resale of the good competes against sales offered by the patent owners.
Parallel Imports
Parallel imports refers to the situation where the patent owner holds patents in more
than one country, and a third party purchases goods in one country and imports the
goods into another country without authorization from the patent owner. Patent
owners typically sell the same goods at different prices in different countries. The
pharmaceutical industry has lobbied against parallel imports because they want to use
price discrimination based upon the degree of competition in each market. Countries
that permit parallel imports benefit from opportunities to acquire pharmaceuticals at
the lowest international prices.
The Food and Drug Administration (FDA)
The FDA regulates the sale of pharmaceuticals. For a new drug, a firm must submit
data to the FDA which is used to evaluate the safety and efficacy of the drug. If a drug
is protected by a patent, or by exclusive marketing protections under the Orphan Drug
Act, the FDA will not grant another company marketing approval. If the drug is not
protected by patent, and not protected by the exclusivity marketing provisions of the
Orphan Drug Act, another firm can seek marketing approval for the same drug.
However, for five years, the FDA requires the any new firms present their own data
which proves the safety and efficacy of the drug, even though the FDA has already
determined the drug to be safe and effective. After 5 years from when the drug was
approved for marketing, and after any patents or Orphan Drug marketing exclusivity
expire, a firm can obtain marketing approval for a drug by showing that a product is
biologically equivalent to the approved drug.
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APPENDIX ONE: MEDICINES AND RELATED SUBSTANCES
AMENDMENT ACT, 2002, ACT No.59, 2002
"To provide that a member of the council or committee shall declare his or her
commercial interest related to the pharmaceutical or health care industry; to provide
that the appointment of members of the executive committee is subject to the approval
of the Minister; to provide for the control of medicines and scheduled substances and
medical devices; to make further provision for the prohibition on the sale of
medicines which are subject to registration and are not registered; to provide for
procedures that will expedite the registration of essential medicines and for the re-
evaluation of all medicines after five years; to provide for measures for the supply of
more affordable medicines in certain circumstances; to provide that labels be
approved by the council; to prohibit sampling and bonusing of medicines; to provide
for the licensing of certain persons to compound, dispense or manufacture medicines
and medical devices and also to act as wholesalers and distributors; to provide for the
generic substitution of medicines; to provide for the establishment of a pricing
committee; to regulate the purchase and sale of medicines by manufacturers,
distributors, wholesalers, pharmacists and persons licensed to dispense medicines; to
make new provisions for appeals against decisions of the Director-General or the
council; to provide that the council may make regulations; to provide for the
rationalization of certain laws relating to medicines and related substances that have
remained in force in various territories on the national territory of the Republic by
virtue of item 2 of Schedule 6 to the Constitution of the Republic of South Africa,
1996; and to provide for matters connected herewith."
146
APPENDIX TWO: PEST ANALYSIS
PEST Analysis
POLITICAL ECONOMIC
• Political stability • Type of economic system
• Risk of military invasion • Government intervention In the free
• Legal framework market
• Intellectual property protection • Comparative advantages of host
• Trade regulations & tariffs country
• Favoured trading partners • Exchange rates & stability of host
• Anti-trust laws country currency
• Pricing regulations • Efficiency of financial markets
• Taxation • Infrastructure quality
• Wage legislation • Skill level ofworkforce
• Work week • Labour costs
• Mandatory employee benefits • Business cycle stage
• Industrial safety regulations • Economic growth rate





• Demographics • Recent developments
• Class structure • Technology's impact on product
• Education offering
• Culture • Impact on cost structure
• Entrepreneurial spirit • Impact on value chain structure




APPENDIX THREE: SWOT ANALYSIS
SWOT ANALYSIS KEY ISSUES IN THE ENVIRONMENT
STRENGTHSI Politics! Link between New Public Demo- Comp-
WEAKNESSES Legislation poverty & technology Expect- Graphic etetive
health (medical) Ation Trends Market
Main Strengths
Innovation + + + ++ + ++
Good GP links + ++ + + + +
Employees + + + + 0 +






No growth + +
Provider agenda 0 0 ++
Govt. decides
Role 0 0 0
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